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…. to Sara  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"The scientific method," Thomas Henry Huxley once wrote, "is nothing but the normal 
working of the human mind." That is to say, when the mind is working; that is to say 
further, when it is engaged in corrrecting its mistakes.  
Taking this point of view, we may conclude that science is not physics, biology, or 
chemistry - is not even a "subject" - but a moral imperative drawn from a larger 
narrative whose purpose is to give perspective, balance, and humility to learning. 
Quoted in: Neil Postman, The End of Education, Alfred A. Knopf, New York, 1995, p 68 
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Abstract 
Bone tissue engineering strategies rely on the complex interplay between cells, 
biomaterials and biomodulators to achieve a successful regeneration of the bone 
tissue, in an intimate synergy with the hosts‘ biological capabilities. In these 
applications, a wide range of biomaterials has been assayed, in order to elicite an 
adequate response from the biological milieu. Regrettably, there is no current available 
material that meets all the desirable biochemical, mechanical and biological 
requirements for each individual bone-related clinical application. Moreover, the 
material‘s form and size, the close interface with body fluids and/or tissues, and the 
estimate duration of use, will further determine selected and individual properties. In 
this way, one material property alone is unlikely to lead to a successful and durable 
device, whereas a lack or inadequacy regarding a single key property, can lead to a 
disastrous failure.   
In this way, biomaterial testing, specifically in which relates to the assessment 
of material‘s biocompatibility - the ability of a candidate biomaterial to perform its 
desired therapeutical function, without eliciting any undesirable local or systemic 
response, but engendering the most appropriate beneficial response in that specific 
situation – is regarded as the central theme concerning the clinical success of 
biomaterials application.  
Initial approaches of biocompatibility assessment usually rely on in vitro 
biomaterial biological testing, embracing the general cytocompatibility evaluation with 
broadly available cell lines, usually of fibroblastic phenotype. A generic characterization 
of the biological behaviour of candidate materials is possible and the detection of 
cytotoxic and/or mutagenic compounds, in direct or indirect culture systems, is 
accomplishable. Nonetheless, a second in vitro phase, in which the specific 
cytocompatibility is assessed, is usually conducted to evaluate the material response to 
primary or early passaged cells of a type relevant to the proposed application of the 
medical device. In the case of bone-related applications, osteoblasts, osteoclasts and 
endothelial cells are commonly used in the biological evaluation.  
Overall, in vitro testing is an attempt to simulate the in vivo situation as closely 
as possible, in a strictly controlled environment. By selecting cell populations most 
likely to modulate the behaviour of implanted materials, a spectra of in vitro changes, 
ranging from inhibition of growth or inadequate expression of cell markers, to 
stimulation of cell proliferation and/or other cell functional factors, may be addressed 
and offer a method to tailor biomaterials in an early phase of development. However, in 
vitro testing, as exhaustive as it is, it does not eliminate the need to test the candidate 
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biomaterial in an in vivo biological system, reaching hand of animal experimental 
models. 
Animal models are essential for evaluating biocompatibility, tissue response 
and mechanical function of candidate materials, prior to clinical use in human trials. 
They allow the evaluation of materials in a wide range of time frames, ages, and in 
different biological constrains, but while they may closely represent the biomechanical 
and physiological conditions of the human clinical situation, it must be remembered that 
it is only an estimated approximation, with each model having unique advantages and 
disadvantages.  
In this work, the general and specific cytocompatibility profile of several 
candidate biomaterials for bone tissue regeneration is addressed, reaching hand of 
multiple in vitro cell culture systems. Materials ranging from calcium phosphate and 
silicon-based ceramics, to glass-substituted materials, composites and film-deposited 
constructs were deeply scrutinized regarding events of cell adhesion, proliferation and 
differentiation. Human cell populations most relevant for biocompatibility assessment 
were used, ranging from human fibroblastic or osteoblastic cell lines to primary or early 
passaged cultures of human fibroblasts, osteoblasts and endothelial cells. Moreover, 
the issue of the in vivo biocompatibility assessment has also been addressed, 
regarding the use of the rodents‘ calvaria model, for the evaluation of the bone 
regeneration process.  
The development of new materials aiming clinical application within bone-
related interventions has become progressively more sophisticated, both in terms of 
design and fabrication methodologies. From the biological point of view, recent 
advances have contributed to shed a new light into the development of research tools, 
and in the understanding of the mechanisms involved in cell and tissue cross-talk with 
biomaterials, during bone regeneration. The greatest challenge of this paradigm, that 
has emerged from the synergic multidisciplinary approach in biomaterials and 
regenerative medicine applications, relies on the exponential increase of possibilities 
that have to be tested and validated by trustworthy and effective methodologies. In vitro 
and in vivo testing both converge to establish a ground base for a preliminary biosafety 
criteria that materials aiming clinical application should obey, prior to any human 
contact, either in trials or perspective clinical applications.   
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Resumo 
As estratégias de engenharia do tecido ósseo têm como base a interacção de 
células, biomateriais e biomoduladores, de forma a promoverem a regeneração óssea, 
numa estreita sinergia com o processo regenerativo do hospedeiro. Nestas aplicações, 
apesar de se utilizar uma grande variedade de biomateriais, nenhum dos actualmente 
disponíveis apresenta todas as características desejáveis de um biomaterial de 
regeneração óssea, do ponto de vista bioquímico, mecânico e biológico. Acresce o 
facto de que alguns factores, como a forma e as dimensões do material, a interacção 
com os fluidos e tecidos biológicos, e o tempo estimado de implantação, contribuem 
para a variabilidade das propriedades individuais do biomaterial, no âmbito de cada 
aplicação.  
Deste modo, a caracterização de biomateriais de regeneração óssea, 
nomeadamente no que se refere à avaliação da biocompatibilidade – a capacidade de 
um material desempenhar a sua função terapêutica, sem desenvolver respostas 
adversas a nível local ou sistémico, ao mesmo tempo que induz a resposta mais 
apropriada por parte do organismo – revela-se fulcral no seu sucesso clínico.  
De uma forma geral, o estudo da biocompatibilidade inicia-se com a 
caracterização in vitro, na qual se avalia a citocompatibilidade geral com recurso a 
linhas celulares de fenótipo fibroblástico. Este processo permite uma avaliação 
genérica do comportamento biológico dos materiais, nomeadamente a detecção de 
compostos e/ou componentes citotóxicos ou mutagénicos. No entanto, esta 
metodologia não dispensa uma segunda fase de caracterização in vitro, na qual se 
avalia a citocompatibilidade específica, utilizando culturas primárias ou subculturas 
iniciais de populações celulares relevantes no contexto da aplicação clínica do 
material. No que se refere às aplicações relacionadas com o tecido ósseo, as 
populações mais utilizadas nesta caracterização são os osteoblastos, osteoclastos e 
células endoteliais. 
A caracterização in vitro procura mimetizar as condições observadas in vivo, 
num ambiente estritamente controlado. Este processo providencia um vasto leque de 
informações relativas à possibilidade de inibição ou estimulação da proliferação e/ou 
da actividade funcional. No entanto, a caracterização in vitro, por mais exaustiva que 
seja, não substitui a avaliação do material em questão num sistema biológico, in vivo, 
nomeadamente em modelos experimentais com animais de laboratório.        
A avaliação biológica in vivo permite a caracterização exaustiva do material, 
considerando um leque variado de tempos de implantação, idades, condições 
fisiológicas e patológicas, mimetizando, desta forma, o contexto clínico. A 
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caracterização in vivo permite ainda a avaliação da resposta biológica local e 
sistémica, assim como a apreciação das propriedades mecânicas dos materiais em 
função. Não obstante, deve ser considerado o facto de que estes modelos são apenas 
aproximações mais ou menos fidedignas das condições fisio-patológicas humanas, 
pelo que cada modelo tem vantagens e limitações inerentes. 
Neste trabalho, procedeu-se à caracterização dos processos de 
citocompatibilidade geral e específica de diversos materiais de regeneração óssea, 
utilizando para isso vários modelos de culturas celulares. Os estudos realizados 
incluíram a avaliação da adesão, proliferação e diferenciação das populações 
celulares na superfície de materiais cerâmicos à base de fosfatos de cálcio e de silício, 
biovidros, compósitos, e cerâmicos com modificações da superfície. Foram utilizadas 
diferentes populações celulares, nomeadamente, linhas celulares de origem 
fibroblástica e osteoblástica, culturas primárias ou culturas de passagens iniciais de 
fibroblastos, osteoblastos e células endoteliais humanas. Adicionalmente, a 
problemática da avaliação in vivo do processo de biocompatibilidade foi também 
considerada, no âmbito da utilização do modelo da calote craniana de roedores, na 
avaliação do processo de regeneração óssea. 
O desenvolvimento de novos materiais que visam a utilização clínica em 
intervenções relacionadas com o processo de regeneração óssea é cada vez mais 
sofisticado, em termos de design e metodologias de fabrico. Do ponto de vista 
biológico, os recentes avanços tecnológicos têm permitido o desenvolvimento de 
novas ferramentas de investigação, bem como um melhor conhecimento dos 
mecanismos envolvidos na interacção célula-biomaterial, durante o processo 
regenerativo. O maior desafio deste paradigma, que emergiu da perspectiva 
sinergética e multidisciplinar dos biomateriais e estratégias da medicina regenerativa, 
é o aumento exponencial de hipóteses que necessitam de ser testadas e validadas por 
metodologias adequadas e eficazes. As técnicas de caracterização biológica, in vitro e 
in vivo, permitem assim a definição de critérios básicos de biosegurança subjacentes à 
utilização dos biomateriais em ensaios clínicos. 
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Aim and structure  
The present thesis aims to compile a significant part of the research work in 
which I have been involved as a researcher of the Laboratory of Pharmacology and 
Cellular Biocompatibility of the Faculty of Dental Medicine, University of Porto, since 
2005.  
In the past years I was given the opportunity to develop collaborative work with 
several multidisciplinary research teams that approach the bone tissue regeneration 
process in different ways. All these projects were developed within the range of action 
of the Laboratory of Pharmacology and Cellular Biocompatibility, directed and 
supervised by Professor Maria Helena Fernandes, which is broadly centred in bone 
metabolism and regeneration, reaching hand of in vitro and in vivo methodological 
approaches.  
Overall, the developed work aimed to contribute to a deeper understanding of 
the metabolic regulation of the bone regeneration process and the differentiation 
pathways of cells with an active role on the bone metabolism. Furthermore, a 
significant effort was also put on the assessment of the cytocompatibility and 
biocompatibility of newly developed or modified materials for bone tissue application 
and prospective bone tissue engineering strategies. A collaborative research 
endeavour has been developed with other academic and industrial institutions that 
have been responsible for the conception and production of materials, ranging from 
calcium phosphate and silicon-based ceramics, to glass-substituted materials, 
composites and film-deposited constructs. Close collaborations were established with 
FEUP - Faculty of Engineering, University of Porto; CICECO – Centre for Research in 
Ceramics & Composite Materials, University of Aveiro; DEM – Department of 
Mechanical Engineering, University of Minho; IST - Instituto Superior Técnico, 
Technical University of Lisbon, within the range of national funded research projects by 
FCT – Fundação para a Ciência e Tecnologia and, more recently, in a European 
covenant supported by the European Micro and Nano Technology  program. Within the 
established partnerships, Laboratory of Pharmacology and Cellular Biocompatibility 
has been held responsible for the assessment of the biological characterization of 
developed materials broadly relying on in vitro testing with established cell culture 
models, which further contributed to improve materials‘ properties, based on data 
ascertained during the biological tests. 
More recently, efforts have been directed into the establishment of reliable 
animal models of the bone regeneration process. Accordingly, specific post-graduation 
formation has been enrolled in order to develop specific competencies in Laboratory 
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Animals research. In 2007, the enrolment in the post-graduation course ―Laboratory 
Animals Science‖, organized by the University of Porto, granted the accreditation by 
the National Veterinary Council as a Coordinator Researcher for animal 
experimentation (according to the Federation of European Laboratory Animal Science 
Associations, FELASA, category C guidelines). Later on, in 2009, the enrolment in the 
Master Program in Laboratory Animal Science and Welfare of the Autonomous 
University of Barcelona – which grants the FELASA category D affiliation as a 
Laboratory Animal Science Specialist – was also conducted and is currently under way. 
Meantime, Laboratory Animal research has been developed in close collaboration with 
several research centres, namely UC - University of Coimbra, and UTAD - University of 
Trás-os-Montes and Alto Douro, which account for accredited researchers and 
infrastructures for the establishment of experimental research with laboratory animals, 
according to the National Veterinary Council.    
In a methodological approach, this thesis presents several stages of the 
biological characterization process of biomaterials, namely regarding cytocompatibility 
and biocompatibility analysis, aiming the potential clinical application of the developed 
constructs. A wide range of in vitro methodologies, using several human cell 
populations, namely cell lines of fibroblastic and osteoblastic origin, as well as normal 
primary and early subcultured osteoblasts and endothelial cells are portrayed in detail, 
as included in the assessment of the biological performance of candidate materials. 
Thus, this thesis is composed of eleven chapters. In chapter 1, a generally overview of 
the literature is conducted and focused on bone biology, bone grafts and 
cytotoxicity/biocompatibility assessment of materials for bone tissue regeneration. In 
chapters 2 to 9, several published papers in international referred journals are 
presented, describing a wide range of methodologies used for the in vitro evaluation of 
materials for bone regeneration. Chapter 10 presents a paper recently accepted for 
publication which critically appraises the use of the calvaria defect model in rodents, for 
the assessment of bone regeneration strategies. The last chapter, chapter 11, presents 
the broad concluding remarks, summarizing the most relevant considerations regarding 
the biological characterization of candidate materials aiming clinical application in bone 
tissue regeneration strategies.  
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Foreword 
In the past half century, an explosive growth concerning the clinical use of 
medical implants has been witnessed by clinicians, patients and industry. Orthopaedic, 
cardiac, plastic and oral maxillofacial/dental surgeons are a small example of the 
medical specialities in which implantable devices, such as pacemakers, artificial joints, 
oral implants, synthetic cardiac valves, etc. are used in millions of patients every year. 
The economic burden of treating diseases and problems, directly or indirectly related to 
the loss of tissue function has been estimated to exceed US$39 billion in the USA 
alone [1]. Additionally, the chief challenges of population aging and the increase in life 
expectancy, now substantiates that tissues and organs may be forced into function 
longer than they may be able to independently withstand.  
In order to deal with these concepts, and in cases where pharmacological 
treatments alone have been reported to be scarce, the gold standard approach has 
been the shifting of tissues from healthy anatomical locations into diseased areas, or 
the transplantation of living tissues or organs from other individuals [2]. Despite the 
satisfactory biological results in short to medium term, the donor site morbidity and the 
shortage of compatible donors moved forward early research into replacing stylish 
tissue and organ transplantation with artificially-produced substitutes. To date, tens of 
millions of individuals worldwide have the quality of their life enhanced for as long as 25 
years, by the implantation of developed products [3]. Nonetheless, far from being 
reliable long-standing replacements, early devices behave as temporary devices for 
critically-ill patients, waiting for a more definitive alternative, while more recently 
developed substitutes report improved biofunctionality. Even so, the established 
question of how to solve the tissue/organ transplantation problems and limitations 
remained unanswered. 
         The absence of an adequate biological response by the use of biomaterials alone 
has been attributed to the poor responsiveness, flexibility and reactivity within the direct 
contact with tissues and/or organs. Material scientists alone are not able to solve the 
complex and intricate biological puzzle as the developing biomaterials, by definition, 
aim to interact with and function within living entities. The current strategy to develop 
smart biomaterials relies in their capacity to instruct biological entities to directly or 
indirectly regenerate the damaged tissues. The visionary of this strategy was Larry 
Hench, in the late 1960s; horrified by the multiple limb amputations of thousands of 
Vietnam war survivors, he aimed to produce biomaterials ―to repair people, instead of 
making materials to destroy them‖ [4]. In this respect, he hypothesized that an implant, 
which was composed of calcium and phosphate at a proportion similar to the one of the 
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bone tissue would not be rejected by the organism – indeed Hench verified a direct 
bonding with the host bone tissue following the implantation of the material developed 
by himself (Bioglass®) [5]. 
 Until now, calcium phosphate-based materials are relatively ―old‖ but their ability 
to trigger bone formation in biological systems continues to be unmatched by more 
recently developed approaches. However, ―classic‖ calcium phosphates are not able to 
support or substitute bone biomechanical demands, showing the yet unmet goal of 
developing a synthetic substitute that could account for the complete substitution, and 
simultaneously regeneration of a damaged or lost tissue.  
  Current strategies still follow the premises of Hench and aim to create synthetic 
systems with adequate responsiveness towards the biological milieu. In order to do so, 
the scrutiny of the detailed mechanisms occurring at organs and tissues, and specially 
at biomaterials interfaces – at molecular, cellular and macroscopic level – continues, 
aiming to point out the essential phenomena that can dictate the understanding and 
modulation of the processes occurring at these systems. The knowledge of these 
mechanisms is essential to develop synthetic substitutes that are able to heal and 
report long-term function within the implanted organism. In a natural way, the 
biomaterials field is shifting towards the development of biologically active materials, as 
a way to progress in performance and clinical usage. Complementary approaches have 
combined synthetic biomaterials with cells and/or biological modulators, i.e. in a tissue 
engineering approach, to render tissues with enhanced capacity to play their expected 
biological role [6].    
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Bone tissue 
 In the early times, around some 540 million years ago, and within a timeframe 
of a few million years, the evolutionary pathway lead a massive amount of multicellular 
organisms to begin the production of mineralized structures that were rapidly 
widespread among beings of higher complexity, like molluscs, echinoderms, plants and 
vertebrates. The mineralized structures were developed in order to fulfill specific 
functions. For instance, among vertebrates, apart from the negligible amount of 
magnetite minerals found in human brain that seem responsible for orientation, 
navigation and homing skills, apatitic calcium phosphate minerals are the main body‘s 
mineral component [1]. They are generally present on hard tissues such as bone and 
teeth, whose major functions include structural protection, motion, support and 
mastication.  
The bone tissue is a specialized form of connective tissue that functions both as 
a tissue and an organ system, being the component of the skeleton that is committed 
with the protection, support and motion of the entire organism. Its high flexibility and 
elasticity allows for the protection of vital organs, e.g. skeletal components of the rib 
cage and vertebrae protect the heart, lungs and other organs and/or tissues in the 
thoracic cavity. The stiffness of the bone tissue also contributes to the maintenance of 
the structural support and mechanical action of muscles and tendons, which are 
broadly responsible for movement. At the cellular level, the bone tissue is a productive 
and metabolic active biological entity, i.e. the bone marrow lies within the trabeculae of 
the cancellous bone and is committed with cell proliferation and differentiation, 
including the hematopoietic process. The importance of bone becomes clearer in the 
case of bone-related diseases such as osteogenesis imperfecta, osteoarthritis, 
osteomyelitis, and osteoporosis in which the adequate physiological performance of the 
bone tissue is not attained. These diseases, along with traumatic injury, orthopaedic 
surgeries, and primary tumour resection lead to or induce the establishment of bone 
defects or voids. Nowadays, the clinical and economic impact of treatment of bone 
defects is astounding [2].  
 
Structural and organizational composition 
Structure, physicochemical and biomechanical properties 
 Bone is a complex organ which plays a wide variety of functions within human 
physiology. In its composition several tissues may be found: mineralized osseous 
tissue, marrow, endosteum and periosteum, nerves and blood vessels and, in close 
association, cartilage. The properties of hard tissues, namely in which regards to shape 
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and macrostructure, can be highly determined by genetic, metabolic and mechanical 
factors.  For instance, flat bones, such as the scapula, function as anchors of large 
muscular masses, while, hollow and thick-walled long bones, such as the femur or the 
humerus, basically support weigh [3]. Either way, all bones consist of a basic twofold 
structure, for which its importance is highly correlated with its function. An external 
layer (cortical) of smooth, dense (of around 1.80 g/cm3), and continuous tissue covers 
the bone; while on the interior, the bone reports a cancellous structure, highly porous 
(around 75-95%), and with a mean density of 0.2 g/cm3.  
Cortical bone consists of closely packed osteons or haversian systems. These 
osteons consist of a central canal (harversian or osteonic canal) that is surrounded by 
concentric lamellae of matrix. Between the concentric rings of matrix, bone cells 
(osteocytes) are located deep in distributed lacunae, while small channels (canaliculi) 
radiate from these lacunae into the harversian canal, which in turn can anastomose 
with obliquely oriented vascular branches (Volkmann‘s canals) that establish 
communication between the periosteum and the endosteum [4]. Osteons are closely 
packed in cortical bone and the harversian channel contains blood vessels parallel to 
the long axis of the bone – these vessels interconnect with vessels located on the 
surface of the bone [4]. 
Cancellous bone is less dense and is composed of plates (trabeculae) and 
struts of bone adjacent to small, irregular cavities that home the bone marrow. These 
calcified trabeculae are composed of irregular osteon fragments and are not generally 
penetrated by large blood vessels; in fact, canaliculi connect to adjacent marrow 
cavities – instead of the central harversian canal – to receive blood supply. Trabecular 
organization may appear arranged in a random manner but a meticulous organization 
follows the lines of stress and can realign if the direction of stress changes – providing 
the maximum strength – and a quick response to changes in mechanical loading and 
unloading [4].  
The representation of the structural organization of cortical and cancellous bone 
is depicted on Figure 1. 
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Figure 1 - Schematic representation of the structure of cortical and cancellous bone [5].  
 
Cortical and cancellous bone can include, in their composition, either woven or 
lamellar bone. Woven bone (primary bone) is broadly found during the embryonic stage 
of bone development and is later resorbed and replaced by lamellar bone (secondary 
bone). Woven bone can also be found in epiphysial plates, ear ossicles, during fracture 
healing processes and the closure of cranial sutures. Comparing to the lamellar bone, 
woven bone has a higher metabolic rate, which substantiates an increased turnover 
during the remodelling phase. From a structural point of view, woven bone has a 
scattered and irregular display while lamellar bone is characterized by a highly and 
ordered arrangement whereas the cells are broadly uniform in size, shape and 
orientation [4].     
The mechanical properties of bone patch up high stiffness and elasticity, in a 
way that has not been achieved in any other synthetic material. Cortical bone presents 
a tensile strength in the range of 75-150 MPa and a yield strength of 130-225 MPa in 
compression, in longitudinal direction; in the transverse axis, bone has a yield strength 
of 50-60 MPa in tension and 100-130 MPa in compression [6]. Estimates of the elastic 
module of the bone tissue are within the order of 15-20 GPa in longitudinal direction, 
and 5-15 GPa in the transversal direction [6]. These outstanding properties are the 
result of an intricate milieu of bone‘s microstructure, in which the organic matrix is 
complexly combined with mineral crystals of calcium phosphate-based apatite. These 
crystals are usually oriented in the longitudinal direction of the bone, contributing to the 
higher strength and stiffness in the longitudinal axis [7]. Cancellous bone is more 
isotropic and soft, and its mechanical properties vary widely and seem to be a function 
of the apparent density/porosity of the trabeculae. The strength and modulus of 
cancellous bone vary roughly as the square of the apparent density. Cancellous bone 
is highly viscoelastic and midrange values of the strength range between 5-10 MPa 
and the modulus ranges between 50-100 MPa [6].    
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Bone extracellular matrix      
 The overall extracellular structure of the bone tissue comprises around 90% of 
its volume, with only the remaining 10% being formed by the cellular component. By 
weight, the bone tissue is constituted of approximately 60% mineral content, 30% 
organic content (in which 90% represents collagenous proteins and the remaining 10% 
include proteoglycans and other non-collagenous proteins) and 10% water.  
Collagen molecules are structurally assembled by tropocollagen, the small 
subunit of larger aggregates such as fibrils. It is approximately 300 nm long and 1.5 nm 
in diameter, made up of three polypeptide strands (-chains), each possessing the 
conformation of a left-handed helix [8]. These helices are twisted together into a right-
handed coiled coil, a triple helix, a cooperative quaternary structure stabilized by 
numerous hydrogen bonds. In fibrilar collagens, like collagen type I – by far the most 
abundant in the bone tissue, nevertheless types V, VI, VIII and XII are also present in 
small amounts - triple-helixes associate into a right-handed super-super-coil that is 
referred to as the collagen microfibril [8, 9]. Each microfibril is interdigitated with its 
neighbouring microfibrils to a degree that might suggest that they are individually 
unstable although within fibrilar organization they are so well ordered as to be 
crystalline. Larger fibrillar bundles are formed with the aid of several different classes of 
proteins, glycoproteins and proteoglycans to form the different types of mature tissues. 
Collagen fibrils/aggregates are arranged in different combinations and concentrations 
in various tissues, in order to provide a diverse range of tissue properties. In the bone 
tissue, entire collagen triple helices lie in a parallel, staggered array. Existing gaps of 
approximately 40 nm between the ends of the tropocollagen subunits probably serve 
as nucleation sites for the biomineralization process in which occurs the deposition of 
long, hard and fine crystals of hydroxyapatite [8, 9].  
Several non-collagenous proteins can also be found among the extracellular 
organic component. Among the several, osteopontin (or bone sialoprotein-1, BSP-1), 
bone sialoprotein-2 (BSP-2), osteocalcin and osteonectin play an important role [10]. 
Their exact biological role is far from completely fulfilled but several functions have 
already been adequately established, e.g. osteopontin has RGD sequences that 
facilitate cell attachment and cell signalling pathways that seem particularly relevant 
during osteoclasts anchorage to the mineral matrix of bones [11]; bone sialoprotein-2 
may act as a nucleation site for the initial apatite crystals and, following, as the apatite 
forms along the collagen fibres within the extracellular matrix, BSP-2 could then help 
direct, redirect or inhibit the crystal growth [12]; osteocalcin is a vitamin k-dependent 
protein and is exclusively produced by osteoblasts – it seems to play a role in 
hydroxyapatite crystals‘ nucleation and modulate osteoclasts migration [13]; 
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osteonectin seems to contribute to the initiation of the mineralization and promotes 
mineral crystal formation by expressing several calcium and collagen binding locations 
[10]. 
 Bone matrix also contains proteoglycans (e.g., decorin and biglycan) whose 
exact role is currently being investigated. These proteoglycans seem to play an 
important role in cell behaviour by blocking adhesion motifs from RGD-containing 
molecules and also by actively modulate collagen fibrillogenesis [14]. Bone 
proteoglycans also display selective patterns of reactivity with several bone 
constituents including cytokines and growth factors, namely transforming growth factor-
beta or osteoprotegerin, thereby modulating their bio-availability and biological activity 
in the bone tissue [14]. Bone‘s extracellular matrix also contains glycoproteins, which 
play a distinctive role in cell signalling. Particular examples include fibronectin and 
vitronectin which contain the integrin-binding peptide motif RGD [15].    
   The inorganic component of the extracellular matrix plays an important role in 
the strengthening of the tissue and in ion storing. The chemical structure of human 
biological apatite can be represented as follows: 
 
Ca10-(x-u)(PO4)6-x(HPO4 or CO3)x(OH, F …)2-(x-2u) 
with 0 ≤ x ≤ 2 and 0 ≤ 2u ≤ x 
 
in which (x-u) cationic vacancies and (x-2u) monovalent anionic vacancies coexist [16].  
 In the hard tissues, nucleation of the mineral component generally begins in the 
nanopores of the collagen fibrils – as the microenvironment is supersaturated in 
calcium and phosphate ionic species [17]. The process begins in a heterogeneous way 
and is catalyzed by the presence of phosphate esters and carboxylate groups at the 
surface of the collagen fibrils. The nucleation process is thoroughly developed until it 
embraces the entire collagenous network. The apatitic crystals are quite irregular in 
shape and formed of thin plates within the range of 20 – 1100 Å [18]. Due to the high 
surface area of crystallized minerals, an intimate contact with the extracellular fluids is 
established and allows a rapid ion exchange with these fluids – bone acts as a calcium 
and phosphor reservoir for the body metabolism [19]. A schematic representation of the 
interaction of apatitic crystals and collagen fibrils is presented on Figure 2.     
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Figure 2 – Schematic representation of the apatite-collagen interface in the bone tissue [20]. 
 
Recent nuclear magnetic resonance (NMR) experiments have provided detailed 
information on the nanocrystal composition and thickness, the apatite surface 
composition, water layers at the apatite-collagen interface, and apatite-binding sites of 
collagen [21]. As reported, the carboxylic groups of most glutamates and around a 
quarter of the C-OH moieties of hydroxyprolines, in collagen fibrils, are near the 
interface, at a ~0.5 nm distance from phosphorus in apatite. A layer of viscous H2O 
detected at the organic-inorganic interface may act as "glue" between apatite and 
collagen, providing continuous bonding. This view is supported by large-amplitude 
motions of the interfacial C-OH groups of hydroxyprolines, which make their specific 
binding to apatite surface sites unlikely [21, 22].  
 
Cellular components 
The skeletal tissue is, in essence, composed of five cellular elements: 
osteoprogenitor cells, osteoblasts, osteocytes, osteoclasts and bone lining cells. Cell 
populations can also be classified according to their biological origin and thus, 
osteoprogenitor cells, osteoblasts, osteocytes and bone lining cells are originated from 
mesenchymal cells, while osteoclasts are originated from hematopoietic progenitors. 
 
Osteoprogenitor cells 
Within the osteogenic commitment, mesenchymal stem cells sustain the 
differentiation cascade that generally trails the following sequence: mesenchymal stem 
cell  immature osteoprogenitor  mature osteoprogenitor  pre-osteoblast  
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mature osteoblast  osteocyte or lining cell. The later on the differentiation phase, the 
reduced capacity for self renewal and proliferation [23]. 
Mesenchymal stem cells, in contrast with differentiated osteoblasts or 
osteocytes are migratory and highly proliferative in nature and have a greater 
differentiation potential. Immunofenotipically they are characterized by being uniformly 
positive for SH2, SH3, CD29, CD44, CD71, CD90, CD106, CD120a, CD124 [24]. 
These cells are able to migrate in a substrate or on blood flow by generating cycles of 
weak adhesion, traction, movement and detachment. At the end of the migration stage, 
progenitor cells adhere to the final targeted location by developing strong focal 
adhesion in order to proceed with the differentiation phase [24]. In vitro and in vivo 
reports have shown the capability of these cells to contribute to the regeneration of 
mesenchymal tissues such as bone, cartilage, muscle, ligament, tendon, fat, and 
stroma [24, 25]. Differentiation pathways of mesenchymal stem cells along several 
lineages are presented on Figure 3. 
Inductive agents that cause the entrance into and progression along individual 
lineages such as bone, cartilage, fat and muscle, are known; nonetheless the 
molecular details that govern regulation of each lineage pathway continue to be active 
areas of research.   
 
 
Figure 3 - Schematic representation of the stepwise cellular transitions from the putative mesenchymal 
stem cell (MSC) to highly differentiated phenotypes. Individual lineage pathways are arranged from the 
best comprehended (left) to the least comprehended (right). This simplified scheme does not represent 
all the transitions and complexities of each individual lineage, neither the potential interrelationships of 
cells moving between different pathways (plasticity) [26].  
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Osteoblasts, osteocytes and bone lining cells  
 Osteoblasts are highly differentiated, non-migratory cells that differ significantly 
depending on their stage of development – from which their function and phenotype 
varies and can be divided in several classes, as follows.  
a) Osteocytes – these cells comprise more than 90% of the bone cells in adult 
skeleton [27]. Young osteocytes result from the embedment of mature 
osteoblasts within the non-mineralized bone matrix and share many 
characteristics with these cells [27]. As osteocytes mature, and more matrix is 
deposited and mineralized, these cells become smaller by cytoplasmic loss, 
and trapped in a small lacuna of 1-2 m wide, around the cell. The lacunae 
have collagen fibrils in their composition, which support osteocytes cytoplasmic 
processes that establish a wide network of intracellular contact via canaliculi. 
This complex network, apart from being responsible for cell-mediated exchange 
of minerals, is believed to sense mechanical deformation that modulates bone 
formation or resorption, at a given site [27, 28]. During the resorptive phase, 
osteocytes are processed along with the extracellular matrix by osteoclasts. 
Osteocytes are non-mitotic cells and their turnover is only achieved during the 
remodelling process of the bone tissue.   
b) Bone lining cells – these cells can be found along bone surfaces that undergo 
neither de novo bone formation nor resorption. They are elongated and 
compactly associated by tight junctions or cytoplasmic extensions which also 
connect them to osteocytes. They are metabolically less active than osteoblasts 
and though present fewer cytoplasmic organelles. The biological role of these 
cells has been a centre of interesting debate in the literature. Some authors 
support that, in the presence of parathyroid hormone, these cells secrete 
enzymes that are responsible for the removal of osteoid, preparing the matrix 
for osteoclastic activity [29]; others, substantiate that bone lining cells may be 
activated and enrol osteoblast-like functions [30]. 
c) Inactive osteoblasts – these are elongated cells, morphologically 
undistinguishable from bone lining cells. During bone forming activity, only 
active osteoblasts and their precursors seem to contribute to tissue production 
[31]. 
A schematic representation of osteoblasts functional activity within matrix 
production and mineralization is shown in Figure 4. 
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Figure 4 – Schematic representation of the deposition of bone matrix by osteoblasts apatite-collagen 
interface in the bone tissue [32].  
 
Osteoclasts 
Osteoclasts are giant multinucleated cells that derive from the fusion of several 
hematopoietic precursor cells that differentiate along the monocyte/macrophage 
lineage. They can be found along bone surfaces undergoing resorption and present a 
high mobility profile [33]. Osteoclasts regulate bone resorption process by acidification 
of their microenvironment  – which leads to the dissolution of the mineral component – 
and is followed by an enzymatic degradation of the demineralised extracellular matrix 
[33, 34]. The mature cell is characterized for having 3 to 20 nuclei that tend to be oval 
and concentrated mid-cell. There are numerous mitochondria and lysossomal 
compartments but reduced endoplasmic reticulum, which contribute to the appearance 
of a foamy cytoplasm [33, 34]. The apical pole attaches to the bone matrix by the 
formation of a tight ring-zone of adhesion, known as the sealing zone, location where 
the resorptive actions take place. Integrins αvß3 of the osteoclasts cell membrane 
interact with RGD-containing proteins, initiating signals that lead to insertion, into the 
plasma membrane, of lysossomal vesicles that contain cathepsin K. Consequently, the 
cells generate a ruffled border above the resorption lacuna, into which is secreted 
hydrochloric acid and acidic proteases, such as cathepsin K. The acid is generated by 
the combined actions of a vacuolar H+ ATPase, its coupled Cl– channel, and a 
basolateral chloride–bicarbonate exchanger. Carbonic anhydrase converts CO2 and 
H2O into H
+ and HCO3–. Solubilised mineral components are released when the cell 
migrates; organic degradation products are partially similarly released and partially 
transcytosed to the basolateral surface [33, 34]. A schematic representation of 
osteoclast structure and function is shown in Figure 5. 
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Figure 5 – Schematic representation of the mechanism of osteoclastic bone resorption [35]. Ctsk - 
cathepsin K.  
  
Bone remodelling  
 Bone is a highly vascular, living and dynamic tissue, which is remarkable for its 
hardness and self regenerative capacity. In its extracellular mineralized matrix, bone 
embeds osteocytes that constitute the major cell type in the mature tissue. Vascular 
canals ramify and establish a dynamic network within bone, providing the living cells 
with the needed metabolic support.  
 Unlike other hard tissues, like enamel or dentin, bone is a very dynamic tissue 
and thus, following the initial ossification process of the embryonic skeleton, 
osteoclasts and osteoblasts begin modelling and remodelling processes that generally 
occur simultaneously. Modelling is generally concerned with changes in shape while 
remodelling deals with bone turnover without shape modification. During skeletal 
growth, removal and replacement of the bone tissue proceeds at a rapid pace – in the 
first year of life the rate of turnover of the skeleton approaches 100% per year, 
decreasing to about 10% in the late childhood, and usually continues at this rate or 
more slowly throughout life [36]. After completion of skeletal growth, bone turnover is 
mainly completed through remodelling. This physiological process occurs without 
affecting the shape or density of the bone, through an organized sequence of events 
that include osteoclast activation, resorption of the bone tissue, the reversal phase and 
formation of cement line, osteoblasts activation, and formation of new bone at the 
same anatomical location (Figure 6). The remodelling patterns vary with age, 
associated disease and environmental conditions [36]. 
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 The particularities of the remodelling and modelling processes are very intricate 
and still not fully understood, but one of the key mechanisms by which osteoblasts 
work in concern with osteoclasts is well established and following summarized. 
Differentiated osteoblasts express a transmembranar protein, receptor activator of NF-
B ligand (RANKL), which binds to its receptor RANK on osteoclasts membrane. 
Osteoblasts can downregulate osteoclasts activity through the expression of a 
transmembranar decoy receptor, osteoprotegerin (OPG), which inhibits osteoclast 
binding. Hormonal control can promote osteoclast activity through the elevation of 
RANKL expression. RANK-RANKL interaction not only activates a variety of 
downstream signalling pathways required for osteoclast development, but crosstalk 
with other signalling pathways that also fine-tune bone homeostasis both in 
physiological and pathological conditions [37].  
 
 
Figure 6 – Schematic representation of the sequence of bone remodeling in healthy individuals [38]. LC – 
bone lining cells; OC – osteoclasts; OB – osteoblasts; OS – osteoid; BRU – bone remodeling unit. 
 
Regulators of bone metabolism 
 The source of the signalization process that determines bone modelling and 
remodelling relates to three broad functions of the skeletal tissue, i.e. homeostasis, 
haematopoiesis and mechanical, but not with the forth function, protection. 
Homeostasis in the skeleton is broadly concerned with the regulation of calcium and 
phosphate levels. Calcium plasma concentration averages about 9.4 mg/dL (generally 
between 9.0 and 10.0 mg/dL) whereas phosphate is present in two anionic forms – 
divalent and univalent anions – at concentration levels of 1.05 mmol/L and 0.26 
mmol/L, respectively [39]. The titration of a regulated calcium concentration is achieved 
through feedback loops in which the liver, the kidney, 1,25-dihydroxy vitamin D3 and 
parathyroid hormone (PTH) participate, as well as with the intestinal epithelium – where 
calcium is reabsorbed via the interaction with a calcium binding protein [39]. Phosphate 
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is a threshold ion, regulated by the kidney, where increased secretion occurs with the 
boost of PTH expression [39].   
 In response to homeostatic demands, cells of the basic remodelling unit (BRU) 
– the multitude of cell phenotypes responsible for remodelling a specific anatomical 
location – can be sensitized by 1,25-dihydroxy vitamin D3, calcitonin, glucocorticoids, 
estrogen, androgen, PTH, growth hormone, and thyroid hormones [36]. PTH and 1,25-
dihydroxy vitamin D3 stimulate resorptive processes and are countered by calcitonin, 
which inhibits resorption – nonetheless, interactive mechanisms are still not completely 
understood. Overall, the key systemic signal for bone is estrogen,  as a decline in this 
hormone causes resorption to outstrip formation, bone mass falls, converging to a 
clinical diagnostic of osteoporosis [40]. Estrogen is synthesized from testosterone and, 
with the advance of age, an increased level of PTH and a decrease in estrogen may 
evoke the increased expression of pro-inflammatory cytokines such as IL-1, IL-6, TNF-
a and RANKL [40]. Estrogen depletion induces the apoptosis of osteocytes and can 
cause bone loss [41]. 
 Local humoral regulators of the bone metabolism seem to include bone 
morphogenic proteins (BMPs), fibroblastic growth factor, insulin-like growth factor, 
transforming growth factor- and platelet-derived growth factor, for formation, and 
granulocyte macrophage colony-stimulating factor and interleukins -1, -4, -6, -11, -13, -
18 and macrophage colony-stimulating factor leading, for resorption [42]. Nonetheless, 
this dichotomy is not absolute and some controversies and contradictory data have 
been reported; for instance, transforming growth factor-, in determined situations, can 
induce both formation and resorption. Among local factors, hematopoietic signals, 
namely cytokines and chemokines, secreted in response to local phenomenon – such 
as inflammation – can also influence bone homeostasis.  
Osteoblasts also produce a fundamental enzyme, alkaline phosphatase (ALP), 
which is expressed in matrix vesicles also containing calcium and phosphorous. This 
enzyme is ubiquitous in bone, liver, kidney, intestine and placental tissues and seems 
to play a determinant role in the induction of hydroxyapatite deposition over 
extracellular matrix proteins. ALP facilitates the biomineralization process by 
hydrolyzing organic phosphate esters, thus producing an excess of free inorganic 
phosphate which initiates the biomineralization process [43]. Although ALP activity is 
an excellent local and systemic marker of osteodifferentiation and mineralization, the 
exact mechanism of action is still not fully understood.  
 Apart from the local and systemic determinants, cells must detect signals to 
elicit a biological response. Remodeling is thought to be initiated by the detection of the 
mechanical stress – the trigger is the deformation of bone due to load (fatigue-demand 
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bone deformation) [44]. The sensor for bone deformation is thought to include the 
osteocyte-bone lining cell complex but it is still unclear how messages are trafficked 
throughout the skeleton [45].  
   
Bone grafts and bone Tissue Engineering 
 A bone graft is a tissue or material used to repair a defect or deficiency in 
contour and/or volume of the bone tissue. There is a wide range of opinions regarding 
what particulate materials should be employed in each clinical procedure, the rationale 
behind its aplication, the rationale for using combinations of materials, and the fractions 
of each material used [46]. The available options for clinical application in orthopaedic, 
trauma, maxillofacial and oral surgical interventions aim to restore the lost integrity and 
function of the skeletal system. The use of these materials in regenerative procedures 
is based on the assumption that they possess osteogenic potential (contain bone-
forming cells), are osteoinductive (contain bone inducing substances), or simply are 
osteoconductive (provide a structure to guide bone formation). Overall, used grafts 
report fundamental biological and biomechanical functions that converge to establish 
an adequate framework for specific cell adhesion, proliferation and differentiation, that 
focus tissue healing.  
 General classification of clinically used bone grafts is established according to 
their origin. Thus, biological-derived grafts can be subdivided in autografts, if the 
grafted tissue is transplanted from one site to another within the same individual; 
isografts, if transferred from one monozygotic twin to another; allografts, if the grafted 
tissue is transferred between two genetically different individuals of the same species; 
and xenografts, if the grafted tissues is obtained from a donor of a different species. 
Moreover, synthetic grafts, also known as alloplastic materials, are non-biological in 
their origin and include a wide variety of prepared ceramic, metallic, polymeric and 
composite materials. Combination of more than one type of biological graft and/or 
alloplastic material is getting increasingly common.  
 
Bone autografts 
Currently, bone autografts remain as the gold standard treatment for bone-
related clinical settings that require bone augmentation or regeneration procedures that 
are outshined by the boundary of physiological repair. Autograft bone reports the 
unique capacity to supply cells, biomodulators and a reliable matrix that supports cell 
adhesion and growth, as well as an adequate degradation profile. In fact, it provides 
optimal osteoconductive, osteoinductive and osteogenic properties, at the same time 
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that reports an established biosafety and prevention of immunologic rejection [47]. 
Clinical procedures includes the grafting of the bone tissue, either of cortical or 
cancellous structure, from the donor site of the patient, being the most frequently used 
donor site the iliac crest. Nonetheless, many other anatomical locations are being 
used, including intra-oral sites [48]. 
 Harvesting of autologous bone, however, has several associated downsides as 
it lengthens the overall surgical procedure, outputs a limited amount of available 
material,  and is commonly complicated by post-operative pain and 
aesthetical/functional disadvantages [49, 50]. Moreover, it may fail in clinical application 
as most of the osteogenic elements – the cellular component – may not survive the 
transplantation procedure [51]. Other potential complications associated with bone 
autografts are associated with the anatomical location, and may include haematoma 
formation, blood loss, vascular and nerve injury, hernia formation, infection, uretal 
injury, fracture, pelvic instability, aesthetical defects, tumour transplantation and chronic 
pain [52-54].   
 
Bone allografts 
The clinical use of allografts aimed to solve some of the limitations verified with 
the use of autograft materials, since they have become more and more available. In 
fact, more than one-third of the bone grafts used in North America are allografts [55]. 
Nonetheless, allograft bone reports more biological limitations in the essential bone 
graft characteristics described for autografts and yield more variable clinical results. 
Clinical studies have shown that allograft-based tissue reconstruction tends to 
incorporate and heal more slowly than with autografts, mainly due to the 
immunoresponse against histocompatibility antigens [56]. Apart from the risk of 
immunological intolerance that may converge to graft rejection,  allografts carry the risk 
of disease transmission, namely of bacterial or viral origin [57].  
The implementation of tissue processing aimed to allow off the shelf use and 
minimize the biological risk but, at the same time, induced significant changes that 
weakened the biological and biomechanical properties. Furthermore it is associated 
with an increase in cost production [58]. Accordingly, fresh allograft bone is practically 
out of use due to the inadequate time for disease screening. Allograft bone, either from 
cortical and cancellous origin, is generally prepared by demineralising, freeze or 
freeze-drying processes.  
Demineralized bone matrix is produced by the acid extraction of allografts. The 
remaining biological material generally contains, following acid treatment, collagen type 
I, non-collagenous proteins and osteoinductive growth factors, mainly from the TGF- 
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superfamily [59]. Several animal models have shown the plausibility of the 
osteoinductive effect of implanted demineralised bone matrix, as well as isolated case 
reports and uncontrolled retrospective reviews. Nevertheless, there is a generalized 
paucity of clinical studies with high evidence level [60, 61]. There are several bone 
matrix formulations, commercially available, based on developed refinements of the 
manufacturing process.  
Frozen grafts are generally stored at temperatures below -60ºC, which aims to 
decrease the enzymatic degradation process and self immunological response. 
Freeze-drying technique is based on the removal of the water from the graft, following 
by packaging under vacuum – which allows storage at room temperature. 
Nevertheless, these grafts report a less vigorous host immunological response than 
that described for fresh or fresh-frozen grafts, mainly due to the destruction of cellular 
content – situation that also limites the osteoinductive capacity [62]. As for 
demineralised bone matrix, freeze and freeze-drying allografts can be produced in a 
diverse array of shapes and formats including powder, chips, wedges, pegs, dowels, 
struts, and can even be machined into specific components like rods or screws.   
Sterility is a major issue in the clinical use of allografts, highlighting the 
conscious need for aseptic processing and careful donor screening. Tissue processing 
and sterilization aim to increase the biosafety of the graft, nevertheless the existing risk 
of transmission of viral infections –  namely HIV and hepatitis B and C – bacterial 
infections, malignant diseases, systemic diseases (e.g. autoimmune diseases) and 
toxins [63]. Accordingly, a research report of the evaluation of candidate tissue for 
allograft banking reported a 8% prevalence of associated diseases – including 
malignant tumours – not previously diagnosed [64].   
 
Bone xenografts 
 The clinical use of xenografts became increasingly popular in clinical application 
due to the wide availability and the possibility to be mixed with autografts or allografts, 
in order to augment graft quantity and modulate the eventual precocious resorption 
associated with the use of these materials [65].  
  Bone xenografts can be obtained from different origins but the most frequently 
available derive from mammalian bone (bovine, porcine and equine origin) and 
exoskeleton of corals. These grafts are considered to be biocompatible and 
osteoconductive. Nonetheless, safety issues, namely regarding the possibility of the 
development of immunological response against specific animal antigens and the 
development of bovine spongiform encephalopathy, following implantation of bovine-
derived grafts, have been reported [66, 67].  
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Alloplastic biomaterials 
Advances in the field of biomaterials and the limitations associated with the use 
of biological-derived grafts have directed attention toward the use of alloplastic graft 
materials in bone-related surgical interventions. An historical perspective shows that 
attempts to replace body parts, specifically hard tissues, dates back from centuries ago 
with the use of several synthetic materials. For instance, pre-Columbian civilizations 
used gold sheets to heal cranial cavities following trepanation, while Chinese reported 
the use of amalgam to repair decayed teeth in 659 AD. Many other attempts to create 
implantable materials have been carried out but generally lead to failure as a result of 
infection or lack of knowledge about toxicity of selected materials [68]. The safety in the 
use of materials to replace diseased body parts was only achieved with the practice of 
aseptic surgery at the end of the 19th century. 
Early used materials included metals and non-degradable ceramics, due to their 
superior mechanical properties, namely regarding resistance to fatigue and high tensile 
strength [69]. In fact, until the 1960s, materials used to replace or substitute body parts 
were borrowed from industrial applications, and some of them are still used in clinical 
practice. Since the 1960s, a trend to develop specific materials for biomedical 
applications was established [68].             
In spite of their composition or intended application, materials aiming to contact 
with living tissues must assemble both the aspects of biofunctionality and 
biocompatibility. The concept of biofunctionality concerns the capacity of the implanted 
material to perform the purpose for which it was designated. These requirements 
include: a) adequate mechanical properties, e.g. fatigue strength, elongation at 
fracture, fracture toughness, tensile strength, Young‘s module, etc.; b) adequate 
physical properties, such as the thermal expansion (in bone cements) and density (in 
bone implants); c) adequate surface chemistry, e.g. corrosion, oxidation, bone bonding 
ability, degradation resistance, etc. [68, 70]. Biocompatibility, on the other hand, is 
defined as the ability of a candidate biomaterial to perform its desired therapeutical 
function, without eliciting any undesirable local or systemic response, but engendering 
the most appropriate beneficial response in that specific situation [71].  
Various types of synthetic materials have been developed in order to meet the 
terms of the proposed characteristics of biofuncionality and biocompatibility. General 
classification is established as follows: a) Metals – such as titanium, titanium alloys, 
stainless stell, cobalt-chromium alloys; b) Ceramics – such as aluminium oxide, carbon, 
calcium phosphates and glass-ceramics; c) Polymers – such as silicon, polymethyl 
methacrylate, polylactide, polyurethane, polyethylene; and d) Composites – such as 
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ceramic coatings on metal implants and ceramic-reinforced polymers. Commonly used 
materials and their application are depicted on Table 1.    
The selection of one specific material over another will depend on the 
application and biological solicitations that need replacement. Regrettably, none of the 
described materials meets all the requirements for all desired applications. For 
instance, for load bearing applications, metals seem to be the only group of materials 
to meet the mechanical requirements. However, they have a limited capacity to 
establish a direct bond with bone tissue, comparing to other materials such as calcium 
phosphates, which have strong bone-bonding capacity but insufficient mechanical 
properties [72, 73].  
 
Table 1 – Biomaterials clinically used for bone and related soft tissue repair. Adapted from [68, 74]. 
Composition Type Origin Clinical applications Main properties 
Calcium phosphate, i.e. 
hydroxyapatite, tricalcium 
phosphate, etc. 
Ceramic Synthetic Bone regeneration, non-
loading sites, filler 
Bone bonding, 
biodegradable, 
tunability of 
degradation 
Alumina Ceramic Synthetic Joint replacement Good mechanical 
properties, non-bone 
bonding 
Silica-based calcium 
phosphate 
Glass 
ceramic 
Synthetic Bone regeneration, non-
loading sites, filler 
Bone bonding, 
biodegradable 
Titanium and alloys Metal Synthetic Bone replacement, load 
bearing sites 
Bone connection in 
some cases, non-
corrosive, resistance to 
fatigue  
Stainless steel and Cobalt 
chrome alloys 
Metal Synthetic Bone replacement, load 
bearing sites 
Corrosive at long term 
Polymethylmethacrylate Polymer Synthetic Bone replacement, load 
bearing sites, filler  
Non-degradable 
Polyesthers, i.e. 
polylactide, polyglycolic 
acid, polycaprolactone 
Polymer Synthetic Degradable bone 
fixation, filler, soft tissue 
suture 
Tunability of 
degradation and 
mechanical properties 
Ultra high molecular 
weight polyethylene 
Polymer Synthetic Articular surfaces of 
orthopaedic prosthesis, 
load bearing sites 
Lubricating properties 
Polyethylene oxide, 
terephtalate, cobutylene 
terephtalate 
Co-polymer Synthetic Cement stopper, filler Tunability of 
degradation and 
mechanical properties, 
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bioactivity 
Polyphosphazene Polymer Synthetic Drug delivery Erosion/degradation 
favourable for long 
term implantation 
Polyanhydride Polymer Synthetic Drug delivery, tissue 
repair 
Erosion/degradation 
favourable for long 
term implantation 
Polyorthoesters  Polymer Synthetic Drug delivery, tissue 
repair 
 
Polyethyleneglycol Polymer Synthetic Drug delivery, tissue 
repair 
Water-based gel, 
degradable 
Coral Mineral Natural Bone filler Similar composition to 
host bone 
Bone Composite 
mineral / 
organic 
Natural Bone filler Similar composition to 
host bone 
Demineralized bone 
matrix 
Organic Natural Bone filler Biodegradable, natural 
source of 
osteoinductive agents 
Collagen Organic Natural Hard and soft tissue 
repair 
Biodegradable 
Hyaluronic acid Organic Natural Soft tissue repair Biodegradable, water-
based gel, injectable 
Alginate Organic Natural Soft tissue repair Drug delivery 
capabilities, 
degradable  
Agarose Organic Natural Soft tissue repair Drug delivery 
capabilities, 
degradable 
Chitosan Organic Natural Soft tissue repair Biodegradable 
Fibrin Organic Natural Soft tissue repair Sealing capacity 
 
Tissue engineering applications and materials for tissue engineering  
 The recent years have witnessed a surge of creative ideas and technologies 
that induced a paradigm change in the problematic of tissue repair/regeneration, 
specifically within hard tissues regeneration. Accordingly, a new field of healthcare 
technology, substantiated by developments in basic and clinical sciences, have 
emerged and has now been referred as tissue engineering. The classic definition of 
tissue engineering has been established by Langer and Vacanti as ―an interdisciplinary 
field that applies principles and methods of engineering and the life sciences towards 
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the development of biological substitutes that restore, maintain and improve the 
function of damage tissues and organs‖ [75].  
The fundamentals of tissue engineering rely on the body‘s natural biological 
response to tissue damage in conjunction with engineering principles. The basic 
approach for bone tissue relies on the harvest and ex vivo expansion of selected cell 
populations – in the presence of adequate biomodulators - that are following seeded 
onto a scaffold where cell proliferation and/or differentiation events occur, previously to 
the surgical implantation into the defined bone defect (Figure 7). 
As the role of cell signalling and subsequent functionality emerges with greater 
clarity, the quest for the ideal scaffold continues, specifically for one presenting a 
physicochemical biomimetic environment, while biodegrading as native tissue 
integrates and actively promotes or prevents desirable or undesirable physiological 
responses, respectively [76]. To address these biomimetic requirements, a bone 
scaffold for tissue engineering applications should [77]: 
 provide temporary mechanical support to the affected anatomical location; 
 allow for osteoid deposition; 
 be highly porous in order to facilitate 
vascular and bone tissue ingrowth; 
 facilitate the homing of 
osteoprogenitor cells; 
 support and promote the osteogenic 
differentiation (osteoinduction); 
 enhance cellular activity towards 
scaffold-tissue integration 
(osteointegration); 
 degrade in a controlled and timely 
fashion in order to facilitate load 
transfer to de new developing 
tissue; 
 generate non-toxic degradation 
products; 
 do not induce adverse biological 
reactions following implantations, 
e.g. chronic inflammatory response, 
foreign body reaction; 
 be easily sterilizable without loss of biomechanical properties; 
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and 
 allow the controlled release of bioactive molecules or drugs to facilitate tissue 
healing or prevent pathology establishment.  
 
Materials aiming to be used in tissue engineering applications must adequately 
interact with cells and culture media in vitro, prior to their clinical implantation. 
Additionally, prepared scaffolds (solid porous structures) and matrices (gel-like 
structures) must assure the hostage of enough cells and support their viability for an 
adequate period of time [78]. 
 Several natural-based materials have been assayed as potential sources of 
scaffolds/matrices for tissue engineering applications. Nonetheless they were able to 
support cell viability and in the adequate microenvironment, cell proliferation and 
differentiation, natural matrices such as hyaluronic acid, fibrin, alginate, chitosan and 
collagen seem to be unable to endure body‘s loading conditions although the attributed 
satisfactory biocompatibility [79]. Furthermore, in determined clinical applications, the 
defect borders may degrade if the defect is not filled with a material with mechanical 
properties similar to those of the host tissue [80] and, even more, some materials – 
namely esterified hyaluronic acid and fibrin – have sporadically demonstrated 
undesirable effects over the host tissue and its repair processes [81]. Natural minerals 
such as demineralized bone matrix, coral- and bovine bone-derived materials are also 
used in tissue engineering applications, providing efficient porosity and 
interconnectivity for cell growth and differentiation, as well as suitable mechanical 
properties for load bearing applications [82, 83].  
Apart from natural derived materials, several synthetic matrices and scaffolds 
have been developed for tissue engineering purposes. Synthetic materials based on 
calcium phosphate constituents and bioactive glasses exhibit excellent bone-bonding 
properties and processes of biological degradation that have contributed to the clinical 
success of more than 40 years [84]. Several materials have been developed and 
successfully used in clinical environment, including: hydroxyapatite, tricalcium 
phosphate, bicalcium phosphate brushite and octacalcium phosphate. As porous 
structures, they are suitable candidates as scaffolds. Additionally, synthetic polymer 
hydrogels have shown promise behaviour nonetheless the limited biocompatibility 
issues and general low mechanical stability [85]. Among polymers, most of the assayed 
materials for these applications belong to the poly(-hydroxy esters) family, including 
polyglycolic acid, polylactic acid and their copolymers that have shown to adequately 
support cell guided growth and differentiation. However, some biocompatibility issues 
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have arise from the produced acidic degradation that is expected to induce an adverse 
biological response [86].    
Notwithstanding the relative simplicity of the (re-)construction of a single-cell 
type tissue, it is clear that currently used technologic advances for the repair of the 
skeletal tissues are generally unsatisfactory and require the development and 
implementation of new approaches for the achievement of the desired clinical 
objectives. Among the currently developed techniques to the repair of damage tissues, 
the immobilization and transplantation of cells on carried scaffolds, or tissues grown in 
vivo or ex vivo, have been assayed. To this end, extensive research has been 
developed in evaluating the range of cell sources, materials for cell transplantation, as 
well as material design that can be used to immobilize cells and support gradual neo-
tissue formation, at the same time that a programmed degradation occurs. In this 
regard, the assessment of a biomaterial biocompatibility outputs a two-way approach: 
in one hand allows the fundamental assessment of a biomaterial behaviour in contact 
with cells and/or tissues in order to make assumptions of its applicability in clinical 
scenario; on the other hand, in vitro cell culture studies allow to preliminary access the 
results of candidate tissue engineering applications, since orthotopic cells are generally 
used for biocompatibility testing and provide data regarding cell proliferation and 
differentiation events.     
 
Biocompatibility assessment in bone regenerative strategies 
 Materials used in medical devices and tissue engineering constructs, namely 
those which aim to contact, be inserted or permanently implanted in the body, are 
broadly described as biomaterials and have unique design requirements. The National 
Institute of Health Consensus Development Conference defined a biomaterial as ―any 
substance (other than a drug) or combination of substances, synthetic or natural in 
origin, which can be used for any period of time, as a whole or as a part of a system 
which treats, augments, or replaces any tissue, organ, or function of the body‖ [87]. 
 The individual and specific requirements of each biomaterial are determined by 
the selected application and functionality of the device. In a generic approach, 
biomaterials can be used in: 1) blood-contacting applications, e.g. external devices that 
remove and return blood from the body, devices that are inserted into a blood vessel, 
or devices that are permanently implanted; 2) soft-tissue device applications, e.g., 
materials aiming the augmentation of soft-tissues; 3) hard-tissue device applications, 
e.g., applications for joint, bone, and tooth replacement and repair; 4) specific organ 
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applications, e.g., neural, pancreatic and liver; and 5) scaffolds for tissue engineering 
aiming tissue and organ replacement/regeneration [88]. 
 The material‘s form and size, the close interface with body fluids and/or tissues, 
and the duration of use will also determine its required properties. Overall, one material 
property alone is unlikely to lead to a successful and durable device, whereas a lack of 
inadequacy regarding a single key property, can lead to a disastrous failure. 
Accordingly, materials aiming biological functions need to meet basic biocompatibility 
requirements, generally substantiated in the ISO 10993 standards (Table 2). This is, to 
be nontoxic, non-thrombogenic, non-carcinogenic, non-antigenic, and non-mutagenic 
[89].   
 
Table 2 - International ISO standards for biological evaluation of medical devices [90]. 
Reference Title 
ISO 10993-1: 2009 Evaluation and testing within a risk management process   
ISO 10993-2: 2006 Animal welfare requirements 
ISO 10993-3: 2003 Tests for genotoxicity, carcinogenicity, and reproductive toxicity 
ISO 10993-4: 2002 Selection of tests for interactions with blood 
ISO 10993-5: 2009 Tests for in vitro cytotoxicity   
ISO 10993-6: 2007 Tests for local effects after implantation   
ISO 10993-7: 2008 Ethylene oxide sterilization residuals   
ISO 10993-8 Withdrawn: Clinical investigation of medical devices – updated by ISO 14155 - Clinical 
investigation of medical devices for human subjects 
ISO 10993-9: 2009 Framework for identification and quantification of potential degradation products   
ISO 10993-10: 
2010 
Tests for irritation and skin sensitization   
ISO 10993-11: 
2006 
Tests for systemic toxicity 
ISO 10993-12: 
2007 
Sample preparation and reference materials   
ISO 10993-13: 
2010 
Identification and quantification of degradation products from polymeric medical devices   
ISO 10993-14: 
2001 
Identification and quantification of degradation products from ceramics   
ISO 10993-15: 
2000 
Identification and quantification of degradation products from metals and alloys   
ISO 10993-16: 
2010 
Toxicokinetic study design for degradation products and leachables   
ISO 10993-17: 
2002 
Establishment of allowable limits for leachable substances   
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ISO 10993-18: 
2005 
Chemical characterization of materials   
ISO 10993-19: 
2006 
Physico-chemical, morphological and topographical characterization of materials   
ISO 10993-20: 
2006 
Principles and methods for immunotoxicology testing of medical devices   
 
In vitro testing 
The assessment of the biocompatibility of a product and/or its components 
based on ISO 10993 offers a ―horizontal‖ approach that, for practical use, offers 
different starting points, potential applicable to the vast majority of the developed and 
developing medical devices. In vitro testing is highly regarded within cytocompatibility 
assessment, offering the opportunity to test early in product development since 
potential toxicity can be assayed and therefore expensive and undesirable 
development work can be circumvented. Moreover, it allows for a rapid biological 
evaluation, uses standardized protocols and produces quantitative and comparable 
data [91]. Additionally, marketed products can be regularly tested with regards to 
cytotoxicity, monitorization in the production process and identification of breaches in 
disinfection and sterilization procedures.  
In vitro characterization methodologies, based on established cell cultures, 
allow for a strict controlled environment which has shown some advantages and 
limitations in its application to biotechnology (Table 3). 
 
Table 3 – Advantages and limitations of cell culture. Adapted from [92].  
 Category Issue 
Advantages Physicochemical environment Control of pH, temperature, osmolality, etc 
 Physiological conditions Control of nutrients and biomodulators concentrations 
 Microenvironment Regulation of the cell-cell and cell-matrix interaction 
Regulation of the gaseous diffusion  
 Cell line homogeneity Cloning capability which enhances reproducibility of the 
assay   
 Characterization 
Replicates and variability 
Quantitative and qualitative data can be assessed 
Specific characterization techniques like cytology and 
immunostaining are easily performed 
 Preservation High life span in adequate freezing conditions 
 Validation and accreditation Origin, history, purity can be authenticated and 
recorded 
Limitations Necessary expertise Sterile handling 
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Risk of chemical and microbial contamination  
Cross-contamination 
 Environmental control Workplace 
Incubation, pH control  
Containment and disposable of biohazards 
 Quantity and cost Capital equipment 
Disposable plastics 
Cell culture reagents, specific media, serum, molecular 
biology assays 
 Genetic instability Heterogeneity, variability 
 Phenotypic instability Dedifferentiation 
Adaptation 
Selective overgrown 
 Cell type identification Markers are not always expressed 
Morphology and microenvironment changes cytological 
responses 
 
Nonetheless the stated advantages and limitations, the development of 
adequate standards regarding in vitro models of cytocompatibility has been conducted 
not without associated precincts which broadly include the discernment of the relevant 
biological reactions for which simulation assays can be devised; and the critical design 
of tests and assays that are moderately easy to perform in laboratory and allow for 
consistent data gathering throughout time, and among repeated procedures. 
Accordingly, moreover than a basic cytotoxic evaluation, in vitro testing ought to allow 
data assessment of a wide range of biological processes which converge to 
substantiate the cytocompatibility characterization. Experimental studies have 
demonstrated the good correlation between in vitro and in vivo tests, thus confirming 
the usefulness of the in vitro test as systems to biologically evaluate materials aiming 
clinical application. 
Cells, in vitro, are generally more sensitive to toxic materials than in vivo 
tissues. In this line of thought, a material toxic in vitro may result not particularly toxic 
for the tissues in vivo, while a material harmless to the cells, even in long-lasting 
assays, is likely to be also toxically inert in vivo. A different picture is seen when a 
material releases wear debris or corrosion particles; reactive processes can be 
triggered, with the risk of loosening the implant and progress to a complete failure of 
the regenerative process [91].    
Methods for direct and/or indirect cell contact can be used depending on the 
nature and duration of the device contact with the biological systems. Either way, a 
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combined execution of direct and indirect cell contact tests can more adequately 
substantiate the biological characterization process [93]. An adequate selection of the 
test series to be performed, oriented to the product particularities, and taking into 
account the specificities of sample preparation, are of the utmost relevance. Moreover, 
positive and negative controls are ought to be used, wherever possible, to assess the 
effect of the candidate material compared to controls.  
Three fundamental cell culture assays are used for evaluating cytocompatibility: 
direct contact, agar diffusion and elution - extract dilution - (Table 4). The three testing 
methodologies vary in the manner in which the material contacts with the in vitro 
system as it can be placed directly in close contact with cells or extracted in an 
appropriate solution that is subsequently placed in contact with the cultured cells.  
 
Table 4 – Advantages and disadvantages of cell culture methods for biocompatibility assessment. 
Adapted from [94]. 
 Advantages Disadvantages 
Direct 
contact 
- Eliminates extraction preparation 
- Allows the assessment of a zone of diffusion 
- Target cells are able to directly contact the 
material 
- Mimics physiological conditions 
- Standardize amount of test material or test 
indeterminate shapes 
- The exposure time can be controlled 
- Cellular trauma if the material moves 
- Cellular trauma with high density materials 
- Decreased cell populations with potential 
highly soluble toxicants  
Agar 
diffusion 
- Eliminates extraction preparation 
- Allows the assessment of a zone of diffusion 
- Better concentration gradient of potential 
toxicants 
- Independent of the material density 
- Requires flat surfaces 
- Risk of thermal shock during agar 
preparation 
- Limited exposure time 
- Risk of water absorption from agar 
Elution 
- Separates extraction from testing 
- Dose response effect 
- Extend exposure time 
- Control of the extract conditions 
- Choice of the solvents 
- Additional time and steps 
 
In order to allow reproducible and comparable results between assays, several 
variables, namely the number of seeded cells, growth phase of the cells, cell type and 
population, duration of exposure, test sample size, geometry, thickness, shape and 
surface area, must be carefully controlled. Bearing in mind these particularities, and 
within the quantitation range of the selected assays, varying slopes of the dose-
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response curve or exposure-effect relationship are expected to occur with different 
cytotoxic agents, in a manner hopefully related to animal bioassays [95].   
In a preliminary approach, cell lines that have been developed for facilitated 
growth in vitro are preferably used in detriment of primary or serial passage cell 
cultures established from biological tissues, since cell lines improve the reproducibility 
of the data gathered and the variability among laboratories [96]. Cell lines maintain 
their genetic, metabolic and morphological characteristics throughout the extended life 
span. For instance, L-929 mouse fibroblasts have been used most extensively for 
biomaterials testing due to the easy maintenance in culture and the ability to output 
results that are highly correlated with specific in vivo bioassays [97]. Moreover, 
fibroblasts have been broadly chosen since they are one of the early cells to populate 
the wound healing location and are often the major cell population in tissues that 
contact to the implanted devices.  
In the screening stage, the functions shared by all types of cells are 
investigated, which generally include the assessment of the metabolic activity (e.g., 
MTT and Alamar blue assay), cell viability (e.g., neutral red uptake, propidium iodine 
staining) and cell proliferation (e.g., cell counting, total protein content, DNA assay, 3H-
TDR uptake) [96]. Moreover, morphology assessment is also generally conducted by 
reaching hand of scanning electron microscopy or confocal laser scanning microscopy, 
following adequate cell staining [91, 96].  
In the supplementary tests for the assessment of the specific cell functionality in 
the presence of the medical device, cell lines from other tissues may also be used and 
generally, cell populations of the tissues that the medical device aims to contact with, 
are selected [96]. In which relates to the assessment of the biocompatibility of bone-
related materials and medical devices, not only osteoblastic, but also osteoclastic and 
endothelial cells are broadly used to study the specific biomaterial/cell interaction.  
A sufficient amount of bone cells is easily available, most of them being 
osteoblast-like cell lines derived from mouse, rat or human osteosarcomas (UMR-106, 
MC3T3-E1, ROS17/2.8, SAOS-2, HOS and MG-63) [98]. Osteogenic sarcoma cells 
retain many markers of the osteoblastic phenotype but differ from physiological bone 
cells in their functional activity, responsiveness to external agents and expression of 
surface molecules [99, 100]. The choice to use a continuous cell line, in spite of finite 
cell line derived from tissue-established primary cultures, should be carefully 
deliberated bearing in mind the specificities and the objectives of the test. Properties of 
both cell populations are presented on Table 5. 
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Table 5 – Properties of finite and continuous cell lines. Adapted from [101].  
Properties 
Cell line derived from a 
biological tissue-established 
primary culture (finite) 
Transformed cell line 
(continuous) 
Ploidy Euplod, diploid Aneuploid, heteroploid 
Transformation Normal Immortal, alterations in growth 
control and chance of 
tumorogenicity 
Anchorage dependence Yes No 
Contact inhibition Yes No 
Density limitation of the cell 
proliferation 
Yes Reduced or lost 
Mode of growth Monolayer Monolayer or suspension 
Maintenance Cyclic Steady state possible 
Serum requirements High Low 
Cloning efficiency Low High 
Markers Tissue specific Chromosomal, enzymatic, antigenic 
Special functions (e.g., virus 
susceptibility, differentiation) 
May be retained Often lost 
Growth rate Slow (TD of 24 – 96h) Rapid (TD of 12 – 24h) 
Yield Low High 
 
Tissues broadly used to obtain osteoblastic cells for a large variety of 
experimental set-ups include cancellous bone specimens from human or animal origin, 
as well as calvaria bone from foetal or neonatal animals. Bone cells can be obtained 
from bone by enzymatic digestion or from outgrowth of bone explants [102]. Human 
first passage cells derived from cancellous bone have been characterised and shown 
to possess a phenotype that is clearly distinct from that of fibroblastic cells derived from 
the dermis [103]. Early characterisation revealed that cultured bone-derived cells 
presented a flattened, multiple morphology and an abundance of cytoplasmic stress 
fibres, while skin-derived fibroblasts showed an elongated bipolar morphology. Bone-
derived cells, in the presence of a glucocorticoid, change their morphology to a more 
polygonal shape – situation that has been associated with the transition to a more 
differentiation stage [104, 105]. Comparing to fibroblasts grown in culture, bone-derived 
cells proliferate less rapidly, reach lower saturation densities and express high levels of 
the non-specific isoform of alkaline phosphatase. Both cell populations synthesize a 
collagen-rich extracellular matrix but the cells derived from the bone express greatly 
collagen type I, less than 10% of collagen type III and small quantities of collagen type 
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V [103, 106]. These cells also synthesize several non-collagenous proteins, including 
bone sialoprotein, osteocalcin – known late stage markers of the osteoblastic lineage. 
The level of expression of these proteins, and alkaline phosphatase as well, is 
markedly influenced by the cell culture stage of maturation – which in turn is a function 
of the initial cell density and the absence or presence of specific biomodulators such as 
glucocorticoids, vitamin D3, ascorbic acid, beta-glycerophosphate, among others [104]. 
In addition to established supplements, members of the bone morphogenetic protein 
(BMP) family of growth factors are also routinely used for osteoinduction. BMP-2 alone 
appears to increase bone nodule formation and the calcium content of osteogenic 
cultures in vitro, while concomitant application of BMP-2 and basic fibroblast growth 
factor increases osteogenesis both in vivo and in vitro [107]. Either way, the most 
compelling evidence for the presence of cells of the osteogenic lineage in culture is the 
demonstration of extracellular matrix mineralization, and the formation of well-
organized mineralised nodules that, through an histological and histochemical 
approach, resemble the mineralised organisation of the woven bone tissue [108].    
Additionally, cells with osteoblastic phenotype can also be differentiated from 
selected precursors from the bone marrow [102]. There are three main cellular systems 
in the bone marrow: haemopoietic, endothelial and stromal, which are histogenetically 
distinct with no common precursor in the post-natal development. Marrow cells 
prepared as a single cell suspension and cultured in vitro with foetal calf serum form 
fibroblastic colonies, each derived from a single cell or colony forming unit-fibroblastic 
(CFU-F) [109]. These colonies are heterogeneous in size, morphology and potential of 
differentiation but when these cells are grown in osteogenic inducing conditions – 
including foetal calf serum, an appropriate level of glucocorticoid, a source of 
phosphate and vitamin C – phenotypical characteristics of the osteoblastic lineage 
develop, including the formation of discrete three-dimensional mineralising nodules 
within focal areas of the cell layer [109]. Nonetheless a single cell, or colony forming 
unit-osteogenic (CFU-O) is sufficient for the production of one mineralised nodule, 
these CFU-O have limited capacity for self-renewal [109].  
In recent years, a thoroughly characterization of the origin and properties of 
stromal cell populations revealed that within this population, cells initially isolated from 
the bone marrow of adult organisms and initially characterized as plastic adherent, 
fibroblastoid cells with the capacity to generate heterotopic osseous tissue when 
transplanted in vivo, correspond in fact, to a defined stem cell population - 
mesenchymal stem cells (MSCs) - shown to reside within the connective tissue of most 
organs, and with a surface phenotype well defined [110]. By using flow cytometry, 
MSCs have been shown to be negative for hematopoietic markers CD14, CD34 and 
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CD45. The cells stain positive for a number of surface markers including SH2, SH3, 
CD29, CD44, CD71, CD73, CD90, CD 105, CD106, CD120a, CD124 and CD166 [24, 
111]. The progeny of ex vivo expanded MSCs reveal that they share a similar gene 
expression profile for a variety of transcriptional regulators, extracellular matrix 
proteins, growth factors/receptors, cell adhesion molecules, and some but not all, 
lineage makers characteristic of fibroblasts, endothelial cells, smooth muscle cells, and 
osteoblasts [111].  
Apart from the differentiation of MSC into the osteoblastic lineage with the aim 
of establishing a homogeneous cell population for biocompatibility assessment, MSCs 
also provide an exciting progenitor cell source for tissue engineering and regenerative 
medicine applications. Developing strategies may include direct implantation and/or ex 
vivo tissue engineering approaches, in combination with biocompatible/biomimetic 
biomaterials and/or biomodulators. MSCs may also be considered for gene therapy 
applications for the delivery of genes or gene products. Another intriguing prospect for 
the future is the use of MSCs to create ‗off-the-shelf‘ tissue banks.  
Practical, biological and technological issues still need to be fixed in order to 
fully harness the potential of these cells, their cellular and molecular characteristics, in 
order to establish an optimal identification, isolation, and expansion, and to understand 
the natural, endogenous role(s) of MSCs in normal and abnormal tissue functions. 
 
In vivo testing 
In the biological assessment of the biocompatibility between a medical device 
and the biological tissues, in vitro procedures are used as a first stage test for acute 
toxicity and cytocompatibility to avoid unnecessary use of animals in the testing of 
inappropriate materials. The term biocompatibility is often inaccurately used within in 
vitro applications, as biocompatibility can be only assessed within the range of testing 
in living organisms  – animals or humans – with the correct term for in vitro tests being 
cytocompatibility [112]. Accordingly, in vitro testing gives information regarding 
cytotoxicity, genotoxicity, cell proliferation and differentiation and is more easily 
standardised and quantifiable than in vivo testing [113]. In vitro studies are also used 
for screening new materials for product quality and the release of potentially harmful 
additives or components [96]. Conversely, in vitro testing is not able to demonstrate the 
tissue response to materials – instead is restricted to the response of cell lines. 
Additionally, cell culture testing may also overestimate the intensity of material toxicity 
and is limited to acute studies, due to the relative short lifespan of the culture systems 
[96]. Moreover, and regarding bone related testing, no cell culture system is able to 
mimic or reproduce loading that stimulates the in vivo behaviour, only approachable in 
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few ex vivo systems [114]. For these reasons animal models are necessary for 
biocompatibility assessment, tissue response and mechanical function of a medical 
device, moreover in the regards of bone-related applications, prior to clinical set up of 
the devices. 
Animal models allow the evaluation of medical devices, in loaded or unloaded 
conditions, potentially for long durations and in different biological conditions (for 
instance, in the absence or presence of associated pathology) and ages [112]. In this 
way, the tissues in the neighbouring area of the implant can be assessed, as well as 
remote locations, which is relevant in the evaluation of the effect of potential released 
particles of wear debris [115]. For this purpose, a wide range of models for implant 
testing, ranging from the evaluation of protein adsorption to soft tissue adherence or 
bone integration, are widely available. Nonetheless, one may keep in mind that each 
model possesses unique advantages and disadvantages and while it may closely 
represent the biomechanical and physiological particularities of the human organism, it 
must be remembered that it is only an approximation. 
When selecting the required animal species for a particular model, several 
factors must be addressed. Following the clear establishment of the research question, 
animal selection factors generally include: cost on the acquisition and maintenance of 
the animals, availability, social and ethical acceptance, easy of housing and handling, 
inter-individual uniformity, susceptibility to disease, biological characteristics in 
similarity with humans, availability of background data, tolerance to surgery,  and team 
expertise (regarding facilities and support staff) [112, 116]. Additionally, the lifespan of 
the species should be adequate to the duration and objectives of the study and, for 
studies dealing with bone-implant interactions, specific bone characteristics of the 
species (within the regards of macro and microstructure, bone composition and 
modelling/remodelling properties) should be particularly considered.  
Overall, no single animal model will be completely appropriate for all testing 
purposes, nor a model can be dismissed as inappropriate for all purposes. In fact, 
multiple animal models are likely required to establish a broadly body of data that 
supports biocompatibility assessment [117]. International standards established 
regarding the use of species suitable for testing implantation of medical devices, state 
that mice, rats, guinea pigs, rabbits, dogs, sheep, goats and pigs are all suitable – a 
comparative approach of the bone tissue characteristics of different species is 
presented on Table 6. The number of animals required, surgical procedures and 
implantation time are also issues addressed on the ISO 10993-6: 2007 Tests for local 
effects after implantation [90].   
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Table 6 – Overview of the key attributes in terms of similarity between animal and human bone. 
Adapted from [112].  
Properties Rodents 
(mice and rat) 
Rabbit Sheep/goat Canine Pig 
Macrostructure + + +++ ++ ++ 
Microstructure + + + ++ ++ 
Bone composition + ++ ++ +++ +++ 
Bone remodelling + + ++ ++ +++ 
+ least similar, ++ moderately similar, +++ most similar. 
 
Animal models play an important role in bone tissue-related research by 
providing methodological approaches to study detailed events and regenerative 
advances, which aim to establish adequate translational knowledge to substantiate 
clinical research in the following phase of biocompatibility assessment of a developed 
medical device. As a result, the never-ending scientific questions related to bone 
physiology and pathological conditions, and disease and regenerative approaches 
demand the availability of a wide range of animal models and the continue innovation 
of new model systems. Opportunities for advancement in animal models are identified 
in four general domains: 1) the development of new models to address new questions 
and relevant variables (e.g., cell transplantation survival in tissue engineering 
approaches, mass transport, in vivo biomodulator delivery, signal transduction 
modifications); 2) application of new methodologies of quantitative analysis (e.g., 
imaging techniques, immunohistochemical and histological evaluations that validate 
features of existing models that have not been previously accessible); 3) improved 
validation and standardization, as well as rigorous use of models in competitive testing 
that enhance the predictability of the clinical performance of the assay; 4) the design 
and implementation of models that more adequately represent the clinical settings 
[118]. 
Many authors converge to the fact that demonstration of similarities with 
humans – both in what relates to physiological and pathological events, as well as the 
capability to address numerous events and subjects within a relatively reduced time 
frame, are advantageous characteristics of an animal model, providing most relevant 
information for the successive testing in clinical scenario [116, 119, 120]. 
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Abstract 
DLC coatings are of enormous interest for biotribological applications due to 
their biocompatibility, auto-lubricious, and non-stick properties. The most demanding 
implant is the hip joint. Alternative materials to metal alloys are being increasingly 
investigated aiming low wear debris volume, in any case innocuous wear particles. 
Silicon nitride (Si3N4) ceramics are light, tough, mechanical resistant, inert materials, 
turning them suitable for high-load medical applications. In this study, Si3N4 polished 
substrates were coated with adherent DLC coatings grown by DC magnetron 
sputtering to reduce of the friction forces against any antagonist material. Surface 
characterization results showed that the developed material is quite hydrophobic, with 
a total surface tension of 45.7 mN/m (polar component: 9.1 mN/m; dispersive 
component: 36.6 mN/m), and a zeta potential of − 35.0 ± 1.3 mV. In vitro testing using 
an acellular simulated body fluid (SBF) showed no apatite layer formation ability, as 
confirmed by SEM observation and analysis of the solution ions concentration with 
immersion time. MG63 osteoblast-like cells showed poor adhesion on the DLC films 
but the adherent cells displayed a normal morphology and, as compared to standard 
polystyrene tissue culture plates, exhibited a higher cell growth rate, suggesting no 
indication of cytotoxicity. Results suggested that the novel DLC-coated Si3N4 
biomaterial should be adequate to be used for articular prostheses medical application. 
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Introduction 
Some medical applications require materials with a non cell-adhesive surface, 
such as devices in contact with human blood (e.g., artificial heart valves), while others 
need a cell-adhesive surface to assure complete tissue integration of the implanted 
material in the human body. In orthopaedic applications, the osteointegration is 
promoted by the formation of an apatite layer on the surface of the biomaterial upon 
implantation. The biomaterial surface properties can be defined aiming to control its 
bioactivity and biocompatibility. For applications such as replacement of the hip joint, 
which is composed of a stem, a femoral head and an acetabulum, the formation of an 
apatite layer is desired on the stem, but not at femur head or acetabulum surface since 
it would compromise the tribo-system performance. There are many different shapes, 
sizes, and designs of artificial components of the hip joint, made of several materials 
such as chrome, cobalt, titanium, polymeric or ceramic materials. Nevertheless, on 
going problems with wear and particulate debris still exist, causing metallosis, and 
eventually periprosthetic osteolysis and aseptic loosening [1]. 
Silicon nitride (Si3N4) based ceramics are well known for their superior 
combination of fracture toughness and hardness [2]. These are key properties for an 
excellent wear resistance, which, combined with Si3N4 chemical inertness, turns this 
material a suitable candidate for high-load medical applications, namely for metal 
prostheses replacement. In order to diminish the friction forces in such kind of bio-
tribological systems, the Si3N4 surfaces must be modified. Diamond-like carbon (DLC) 
coatings are of enormous interest for biomedical applications due to their 
biocompatible, auto-lubricious, and non-stick properties [3-5]. Therefore, DLC is a very 
good candidate for coating the hip joint tribosystem, especially when combined with the 
adequate bio-mechanical properties of the Si3N4 ceramic [6]. 
Surface properties such as surface chemistry, surface energy and surface 
topography can be critical for biomaterials biocompatibility, together with bulk 
properties characteristics. Protein adsorption, which is a virtually instantaneous 
process during an implantation procedure, is a dynamic and a very complex 
phenomenon that precedes any cell-mediated effects either in vitro or in vivo. 
Biomaterial surface properties, important in protein adsorption, that can be readily 
quantified, include interfacial free energy, hydrophobicity and surface charge density. 
In this study, Si3N4 polished substrates were coated with adherent DLC 
coatings grown by DC magnetron sputtering. An intermediate Si layer promotes the 
adhesion between the ceramic and the DLC film. Wettability and zeta potential studies 
were performed to characterize the hydrophobicity, surface tension and surface charge 
of the DLC Si3N4 coated material. In vitro bioactivity was assessed through an acellular 
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simulated body fluid (SBF) testing assay and biocompatibility evaluation using MG63 
osteoblast-like cells. 
 
Materials and methods 
Silicon nitride ceramic discs (empty set 10 mm × 3 mm), whose preparation is 
described elsewhere [6], were coated with continuous, homogeneous and adherent 
DLC films, by DC magnetron sputtering from a graphite target of 3 mm thickness. 
Before deposition of the amorphous carbon, an intermediate layer of Si was deposited 
by the same technique from a silicon wafer target, in order to promote adhesion 
between the substrates and the DLC films. 
Zeta potential measurements were performed in Anton Paar EKA — Electro 
Kinetic Analyser equipment, using a rectangular cell in which the solution passes along 
a channel formed by two layers of the sample separated by an inert spacer. AgCl 
electrodes at each end of the channel were used to determine the potential generated 
by the flow. The measurements were performed using 0.001 M KCl as electrolyte 
solution, at pH 7.4 ± 0.2. The zeta potential, δ, is calculated from:  
 
where VS is the streaming potential, Δp the hydrodynamic pressure difference 
across the sample, ε is the viscosity and  the permittivity of the liquid, 0 the 
permittivity of free space, L and A are the length and cross sectional area of the sample 
and R is the electrical resistance across it. Fairbrother and Mastin's [7] approach was 
used to determine the term L/A. 
For surface tension and contact angle determinations, water, glycerol and 
diiodomethane (Merk Schuchardt, > 99%) were the test liquids. Water was distilled and 
deionised, while diiodomethane was doubly distilled under vacuum. Contact angles 
were measured on the DLC coated surfaces using the sessile drop technique in a 
video-base system DATA Physics Contact Angle System OCA 15. The drop is 
deposited directly on the surface of the material from a micrometric syringe with a 
metallic needle. The ellipse method was used to fit a mathematical function (Laplace–
Young Fitting) to the measure drop contour line. For each experiment, were analysed 
no less than 12 drops. The measurements were carried out at 25 °C inside a 
refrigerated stainless steel chamber, with glass windows of optical quality and 
saturated with the liquid in analysis. Young's equation establishes the contact angle of 
a liquid drop resting on a solid surface, ζ, from the relation between the surface tension 
of a liquid in equilibrium with its vapour, γLV, the solid-vapour surface tension, γSV, 
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and the solid–liquid interfacial tension, γSL:γLVcosζ = γSV − γSL. The Owen and 
Wendt's approach [8] postulates that the total surface tension can be expressed as the 
sum of the dispersive, γd, and the polar, γp, components. The solid–liquid interfacial 
tension can be rewritten as: 
 
Using Young's equation and Eq. (2), γSV and γSL can be determined taking the 
values of contact angles measured with some testing liquids whose surface tension 
components are known. 
A simulated body fluid (SBF) solution was prepared as reported in literature [9] 
for in vitro testing, by dissolving reagent-grade NaCl, NaHCO3, KCl, K2HPO43H2O, 
MgCl26H2O, CaCl2 and Na2SO4 into deionised water, and buffered at pH 7.40 with 
tris(hydroxymethyl)amminomethane ((CH2OH)3CNH3) and hydrochloric acid (HCl) at 37 
°C. Triplicate samples were soaked into SBF solution in sterile polystyrene bottles for 
7, 21 and 35 days. A ratio of solution volume to surface area of the specimen was kept 
at 0.1 ml/mm2. After soaking, samples were analyzed using SEM to detect apatite layer 
formation, and changes in ionic concentrations were evaluated by inductive plasma 
coupled atomic emission spectrometry (ICP-AES). Changes in the pH of the fluid were 
also registered. 
MG63 osteoblast-like cells were cultured in α-Minimal Essential Medium 
containing 10% fetal bovine serum, 50 μg ml−1 ascorbic acid, 50 μg ml−1 gentamicin 
and 2.5 μg ml−1 fungizone, at 37 °C in a humidified atmosphere of 5% CO2 in air. For 
subculture, adherent cells were enzymatically released (0.05% trypsin, 0.25% EDTA) 
and cultured (104 cell cm−2) for 3 days in control conditions (absence of materials, 
standard polystyrene tissue culture plates) and on the DLC coated Si3N4 material 
surface. Control cultures and seeded DLC films were evaluated for cell adhesion and 
morphology (SEM) and cell viability/proliferation (MTT assay). For SEM observation, 
samples were fixed with 1.5% glutaraldehyde in 0.14 M sodium cacodylate buffer (pH 
7.3), dehydrated in graded alcohols, critical-point dried, sputter-coated with gold and 
analysed in a JEOL JSM 6301F scanning electron microscope. Cultures were 
observed at 1, 5, 24 and 72 h. In the MTT assay, cultures were incubated with 0.5 mg 
ml−1 of MTT (3-[4,5-dimethylthiazol-2-yl]–2,5-diphenyltetrasodium bromide) during the 
last 4 h of the culture periods tested (24 and 72 h); the medium was then decanted, 
formazan salts were dissolved with 200 μL of dimethylsulphoxide and the absorbance 
was measured at 600 nm in an ELISA reader. The results were normalized in terms of 
macroscopic area and expressed as A cm−2. 
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Results and discussion 
Figure 1 shows the surface of DLC coated Si3N4 samples before (a) and after 
35 days of immersion in SBF solution (b), as observed by SEM. No apatite layer or any 
other type of deposits can be seen on these ultra-high smooth surfaces. Also, ICP 
measurements showed no significant changes on the ionic concentration levels of 
calcium, phosphorous, magnesium and sodium with immersion time. The DLC coated 
surface is only slightly negative charged, as denoted by the zeta potential value of − 
35.0 ± 1.3 mV at pH 7.4 ±0.2, which explains the low Ca2+ ions adsorption that would 
be imperative for further nucleation of an amorphous apatite layer. 
 
 
 
Figure 1 – Surface of DLC coated Si3N4 samples before (a) and after 35 days of immersion in SBF solution 
(b), as observed by SEM. 
 
The surface tension of DLC coated samples was found to be 45.7 mN/m (Table 
1). The dispersive component of the surface tension is predominant (36.6 mN/m), 
corresponding to a contribution of about 80% to the total surface tension. Values in 
Table 1 were calculated from the measurements of contact angles on DLC (65.8° ± 
5.8° for water; 55.4° ± 4.7° for glycerol; and 40.9° ± 3.8° for diiodomethane), which are 
in the range of the values published in the literature, obtained for samples coated with 
DLC by other methods [11]. 
 
Table 1 - Surface tension of testing liquids [10] and the values determined for the DLC-coated Si3N4 
biomaterial. 
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MG63 osteoblast-like cells were used for a quick screening biocompatibility 
assay of the prepared DLC coated Si3N4 samples. After cell plating, few cells were able 
to attach to DLC films, as evident in Figure 2a, showing the appearance of the surface 
at 1 h. After 24 h, adherent cells presented a normal morphology (Figure 2b). 
Neighbouring cells have connection with each other through cytoplasmic extensions 
and proliferated with culture time (Figure 2b and c). As compared to control cultures 
(performed in standard polystyrene tissue culture plates), MTT reduction was very low 
at 24 h, but results at 72 h showed that cell growth rate was significantly higher on the 
seeded DLC surface (Figure 3). 
 
 
Figure 2 – Surface of DLC coated Si3N4 samples seeded with MG63 osteoblastic-like cells. SEM 
appearance at 1 h (a), 24 h (b) and 72 h (c). 
 
 
 
 
Figure 3 - Cell viability/proliferation. Control (▲) and DLC surface (■). *Significantly different from 
control. 
 
It is well known that surface charge, along with wettability, plays an important 
role in the biological response to implant materials and, despite the widely varied 
observations reported in the literature, some generalizations may be made from in vitro 
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published studies [12]. Given that virtually all interfaces are charged in aqueous 
solution, and that biomolecules carry a net charge, it is intuitive that electrostatic 
interactions will play a role in the cell response. Moderately hydrophilic surfaces appear 
to induce more favourable cell responses than hydrophobic materials, by favouring 
adsorption of proteins and better preserving their bioactivity. Both positively- and 
negatively-charged surfaces are able to bind adhesion proteins and support cell 
adhesion. However, the mode of cell adhesion is distinct for positive and negative 
charges, since cell membranes, that carry a negative charge, adhere very closely to 
positively charged surfaces, whereas contact occurs only at distinct points on near-
neutral and negatively charged surfaces [13-15]. These differences can be attributed 
primarily to electrostatic attraction and repulsion, respectively, but also demonstrated 
quantitative and qualitative patterns in protein adsorption and functionality. The results 
of the present work regarding the interaction of MG63 osteoblastic cells with the DLC 
coated Si3N4 material during the first 24 h do not suggest an optimum surface for cell 
adhesion. Although with an optimized experimental design favouring the cell adhesion 
process (plating of a cell suspension over a plane surface), only few cells were able to 
attach to the DLC films, as evident by SEM observation and also from the MTT 
reduction values measured at 24 h. The negative value of ZP of the surface may have 
contributed, in synergy with its wettability properties, to the poor cell adhesion 
observed. However, it is worth to mention that attached cells presented a normal 
pattern of cell spreading displaying the typical morphology at 24 h without no evidence 
of cytotoxicity. In addition, compared to the cell behaviour observed in standard 
polystyrene culture plates, the DLC adherent cells showed a significantly higher cell 
growth rate, as suggested by the MTT assay. These observations are in line with 
previous biocompatibility studies performed in several cell culture systems, namely 
mouse peritoneal macrophages, mouse fibroblasts, murine macrophage cell line IC-21, 
human synovial fibroblasts, osteoblast-like SaOS-2 cells and glial and fibroblast cell 
lines with no indication of cytotoxicity in vitro and cell growth kinetics studies reporting 
that cells generally grew faster on DLC [[16], for a review]. 
 
Conclusions 
The excellent set of intrinsic characteristics of Si3N4 (bioinertness, low density, 
high fracture toughness) ceramics can be further improved by adherent, biocompatible, 
auto-lubricious, DLC coatings, regarding hip replacement medical applications. The 
DLC films are slightly negative surface charged, exhibiting a zeta potential of − 35.0 ± 
1.3 mV. The total surface tension is 45.7 mN/m, with a minor polar component (9.1 
mN/m), which turns the DLC coating quite hydrophobic. As a result of this, DLC 
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showed no apatite layer formation ability in vitro testing using an acellular simulated 
body fluid (SBF). Also, no evidence of cytotoxicity was demonstrated by cells normal 
morphology and higher cell growth rate compared to standard culture plates, although 
with low cell adhesion. These properties render DLC-coated Si3N4 attractive to be 
used as femoral head and the acetabulum hip joint components, in which cell adhesion 
is not desirable. 
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Abstract 
Hydroxyapatite (HA), Ca10(PO4)6(OH)2, and tricalcium phosphate (TCP) 
bioceramics have been used as a graft materials in vivo. However, zinc is a biosafe, 
biocompatible element, and incorporation of Zn could favor for specific proliferative 
effect on osteoblastic cells and inhibitory effect on osteoclastic bone resorption. 
Therefore, this paper investigates the preliminary results and potential impact on zinc 
glass reinforced hydroxyapatite (Zn-GRHA) on cell proliferation studies. The biological 
behaviour of Zn-GRHA samples was assessed by confocal laser scanning microscopy 
and material characterization performed by SEM-EDX and XRD analysis. From these 
results, an increased proliferation and a confluent cell layer were verified in some areas 
of the material surface, at day 2. Cells were spread all over the material surface and 
established multiple cell-to-cell interactions relying on prominent cytoplasmic 
processes. At day 6, a confluent cell monolayer was verified on the Zn-GRHA 
material‘s surface. 
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Introduction 
In tissue engineering strategies, there is a great effort into the development of 
degradable tridimensional scaffolds since they allow for improved cell transport and 
viability, both for soft and hard tissue regenerative approaches. After implantation, they 
should allow for cell proliferation and maintenance of the local phenotype, at the same 
time that should be gradually resorbed and substituted by natural formed tissue [1]. 
Scaffold constructs made of natural and synthetic polymers have limited applications, 
since they are mechanically weak and report an inadequate degradation profile [2]. On 
the other hand, bioceramics are widely used, especially within hard tissue 
regeneration, due to their physicochemical and mechanical properties [3].  
Bone tissue engineering strategies may reach hand from a diverse range of 
bioactive ceramic materials that have been employed to repair bone associated 
defects, namely because of their adequate biocompatibility and ability to bond with 
mineralized tissues. Synthetic hydroxyapatite (HA), with the chemical composition of 
Ca10(PO4)6(OH)2, is one of the most widely available and clinically used biomaterials, 
although it differs from the biological apatite (the mineral content of the bone 
extracellular matrix) regarding composition, crystalinity, stoichiometry, and reports a 
low dissolution rate, limited physical and mechanical properties, when implanted in vivo 
[4]. Biological apatite results from crystal nucleation and mineralization events that 
occur naturally in mammals‘ biological systems, both in physiological (i.e., bone tissue 
remodeling and teeth formation) and pathological (i.e., hyperostosis and ossifying 
cartilage) conditions. Deposited crystals have been shown to adapt (both in terms of 
crystalinity and orientation), according to mechanical strength and turnover 
characteristics of the local tissue. Several ionic substitutions within the lattice are 
reported and seem to modulate these processes [5, 6]. These substitutions include 
carbonate, fluoride, chloride, sodium, magnesium, potassium and zinc, among others, 
and although the exact role of many of these ions has not been established yet, most 
of them seem to play an important role in the physiological process of bone remodeling 
[7], as well as during bone healing [8].   
Zinc has been recognized to be essential for animals‘ and humans‘ metabolic 
processes since the mid-20th century. It is known to be an essential trace element 
during fetal growth and development [9-10] and it plays an important biological role 
since it is a cofactor for more than 200 enzymes and is a constituent of nearly every 
cell type in the human body [11]. It contributes to the immune response, wound healing 
and participates actively on the bone metabolic process, namely by inducing 
osteoblastic proliferation, biomineralization and bone formation [12, 13]. Including, it is 
a co-factor of the alkaline phosphatase (ALP) enzyme, which is known to play an 
60 
 
important role in the initiation of the mineralization process of the extracellular matrix, 
during in vitro and in vivo bone formation [12, 14]. Selected concentrations of Zn 
increase ALP activity on osteoblastic cells [12, 15]. On the other hand, Zn deficiencies 
led to the activation of the monocyte-macrophage lineage affecting the cell-mediated 
immune response [16] and, in the elders, it has been associated with the development 
of osteoporosis [17].  
In order to assure a local delivery of adequate amounts of Zn, several attempts 
have been assayed including the development of Zn-containing bone-regenerative 
bioceramics. Webster et al. showed that Zn-doped HA improved osteoblast adhesion 
when compared to undoped HA [18].  Ramaswamy et al. report that the incorporation 
of Zn into a Ca-Si system, forming Hardystonite (Ca2Zn-Si2O7) improved the 
mechanical properties of the ceramic, as well as its bioactivity, by inducing the 
attachment, proliferation and differentiation of human bone marrow-derived 
osteoblastic cells, comparing to CaSiO3 [19]. Further, this ceramic allowed the 
differentiation of mature and functional osteoclasts, reflected by the presence of 
resorption imprints, while CaSiO3 failed to allow the differentiation of osteoclasts from 
their hematopoietic precursors [19]. Ikeuchi et al. reported an increased osteogenic 
differentiation (assessed by ALP activity and matrix mineralization) both in human- and 
rat-derived bone marrow cells, cultured on the surface of Zn-releasing Ca-P ceramics 
[20].  
In vivo anabolic effects have also been achieved with Zn-containing 
bioceramics that reported a quantitative stimulation in bone formation around implants 
and bone mineral density (BMD), in a model of femoral implants in rabbits [21]. 
Furthermore, Zn has been shown to induce bone remodeling and regeneration in 
experimental models of systemic pathological conditions. For instance, the controlled 
release of Zn has been shown to increase BMD in osteoporotic rats [22], while a 
composite ceramic of Zn-tricalcium phosphate and HA has shown increased stability at 
the bone-implant interface in osteopenic rabbits, comparing to control (composite 
ceramic of TCP and HA) [23]. Further, the intramuscular injection of ZnTCP powders 
increased the BMD in the vicinity of the injection site, in a Zn2+-deficient osteopenic rat 
model [24].      
Zn has also proven to be a useful antibacterial agent in bone associated 
infections. When associated with glass-based cements and coatings for bone 
regeneration, Zn has proven activity against Staphylococcus aureus and other bacteria 
associated with acute or chronic bone infections [25, 26].  
In this work, the authors report the preparation, characterization and biological 
assessment of two compositionally different novel Zn-glass reinforced hydroxyapatite 
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composites obtained by a liquid phase sintering process, via the combination of ZnO-
P2O5-CaO-Na2O-CaF2 glass with a HA matrix. Biological assessment was conducted in 
vitro by the direct culture of MG63 human osteoblast-like cells over the composites. HA 
was used as control. 
Previously, the present group has developed and characterized, both in vitro 
and in vivo, the osteogenic potential of a CaO-P2O5-Na2O-CaF2 glass reinforced 
hydroxyapatite, without ZnO, and patented the composite as Bonelike®. When 
compared to HA, Bonelike® reports enhanced bioactivity and improved mechanical 
properties resulting from the addition of the phosphate based bioactive glasses. During 
the sintering process, these glasses induce HA decomposition into -tricalcium 
phosphate, which in turn, at higher sintering temperatures, is decomposed into α-
tricalcium phosphate [27, 28]. Bonelike® appears to induce bone formation through 
specific activation of osteoblasts with the regulated release of ionic species, namely F-, 
Mg2+, Na+, among others. The incorporation of ZnO is expected to further improve the 
composite bioactivity. 
 
Materials and Methods 
Preparation of ZnO glasses 
Two ZnO based glasses (5ZnO or 10ZnO), with a chemical composition of 
xZnO–(70-x) P2O5–15CaO- 5Na2O- 10CaF2 (%mol), where x = 5 or 10, have been 
prepared by employing conventional glass making techniques as described in Chap. 6 
of this book.  Briefly, reagent analytical graded chemicals, i.e., ZnO, P2O5, CaHPO4, 
Na2CO3 and CaF2 were mixed and placed in a platinum crucible for about an hour, in 
an electrical furnace at 1450 °C. Following, the prepared glasses were crushed and 
sieved to granules (≤ 75 m). 
 
Preparation of the Hydroxyapatite (HA)  
HA, with the chemical composition of Ca10(PO4)6(OH)2, has been prepared in 
accordance with the following chemical equation: 10Ca(OH)2+6H3PO4 → 
Ca10(PO4)6(OH)2 + 18 H2O, as described in Chap. 6 of this book. 
In brief, analytical grade calcium hydroxide - Ca(OH2) - and ortho phosphoric 
acid - H3PO4 -  have been independently mixed with deionised water and subsequently, 
Ca(OH2) has been slowly transferred into H3PO4, during 4 hours, in constant mixing 
conditions  (100 rpm) and with maintenance of the pH at 10.50. After 24 hours, the 
material was filtered to remove the excess of water and dried, at 60°C, for 
approximately 48 hours. The dried product was finally crushed and sieved to granules 
(≤ 75 m). Following, they were isostatically pressed at 200 MPa and the obtained 
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disks were sintered at 1300°C for 1 hour. After cooling, specimens were polished down 
to 1 mm finishing using silicon carbide paper, ultrasonically degreased with ethanol and 
cleaned with deionised water. Prior to cell seeding, HA discs were sterilized in a steam 
autoclave. HA was used as control. 
 
Preparation of Zn-GRHA Composites  
The Zn-GRHA composites were obtained by mixing 2.5%wt of either 5ZnO- or 
10ZnO-based glasses with HA, in isopropanol. Composites were designated, 
respectively, as 5Zn-GRHA and 10Zn-GRHA. The obtained composites were dried at 
60°C for 24 hours and sieved to less than 75 m. Composite disks were prepared 
following isostatic pressure and sintering, as previously reported for HA. Zn-GRHA 
discs were sterilized in a steam autoclave.  
 
Materials’ Characterization 
X-ray diffraction (XRD) was performed on powder samples of 5ZnO and 10ZnO 
glasses, as well as on 5Zn-GRHA, 10Zn-GRHA and HA, by using Siemens D 5000 
diffractometer with Cu-Kα radiation (λ= 1.5418Å). The scans were made in the range of 
25-40° (2ζ) with a step size of 0.02° and a count time of 2 sec/step. A scanning 
electron microscopy (JEOL JSM 630IF), equipped with an energy dispersive analyzer, 
was used to investigate the microstructure of the samples. 
 
In vitro testing with osteoblastic cells  
MG63 cells, human osteosarcoma-derived osteoblastic cells, were cultured in a 
standard culture medium, α-Minimal Essential Medium, supplemented with 10% foetal 
bovine serum, ascorbic acid (50 μg.ml-1), penicillin-streptomicin (100 IU.ml-1 and 10 
mg.ml-1, respectively) and fungizone (2.5 μg.ml-1), at 37ºC, in a humidified atmosphere 
of 5% CO2 in air. For subculturing, adherent cells were enzymatically released (5 
minutes at 37ºC - 0.05% trypsin - 0.25% EDTA) and resuspended in complete medium 
for reseeding. 
Cells were cultured at a density of 104 cells.cm-2, for 6 days, on the surface of 
HA, 5Zn-GRHA and 10Zn-GRHA discs, that had been previously immersed in 
complete culture medium for 1h. Seeded material samples were evaluated throughout 
the incubation time at days 1, 2 and 6, for cell morphology and cell growth, by confocal 
laser scanning microscopy (CLSM), following the subsequent technique. Briefly, cells 
grown over the samples were fixed in 3.7% methanol-free formaldehyde and 
permeabilized with 0.1% Triton. Cell cytoskeleton filamentous actin (F-actin) was 
visualized by treating the fixed cells with Alexa Fluor® 488-conjugated phalloidin dye 
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(1:100 in PBS, 20 minutes), after initial incubation with bovine serum albumin 
(10mg.ml-1 in PBS 1 hour), in order to block non-specific interactions. Cells were 
counterstained with propidium iodide (10 mg.ml-1) for cell nuclei labelling, for 10 
minutes. Labeled cultures were mounted in Vectashield® and examined with a Leica 
SP2 AOBS (Leica Microsystems®) microscopy. 
 
Results and Discussion 
Physicochemical and morphological analysis of the Zn-GRHA composites 
The EDX analysis of 5ZnO and 10ZnO glasses are reported on Figure 1, while 
the microstructure of the glasses‘ surface is shown on Figure 2, where representative 
SEM micrographs are presented at 150x and 1000x magnification.   
 
Figure 1 - EDX analysis of ZnO-based glass materials: 5ZnO (left) and 10ZnO (right). 
                         
 
Figure 2 - SEM  micrographs of  5ZnO (A and B) and 10ZnO-based glasses (C and D). A and C - 150x 
magnification. B and D – 1000x magnification. 
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Similarly, Figure 3 shows the EDX analysis of 5Zn-GRHA and 10Zn-GRHA 
composites, while Figure 4 reports high magnification SEM images of the composites‘ 
surface. 
 
 
Figure 3 - EDX analysis of 5Zn-GRHA (left) and 10Zn-GRHA composites (right). 
 
When observing the microstructure of the Zn-GRHA composites by EDX 
(Figure 3), Zn was not detected although this element was identified by the same 
analysis, conducted on the prepared glasses (Figure 1). This might be related to the 
fact that the composites contain only a small amount of added glass (2.5%wt). In 
addition, Zn also might be expected to become widely distributed throughout the 
crystallographic structure of the composite, following the sintering process.     
SEM evaluation of the composites‘ surface showed that both 5Zn-GRHA and 
10Zn-GRHA are almost fully dense materials (Figure 4). 
 
 
Figure 4 -  SEM  micrographs of  5Zn-GRHA (left) and 10Zn-GRHA (right) composites, with a magnification 
of 10000x. 
 
Figure 5 shows the XRD phase analysis of prepared HA, which reveals a pure 
phase material. The XRD of 10Zn-GRHA composite is shown in Figure 6. From this 
diffractogram, the following phases can be identified: HA - Ca10(PO4)6(OH)2, β- and α-
TCP - Ca3(PO4)2. No zinc containing phases were detected. It means that the zinc ions 
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are expected to be incorporated in the tridimensional lattice of HA or TCP phases. 
Further, Rietveld analysis of the XRD spectrum obtained should be done to confirm this 
incorporation by quantifying the lattice parameters and the distortion index.  
The presence of TCP phases in the composition of the Zn-GRHA were 
expected, since previous reports of this research team have already demonstrated that 
the liquid sintering process leads to the reaction of HA with the added glass, resulting 
in a partial conversion of HA into TCP phases [27, 28].  
 
Figure 5 -  XRD diffraction pattern of the prepared Hydroxyapatite. 
 
Figure 6 - XRD diffraction pattern of the 10Zn-GRHA composite. 
 
In vitro biocompatibility of the Zn-GRHA composites 
MG63 human osteoblast-like cells were cultured on the surface of 5Zn-GRHA, 
10Zn-GRHA and HA samples for 6 days. The biological assessment of the seeded 
materials was established by confocal laser scanning microscopy, following staining for 
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F-actin cytoskeleton and nucleus counterstaining. Representative micrographs of the 
colonized surfaces are shown in Figures 7 – 9.  
CLSM images of seeded HA samples, at day 2 of culture (Figure 7A), revealed 
that the materials‘ surface was colonized with well-spread MG63 cells, establishing 
multiple cell-to-cell contacts. Cells proliferated actively throughout the culture time and, 
at day 6, a significant percentage of the materials‘ surface allowed the organization of 
high cell density areas (Figure 7D). Comparing to HA, both 5Zn-GRHA (Figure 7B) and 
10Zn-GRHA (Figure 7C) reported improved adhesion and early proliferation events, 
since an increased cell number was visualized on both composites‘ surface, at day 2. 
Comparatively, and in a qualitative way, significant more cells could be visualized over 
the 10Zn-GRHA surface. Following, at day 6 of culture, multiple cell layers could be 
visualized over both composites (Figure 7E and 7F).   
Attained differences might be associated with the composition of the tested 
materials as well as with differences regarding surface microstructure, which can be 
assessed on Figure 8, by CLSM, following immersion in complete culture medium for 6 
days. 
 
 
Figure 7 - Proliferation of MG63 cells seeded on HA (A, D), 5Zn-GRHA (B, E) and 10Zn-GRHA (C, F), at 2 
(A, B and C) and 6 (D, E and F) days of culture. CLSM observation following actin filaments (green) and 
nucleus (red) staining. 
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Figure  8 - Surface characteristics of HA (A), 5Zn-GRHA (B) and 10Zn-GRHA (C) samples. CLSM 
observation of the materials, following 6 days of incubation with fully supplemented culture medium.  
 
Regarding morphological analysis, all the biomaterials allowed the display of 
normal cell morphology, with adequate cytoplasmic spreading, prominent nucleus and 
nucleoli, as well as numerous filipodia that contributed to the extensive cell-to-cell 
contact. Representative data is presented in high magnification micrographs of Figure 
9, regarding the seeded materials at 24 hours of culture.  
  
 
Figure 9 - High-magnification morphologic appearance of MG63 cells seeded on HA (A), 5Zn-GRHA (B) 
and 10Zn-GRHA (C), at 24 hours of culture. CLSM observation following actin filaments (green) and 
nucleus (red) staining. 
 
The acquisition of normal morphology following adhesion is in agreement with 
the adequate reorganization of the cytoskeleton during the first 12-24 hours. The 
cytoskeleton is a dynamic structure that maintains cell shape, enables cellular motion 
and plays an important role, both in intracellular transport and cellular division. Further, 
the dynamic regulation of cytoskeleton is very sensitive to substrates‘ characteristics 
and early disturbances, associated with chemical or physical properties may 
compromise adhesion, proliferation and differentiation events [29]. In this way, early 
cytoskeleton re-organization events might be of relevance to the cell long term fate on 
the biomaterials‘ surface. 
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Obtained results converge to an improved biological performance of Zn-GRHA 
composites, comparing to HA. Both formulations (5Zn-GRHA and 10Zn-GRHA) 
increased cell proliferation at days 2 and 6 of the established culture system. Also, in 
all experimental conditions, seeded cells presented an adequate cytoskeleton 
organization, compatible with adhesion to a non cytotoxic substrate. These results are 
in line with previous reported in vitro and in vivo studies carried out on various Zn-
containing or Zn-releasing ceramic substrates [12, 18-26].  
Some mechanisms have been purposed to justify the anabolic effect of Zn over 
bone metabolism, including the increased activity of aminoacyl-tRNA synthetase, an 
enzyme associated with the initiation of protein synthesis [30]. This initial event is 
connected to the production of ALP and type I collagen by osteoblastic cells [31]. Even 
so, although Zn may be adequate to treat bone-associated diseases, a high 
concentration of this ion may induce significant cytotoxicity over cells [32]. Yamamoto 
evaluated the cytotoxicity of zinc salts and reported that the IC50 of zinc for MC3T3-E1 
osteoblastic cells was about 5.85 mg/l [33]. In addition, the releasing conditions of Zn 
may also determine its biological role: for instance, an eventual initial burst, which is 
obtained in many delivery systems, may be adverse for biological tissues. In this way, it 
is clear that the therapeutic index for Zn is very narrow and that a strictly controlled 
slow and sustained release rate must be assured for the establishment of an eventual 
anabolic effect over the biological tissues. 
 
Conclusions 
The novel Zn-glass reinforced hydroxyapatite composites have reported 
adequate biocompatibility, further enhancing adhesion and proliferation of human 
osteoblastic-like cells. Regarding biological evaluation by confocal laser scanning 
microscopy, increased cell adhesion was verified in Zn-GRHA materials compared to 
pure phase HA. Also, Zn-GRHA composites induced cell proliferation in a more 
effective way than HA and, at 6 days of culture, multiple cell layers were visualized on 
the surface of both composites. 
  Although further in vitro and in vivo studies must be accomplished to assess the 
osteoblastic response of these materials, composites of the Zn-GRHA system may be 
adequate scaffolds for bone tissue engineering applications.  
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Abstract 
The cytotoxicity profile of nanocrystalline diamond (NCD) coatings on a Si3N4 
ceramic was investigated. This material is envisaged to have biomedical dental 
applications such as burrs and surgical instruments. Two fibroblast cell culture systems 
were used to address the cytotoxicity of NCD-coated samples: L929 cells (a mouse 
permanent cell line) and human gingival fibroblasts. Cell behavior was evaluated in 
terms of cell adhesion, cell viability/proliferation (mitochondrial function, MTT assay) 
and the pattern of cell growth. Fibroblast cell behavior on standard polystyrene culture 
plates was used as control, as Si3N4 substrates have previously been shown to be 
biocompatible. NCD coatings provided a suitable surface for cell attachment, spreading 
and proliferation. Human gingival cells showed a homogeneous cytoplasm spreading, a 
flattened elongated morphology and a typical parallel alignment on confluent cultures. 
In comparison, L929 cells denoted a lower cytoplasm expansion, a heterogeneous 
spreading but a higher proliferation rate. For both cells, after few days, the NCD 
coating was completely covered with continuous cell layers. As compared to standard 
polystyrene culture plates, no deleterious or cytotoxic responses were observed with 
L929 and human fibroblast cell cultures, and in both a slight enhancement in cell 
proliferation was observed. In addition, the seeded NCD film allowed reproduction of 
the typical features of the two cell culture systems tested, further suggesting the lack of 
cytotoxicity of this coating. 
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Introduction 
Nanocrystalline diamond (NCD) films have attracted the attention of 
researchers from different areas, and have therefore been the object of several studies 
in recent years. NCD is a unique material presenting the exceptional properties of 
diamond combined with smoother surfaces, higher toughness, lower friction coefficient, 
wide band gap and higher electron emission efficiency [1]. Thus, a wide range of 
applications is anticipated for NCD, particularly in the biomedical field. Implants and 
surgical instruments for dentistry, cardiology, orthopedics, ophthalmology, arterial and 
venous disorder repair, as well as biosensors and scaffolds for tissue engineering, are 
just some examples where the use of NCD is particularly innovative [2-9]. In addition, 
NCD films exhibit the highest resistance to bacterial colonization when compared to 
medical steel and titanium [10], a relevant issue since bacterial infection associated 
with the use of biomaterials is still a significant clinical problem. 
Dental applications may take advantage of NCD films. In particular, NCD 
coating of surgical and dental instruments, such as scalpels and dental burrs, may 
improve the performance and lifetime of tools, as well as their biocompatibility. 
Diamond-coated dental burrs are an excellent option to substitute the conventional 
ones [11-12], which are made by embedding synthetic diamond particles into the 
working surfaces using a binder matrix material containing metallic ions. Those ions 
are responsible for contaminating of oral tissues, inflammatory responses, tissue 
disturbance and metal artifacts on magnetic resonance images [5], [11-13]. The 
deposition of a diamond coating without metallic binder between the crystals would be 
extremely helpful in terms of reducing contamination-related problems. Furthermore, 
diamond-coated burrs can work with no signs of deterioration in more than 1000 
operations, while the conventional burrs are ineffective after 30–60 operations [12]. To 
date, only chemical vapor deposition of microcrystalline diamond (MCD) has been 
reported in the literature [11-12], and, to the best of our knowledge, there are no 
references about the use of NCD on dental burrs. Clinical application of MCD-coated 
dental burrs, mounted on an ultrasonic handpiece, allow for a more precise cavity 
preparation in hard tissue ablation, resulting in a greater conservation of sound tooth 
structure [14]. Further, this system allows a higher angulation during tissue ablation 
and this makes interproximal preparation and finishing safer, reducing the chances of 
hitting adjacent structures [14]. In addition, patient discomfort, which is usually 
associated with mechanical vibrations, is greatly reduced [14]. Even with the early 
satisfactory clinical results with MCD diamond burrs, NCD may additionally improve the 
burr performance due to its lower surface roughness and higher toughness when 
compared to MCD [1]. 
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NCD films can be deposited in several types of substrates used in biomedical 
applications, such as silicon [7, 8], stainless steel [10, 15], cobalt–chromium alloys [16], 
titanium alloys [6, 17, 18] and WC–Co cement carbide substrates [19]. An 
advantageous substrate is the silicon nitride (Si3N4) ceramic because it presents a 
thermal expansion coefficient very close to that of diamond [20], ensuring good film 
adhesion, a crucial requirement for biomedical applications. In addition, Si3N4 
substrates possess the mechanical resistance necessary to work as a substrate for 
coated materials for biomedical applications [21] and were previously shown to elicit 
positive responses on cultured cells [22, 23]. 
This work aims to evaluate the cytotoxicity profile of a NCD-coated Si3N4 
ceramic, as part of ongoing projects regarding the use of this material combination in 
biomedical dental applications, namely burrs and surgical tools. The few reported 
publications on the biological behavior of NCD coatings are very specific regarding the 
cell type/application [3, 24, 25, 26]; in the present work, two fibroblast cell culture 
systems were used to address the cytotoxicity of NCD-coated Si3N4 samples: L929 
cells (a mouse permanent cell line) and human gingival fibroblasts. Cell behavior was 
evaluated in terms of cell adhesion on the NCD films, cell viability/proliferation 
(mitochondrial function, MTT assay) and pattern of cell growth.  
 
Materials and methods 
Materials preparation and characterization 
Disc-shaped Si3N4 substrates (diameter = 10 mm, thickness = 3 mm) were 
manufactured according to a processing route described in detail in a previous work 
[20]. Before deposition, the 15 μm lapped substrates were scratched in an ultrasonic 
bath for 1 h in a 1 μm diamond powder suspension in n-hexane and then ultrasonically 
cleaned in ethanol for 10 min. The Si3N4 discs were coated by NCD using the hot 
filament chemical vapor deposition (HFCVD) method. A Ar–CH4–H2 gas mixture was 
used with volume ratios of Ar/H2 = 0.1 and CH4/H2 = 0.04. Other deposition parameters 
were as follows: P = 5 kPa (total gas pressure); F = 50 ml min−1 (total gas flow); Ts = 
750 °C (substrate temperature); Tf = 2300 °C (filament temperature); td = 2 h 
(deposition time). 
The as-grown NCD films were observed by atomic force microscopy (AFM, 
Digital Instrument Multimode IIIa) and micro-Raman spectroscopy (Jobin-Yvon T64000, 
Ar+ 514.5 nm line). 
Before being seeded with the fibroblast cells, the NCD-coated Si3N4 samples 
were washed with ethanol in an ultrasonic cleaner and sterilized by autoclaving. 
 
79 
 
Cell cultures 
Fibroblast cell line L929 
The fibroblast cell line L929 was cultured in α-minimal essential medium (α-
MEM) containing 10% fetal bovine serum, 50 μg ml−1 ascorbic acid, 50 μg ml−1 
gentamicin and 2.5 μg ml−1 fungizone, at 37 °C, in a humidified atmosphere of 5% CO2 
in air. For subculture, the cell monolayer was washed twice with phosphate-buffered 
saline (PBS) and incubated with trypsin–EDTA solution (0.05% trypsin, 0.25% EDTA) 
for 5 min at 37 °C to detach the cells. Cells were resuspended in culture medium and 
cultured (104 cells cm−2) for 8 days in standard plastic culture plates and on the surface 
of the NCD films in the ―as-prepared‖ condition. The medium was changed every 2–3 
days. Cultures were evaluated for cell viability/proliferation at days 1, 4 and 8 (MTT 
assay) and observed by scanning electron microscopy (SEM) and confocal laser 
scanning microscopy (CLSM), to assess cell morphology during cell adhesion to the 
substrate (1, 6, 12 and 24 h) and throughout the culture period. 
 
Human gingival fibroblast cells 
Gingiva was collected from a patient undergoing a third molar extraction for 
orthodontic reasons. Informed consent to use this biological tissue, which would be 
otherwise discarded, was obtained. Primary cultures were obtained by culturing 
explants of gingiva, following established procedures [27, 28, 29]. Briefly, the tissue 
was washed in PBS, cut into small pieces and cultured in the same experimental 
conditions as those used in the culture of L929 cells. Cell outgrowth from the tissue 
explants was observed 1–2 weeks after the beginning of the incubation. Cultures 
showed a high proliferation rate and reached confluence in approximately 1 week, with 
cells oriented along parallel lines, a typical feature of this culture system [27, 28, 29]. 
Primary cultures were subcultured (trypsin–EDTA solution) after reaching 70–80% 
confluence. First-passage human gingival (HG) cells were cultured (104 cells cm−2) for 
14 days in standard plastic culture plates and on the surface of the NCD films in the 
―as-prepared‖ condition. The medium was changed every 2–3 days. Cultures were 
characterized for cell morphology and proliferation, as described above. 
 
Biochemical and microscopy assays 
Cell viability/proliferation 
MTT assay (reduction of 3-[4,5-dimethylthiazol-2-yl]–2,5-diphenyltetrasodium 
bromide (MTT) to a purple formazan reaction product by living cells) was used to 
estimate cell viability/proliferation. Cultures were incubated with 0.5 mg ml−1 of MTT for 
the last 4 h of the culture period tested. Subsequently, formazan salts were dissolved 
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with dimethylsulfoxide (the seeded material samples had previously been transferred to 
a new plate) and the absorbance (A) was measured at 600 nm in an ELISA reader. 
The results were normalized in terms of macroscopic area and expressed as A cm−2. 
 
SEM and CLSM microscopy 
For SEM/EDS observation (JEOL JSM 6301F; Voyager XRMA System, Noran 
Instruments), samples were fixed with 1.5% glutaraldehyde in 0.14 M sodium 
cacodylate buffer (15 min, pH 7.3), then dehydrated in graded alcohols, critical-point 
dried, and sputter-coated with gold. 
For CLSM assessment, samples were fixed in 3.7% paraformaldehyde (10 
min). Cell cytoskeleton filamentous actin (F-actin) was visualized by treating the cells 
with Alexa Fluor® 488 Phalloidin (1:20 dilution in PBS, 1 h). Cultures were 
counterstained with propidium iodide (1 μg ml−1, 10 min) for cell nuclei labelling. 
Labelled cultures were mounted in Vectashield® and examined with a Leica SP2 
AOBS (Leica Microsystems) microscope. 
 
Statistical analysis 
Three experiments were performed for each period of culture evaluation. The 
results are shown as the arithmetic mean ± SD. Analysis of the results was carried out 
using the non-parametric Kruskall–Wallis test, with a significance level of P < 0.05. 
 
Results 
Characterization of the as-grown NCD coating 
The HFCVD deposition method enabled a NCD growth rate of about 1 μm h−1, 
allowing the coating of Si3N4 discs with a 2 μm film formed by tiny agglomerates of 
diamond nanocrystals (Figure 1A and B). The AFM 100 × 100 μm scans on the surface 
assessed a root mean square (RMS) roughness value of 68 ± 5 nm. The NCD 
signature is demonstrated by the micro-Raman spectrum in Fig. 1C. Here, a set of 
typical bands are visible: (i) the 1332 cm−1 diamond band; (ii) the graphitic D (1360 
cm−1) and G (1560 cm−1) bands; (iii) the transpolyacetylene 1140 and 1480 cm−1 
shoulders; (iv) the 1228 cm−1 nanophase diamond band. 
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Figure 1 – AFM scan (A and B) and micro-Raman spectrum (C) of the as-grown NCD films.  
 
Cytotoxicity assessment of the NCD coating 
Cell morphology and pattern of cell growth 
Upon seeding, L929 and HG fibroblast cells contacted with the NCD film within 
minutes. Morphological changes occurring during cell adhesion and spreading (first 24 
h) were observed by SEM and CLSM and are presented in Fig. 2. For both cell types, 
expansion of the cytoplasm was already evident after 1 h of culture time (Figure 2A and 
D, inset). After a few hours (12 h), the nucleus was evident and cells already presented 
an elongated morphology, although coexistence of cells in different stages of spreading 
could be observed (Figure 2A and D). In 24 h cultures, cells showed a fibroblast-like 
appearance with cytoplasmic expansions and cell–cell contact (Figure 2B, C, E and F). 
HG cells presented a higher degree of spreading and a more elongated appearance 
than L929 cells, as evident in Figure 3 which compares the cell morphology at 24 h. 
Observation of the seeded materials at longer incubation times showed a high 
proliferation rate, as suggested by the presence of a flattened sheet of continuous 
multilayers after approximately 1 and 2 weeks, respectively, for L929 and HG cells (Fig. 
4), with HG cells presenting a typical parallel alignment on confluence (Figure 4D and 
E) and abundant fibrillar matrix (Figure 4F). 
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Figure 2 – Morphological appearance of fibroblast cells cultured on the NCD coating, at 12 and 24 h of 
culture. A, B, D and E: SEM (inset in A and D: 1 h); C and F: CLSM, actin filaments and nucleus staining. 
 
 
 
 
Figure 3 – Comparison of the morphological features of L929 (A) and human gingival fibroblast cells (B) 
cultured on the NCD coating, at 24 h (SEM images). 
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Figure 4 – Time-behavior appearance of fibroblast cells cultured on the NCD coating. (A–C) CLSM, actin 
filaments and nucleus staining; (D–F) SEM. 
 
The morphological events observed during cell adhesion and spreading on the 
NCD coating and the subsequent pattern of cell growth described above were similar to 
those found in the cultures performed on the standard tissue culture plates (Figure 5). 
 
 
Figure 5 – Time-behavior appearance of fibroblast cells cultured on standard polystyrene culture plates. 
(A–C) CLSM, actin filaments and nucleus staining; (D–F) SEM. 
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Cell viability/proliferation 
Results regarding cell viability/proliferation (MTT assay) of cultures performed in 
standard tissue culture plates and on NCD films are shown in Figure 6. L929 cells 
presented a high proliferation rate throughout the culture time (Figure 6A). HG cells 
showed a lag phase during the first week, followed by an exponential cell growth, 
although with a lower growth rate than that exhibited by L929 cells (Figure 6B). At early 
incubation times, i.e., day 1 (L929 cells) and day 3 (HG cells), values of MTT reduction 
were similar in standard tissue culture plates and seeded NCD films, suggesting an 
identical number of attached cells. Subsequently, cells growing in the NCD samples 
presented a slightly higher proliferation rate, but differences did not attain statistical 
significance. 
 
 
Figure 6 – Cell viability/proliferation of fibroblast cells cultured on the NCD coating (MTT assay). (A) L 
929 cells; (B) HG cells. Control cultures (open bars) and seeded NCD coating (black bars). 
 
Discussion 
Diamond is one of the allotropic forms of carbon, the element that is the basis of 
all plant and animal tissue. For this reason, carbon is likely to exhibit excellent 
biocompatibility and be capable of close binding with human cells [30]. Diamond 
coatings, particularly NCD, can be obtained by CVD. Raman spectroscopy analysis of 
the present hot filament-grown NCD films (Fig. 1C) revealed their composite nature, 
attested by the occurrence of the diamond peak combined with the graphitic peak and 
the typical bands of nanometric diamond (ν = 1228 cm−1 [31]; ν = 1140 and 1480 cm−1 
[32, 33]). In addition, NCD films are formed by diamond crystals of nanometric size, 
usually between 10 and 100 nm [34, 35]. The crystallite size of the present NCD films 
has an average value of 28 nm, as estimated by X-ray diffraction in a previous work 
[36]. The higher value of the surface roughness of the NCD films (RMS not, vert, 
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similar 68 nm) reveals the overlapping effect of the substrate surface finishing with the 
intrinsic value of the NCD agglomerates. 
In the present study, the continuous fibroblast cell line L929 and HG cells were 
used to assess the cytotoxicity profile of NCD films deposited on a Si3N4 ceramic. F-
actin staining and SEM observation showed that, upon seeding, cell adhesion and 
spreading on the NCD coating followed a similar pattern, compared to that found on 
standard tissue culture plates. Morphological changes occurring during these initial 
events correspond to the reorganization of the cytoskeleton, a process reflected by a 
cytoplasmic expansion and acquisition of phenotypic morphological features after 12–
24 h. The cytoskeleton is a key structure that controls cellular shape and surface 
movements modulating cellular mechanics subjacent to the proliferation and 
differentiation events [37]. Thus, cytoskeleton dynamics is very sensitive to the material 
surface properties, and early induced disturbances may compromise adequate cell 
growth and phenotype expression [37, 38]. Regarding this, L929 and HG cells 
presented a pattern of cell growth on the NCD coating similar to control, with HG cells 
exhibited phenotypic features, i.e., a parallel alignment on confluence which is typical 
of human fibroblastic cell populations derived from adult tissues and abundant fibrillar 
matrix [27, 28, 29]. In addition, assessment of mitochondrial function (MTT assay) 
further suggested the lack of cytotoxicity of the NCD coating. Mitochondria are 
vulnerable targets for toxic injury because of their crucial role in maintaining cellular 
structure and function via aerobic ATP production. L929 and HG cells presented a 
profile of cell viability/proliferation representative of the two cell populations: a 
permanent cell line (high growth rate from the beginning of the incubation) and normal 
cells in culture (initial lag phase followed by an exponential cell growth) [29, 39]. 
The biocompatibility of diamond, and more specifically of CVD diamond, has 
already been proved in the literature [5, 40-46]. Regarding NCD coatings, it has been 
suggested that this feature can be extrapolated from the behavior of nanometric 
powders [2, 15, 47], but the purity, defect concentration, amorphous carbon content, 
specific surface area and morphology is quite different from those of a NCD coating. 
Only few publications have report on the biocompatibility of NCD coatings, some of 
them addressing very specific cell responses. Okrój et al. [3] demonstrated that NCD-
coated medical steel exhibits a higher level of resistance to blood platelet adhesion and 
thrombus formation than the bare material. Popov et al. [24] showed that a composite 
of NCD and amorphous carbon was not cytotoxic to osteoblastic SaOS-2 cells cultured 
for 3 days, as observed by SEM. Recently, Chong et al. [25] investigated the adhesion 
properties of human dermal fibroblasts on photochemically functionalized 
ultrananocrystalline diamond surfaces, and Bajaj [26] reported that for several cell lines 
86 
 
ultrananocrystalline diamond exhibited superior cell adhesion and proliferation 
compared to silicon and platinum film substrates. The present work addresses the 
biological profile of NCD coatings regarding the response of fibroblastic cells, namely 
the permanent cell line L929 and early passage gingival cells, in agreement with the 
standard ISO guidelines for in vitro cytotoxicity evaluation of medical devices [48, 49]. 
The cell line L929 is constituted by a highly proliferative population allowing rapid 
screening assays, mainly regarding acute toxicity testing towards cellular vitality and 
proliferation, whereas early passage fibroblast cell cultures, established from normal 
tissues, provide a more representative model of the in vivo fibroblast cell population 
being very sensitive to external environmental changes, allowing the detection of subtle 
cell responses. Fibroblast cells are the most common cells of all types of connective 
tissues, being actively engaged in the synthesis and upkeep of the collagenous 
extracellular matrix, and, in this context, biological evaluation with fibroblast cell 
cultures is regarded as a general bioassay providing information on acute and long-
term cell responses [48, 49]. 
Results showed that the present NCD coating provided a suitable surface for 
normal cellular attachment, morphology and growth. In addition, the seeded NCD 
coating reproduced the expected features of the two tested cell culture systems [29, 
39], suggesting the lack of cytotoxicity of this coating. It is known that nanophase 
materials are able to simulate surface properties of the constituents of living systems. 
Proteins, nucleic acids, lipids and carbohydrates possess unique properties determined 
by the size, folding and patterns at the nanoscale [50]. Therefore, in vivo, cells interact 
with surfaces with a large degree of nanometric roughness. In addition, the unique 
surface properties of nanophase materials, namely a higher number of atoms at the 
surface compared to bulk, greater areas of surface defects (such as edge/corner sites 
and particle boundaries) and larger proportions of surface electron delocalization [51] 
have been shown to influence initial protein interactions that control cell adhesion [52, 
53], a determinant event for the subsequent cell proliferation and function [37]. In 
general, nanophase materials present improved biocompatibility [54-57] and the 
present results are in line with the published studies. 
 
Conclusions 
The HFCVD deposition technique allows the growth of dense, homogeneous 
NCD coatings at a moderate rate (1 μm h−1) on bioinert Si3N4 ceramic substrates. NCD 
coatings provide a suitable surface for cell attachment, spreading and proliferation, as 
assessed by the behavior of a continuous fibroblast cell line (L929 cells) and normal 
human gingival fibroblast cells. Compared to standard polystyrene culture plates, cell 
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proliferation is slightly enhanced in both L929 and HG cells. In addition, the seeded 
films allow reproduction of the typical features of the two cell populations, further 
suggesting the lack of cytotoxicity of this coating. The cellular biocompatibility of the 
NCD coatings, allied with the excellent physicochemical performance, anticipates a 
wide range of applications in the dental biomedical field. 
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Abstract 
Nanocrystalline diamond (NCD) has a great potential for prosthetic implants 
coating. Nevertheless, its biocompatibility still has to be better understood. To do so, 
we employed several materials characterization techniques (SEM, AFM, micro-Raman 
spectroscopy) and cell culture assays using MG63 osteoblast-like and human bone 
marrow cells. Biochemical routines (MTT assays, Lowry‘s method, ALP activity) 
supported by SEM and confocal microscopy characterization were carried out. We 
used silicon nitride (Si3N4) substrates for NCD coatings based on a previous 
demonstration of the superior adhesion and tribological performance of these NCD 
coated ceramics. Results demonstrate an improved human osteoblast proliferation and 
the stimulation of differentiated markers, like ALP activity and matrix mineralization, 
compared with standard polystyrene tissue culture plates. The nanometric featuring of 
NCD, associated to its chemical affinity are key points for bone regeneration purposes. 
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Introduction 
Nowadays, the hip and the knee are the most replaced joints. The life span for 
these artificial joints is 10–15 years and their failure is normally associated to the 
generation of wear debris which causes periprosthetic osteolysis and aseptic 
loosening, incomplete osseointegration, and severe stress shielding [1,2]. When 
considering the young patients‘ joint replacement, this is a very short life time and the 
need for long-lasting prosthesis that allow reducing the number of revision surgeries is 
therefore evident [2]. 
Recently, the research of novel materials for orthopaedic implants had been 
focused on the incorporation of a certain degree of nanostructured surface features 
that mimic the nanometric structures and molecules found in bones. In particular, these 
appear to reduce the chances of rejection of the hip or knee prosthesis [3,4]. Most of 
the studies reported that nanophase topography fosters cell adhesion on polymers, 
ceramics and metals, and suggested a positive effect on osteoblasts metabolic 
activities [5–8]. 
The deposition of nanocrystalline diamond (NCD) coatings on implant surfaces 
is likely to improve the durability of orthopaedic prosthesis. NCD mimics the bone 
surface roughness, and it is very hard, simultaneously presenting a suitable fracture 
toughness. Moreover, diamond is biocompatible [9–16] and possesses a high chemical 
resistance. This set of properties envisages a high potential of NCD for biotribological 
purposes. Aspenberg et al. [11] showed that diamond particles are harmless when 
compared with UHMWPE, bone cement and chromium-cobalt particles that cause 
inflammatory reaction and a marked decrease in the amount of bone ingrowth. 
Furthermore, Nordsletten et al. [12] showed that diamond particles are inert in serum-
free monocyte culture and the cell morphology did not change after the ingestion of 
diamond. Histopathological studies revealed excellent biotolerance of AISI 316L 
stainless steel disks coated with NCD layers [13,14] and some investigations proved 
the haemocompatibility of diamond [13,15–17]. Other studies revealed that CVD 
diamond is as biocompatible as titanium and 316 stainless steel, which have been 
proved to have good biocompatibility and are frequently used in implantable devices 
[16]. Recently, it has been reported that NCD and NCD/amorphous carbon composite 
films were not cytotoxic to human osteoblast-like SaOS-2 cells [18,19]. 
NCD coatings can be grown on a great variety of possible substrates, however, 
exceptional film adhesion is one of the crucial requirements for the NCD use in 
biomedical implants. Silicon nitride (Si3N4) based ceramics are able to provide an 
excellent film adhesion due to the small thermal expansion coefficient mismatch with 
diamond, among other advantages [20]. The intrinsic mechanical resistance and 
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biocompatibility of Si3N4 ceramics envisage their superior behaviour as substrate 
bodies of the coated prosthesis. Some reports showed that human osteoblastic cells 
proliferated on polished surfaces of Si3N4 [21] and porous intramedullary Si3N4 rods 
implanted in rabbit femurs supported bone ingrowth [22]. Furthermore, Si3N4-bioglass 
composites proved to have an inductive effect on the proliferation of MG63 osteoblast-
like cells and were able to allow the complete expression of the osteoblastic phenotype 
[23]. The main purpose of the present work is to evaluate the NCD biocompatibility by 
in vitro cytotoxicity testing using the human cell system characteristic of the tissue, 
which the biomaterials it will confront in vivo. Highly adherent NCD films were grown on 
suitable Si3N4 ceramics. In the first stage of this study, NCD coatings were exposed to 
MG63 osteoblast-like cells for screening toxicity. Then, in the second stage, the NCD 
films were seeded with human bone marrow cells to assess the effects of the material 
in cell growth and expression of the osteoblastic phenotype, that is, the formation of a 
mineralized extracellular matrix. 
 
Material and Methods 
Materials preparation and characterization 
Details on composition and preparation of silicon nitride ceramics substrates 
can be found elsewhere [24]. Dense Si3N4 disc shaped substrates (diameter = 10 mm, 
diamond slurry. Before deposition, the Si3N4 substrates were scratched for 1 h in an 
ultrasonic -hexane (1 g/100 mL), followed 
by ultrasonic cleaning with ethanol for 10 min. NCD films were grown by the HFCVD 
technique using a Ar-CH4-H2 gas mixture and four linear tungsten filaments (ø= 0.25 
mm) precarburised for 30 min under 2% CH4 in H2. The filament and substrate 
temperatures (Tf and Ts, respectively) were monitored by a two-colour pyrometer and a 
K-type thermocouple in the substrate underside, respectively. NCD films were 
deposited using the following conditions: Ar/H2 = 0.1, CH4/H2 = 0.04, total gas pressure 
(P) = 5 kPa, total gas flow (F) = 50 mL min-1, substrate temperature (Ts) = 750ºC, 
filament temperature (Tf) = 2300ºC and deposition time (td) = 2 h. 
Before being seeded with cells, the NCD coated Si3N4 samples were washed 
with ethanol in an ultrasonic cleaner and sterilized by autoclaving.  
The NCD films were characterized by scanning electron microscopy (SEM; 
Hitachi S4100), atomic force microscopy (AFM, Digital Instrument Multimode IIIa) 
and micro-Raman spectroscopy (Jobin-Yvon T64000, Ar+ 514.5 nm line) to assess the 
morphologic features and quality of the films. 
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Cell cultures 
MG63 osteoblast-like cells 
MG63 cells were cultured in a-Minimal Essential Medium (-MEM) containing 
10% fetal bovine serum, 50 g mL-1 ascorbic acid, 50 g mL-1 gentamicin and 2.5 g 
mL-1 fungizone, at 37ºC in a humidified atmosphere of 5% CO2 in air. For subculture, 
the cell monolayer was washed twice with phosphate-buffered saline (PBS) and 
incubated with trypsin – EDTA solution (0.05% trypsin, 0.25% EDTA) for 5 min at 37ºC 
to detach the cells. The effect of trypsin was then inhibited by adding the complete 
culture medium at 37ºC. Cells were resuspended in culture medium and cultured (104 
cells cm-2) for 7 days in standard polystyrene culture plates (control) and on the surface 
of the NCD films in the ‗‗as-prepared‘‘ condition. The medium was changed every 2–3 
days. Control cultures and seeded material samples were evaluated at days 1, 3, and 7 
for cell viability/proliferation and observed by SEM and confocal laser scanning 
microscopy (CLSM; Leica SP2 AOBS). 
 
Human bone marrow cells 
Human bone marrow, obtained from orthopaedic surgery procedures after 
patient‘s (male, 27 years) informed consent, was cultured in the same experimental 
conditions as those used in the culture of MG63 cells. Primary cultures were 
maintained until near confluence (10–15 days) and, at this stage, adherent cells were 
enzymatically released (trypsin – EDTA solution) and seeded at a density of 104 cells 
cm-2 in standard polystyrene culture plates (control) and on the surface of the ‗‗as-
prepared‘‘ NCD films. Control and seeded material samples were cultured for 28 days 
in similar experimental conditions but the culture medium was further supplemented 
with 10 mM -glycerophosphate and 10 nM dexamethasone. All the 
experiments were performed in the first subculture, since the sequential passage of 
bone marrow cells fallout in a progressive loss of the osteoblast phenotype [25]. 
Control cultures and seeded material samples were characterized at days 2, 7, 
14, 21, and 28 for cell viability/proliferation, total protein content, alkaline phosphatase 
(ALP) activity, and observation by SEM and CLSM to evaluate cell morphology and 
matrix mineralization. 
 
Biochemical and microscopy assays 
Cell viability/proliferation 
MTT assay (reduction of 3-[4,5-dimethylthiazol-2-yl]–2,5diphenyltetrasodium 
bromide (MTT) to a purple formazan reaction product by living cells) was used to 
estimate cell viability/proliferation [26,27]. Cultures were incubated with 0.5 mg mL-1 of 
100 
 
MTT in the last 4 h of the culture period tested; the medium was then decanted, 
formazan salts were dissolved with 200 L of dimethylsulphoxide and the absorbance 
was measured at 600 nm in an ELISA reader. The results were normalized in terms of 
macroscopic area and expressed as A cm-2. 
 
Total protein content and alkaline phosphatase activity 
Culture samples were washed twice in PBS, frozen at -20ºC and evaluated at 
the end of the culture time. The total amount of protein present in the material surface 
was assayed by the Lowry‘s method with bovine serum albumin used as a standard. 
The results are expressed as g cm-2. ALP activity was determined in cell-layer lysates 
(obtained by treatment of the cultures with 0.1% triton in water) and assayed by the 
hydrolysis of p-nitrophenyl phosphate in alkaline buffer solution, pH 10.3, and 
colorimetric determination of the product (p-nitrophenol) at 405 nm. Hydrolysis was 
carried out for 30 min at 37ºC (NaOH (1M) was added to stop the reaction). Results are 
expressed in nanomoles of p-nitrophenol produced per min per g of protein (nmol min-
1 g protein-1). 
 
SEM and confocal microscopy 
For SEM observation, samples were fixed with 1.5% glutaraldehyde in 0.14M 
sodium cacodylate buffer (pH 7.3), then dehydrated in graded alcohols, critical-point 
dried, sputter-coated with gold and analyzed in a JEOL JSM 6301F scanning electron 
microscope equipped with a X-ray energy dispersive spectroscopy (EDS) 
microanalysis capability (voyager XRMA System, Noran Instruments). 
Cultures were labeled with calcein for the visualization of calcium-containing 
deposits. At each testing-point, the cultures were incubated with calcein (25 g/mL) for 
the last 3 h at 378C, washed several times in PBS and fixed in 3.7% paraformaldehyde 
(10 min). Cell cytoskeleton filamentous actin (F-actin) was visualized treating the cells 
with Alexa Fluor® 488 Phalloidin (1:20 dilution in PBS, 1 h). Cultures were 
counterstained with propidium iodide for cell nuclei labeling. Labeled cultures were 
mounted in Vectashield® and examined with a Leica SP2 AOBS (Leica Microsystems) 
microscopy. 
 
Statistical analysis 
Triplicate experiments were performed. The results are shown as the arithmetic 
mean ± the standard deviation (± SD). Analysis of the results was carried out using the 
Student‘s t-test, with a significance level of p < 0.05. 
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Results 
Materials characterization 
Representative SEM micrographs of the NCD films before being seeded are 
presented in Figure 1. The film, with ≈2 m of thickness, is composed by agglomerates 
of diamond nanocrystals (Figure 1a and b). The NCD coatings surface topography can 
be observed in Fig. 1c. The root-mean-square value (RMS) from AFM scans over 100 
m x 100 m regions was 68 ± 5 nm. A representative -Raman spectrum is given in 
Fig. 1d. The 1140 and 1480 cm-1 shoulders, usually attributed to trans-polyacetylene, 
are an indirect proof of the presence of NCD [28,29]. A band at 1228 cm-1 is also visible 
that appeared to be conjugated with vibration modes of C-H chains characteristic of 
nano- and ultrananocrystalline diamond [30]. Furthermore, it is also visible the 1332 
cm-1 diamond band as well as the D (1360 cm-1) and G (1560 cm-1) graphite bands. 
 
 
Figure 1 – SEM plan (a) and cross-sectional (b) views, AFM scan (c) and -Raman spectrum (d) of the as 
grown NCD films. 
 
Biological performance 
Behavior of MG63 osteoblast-like cells  
The results of viability/proliferation (MTT assay) are represented in Figure 2. 
MTT is metabolized to a purple formazan salt by mitochondrial enzymes in living cells 
and the absorbance is proportional to the number of viable cells. Comparing to 
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standard polystyrene culture plates, MTT reduction values for the seeded material 
samples were similar at day 1 and significantly higher at days 3 and 7. Both in control 
and in NCD films, cultures reached confluence by day 3 and soon after formed a dense 
cell layer that was easily lost during routine medium change, explaining the significant 
decrease in the MTT reduction values observed from day 3 to day 7. 
 
 
Figure 2 - Cell viability/proliferation of MG63 cells cultured on NCD coated Si3N4 substrates for 7 days, 
estimated by the MTT assay. Open bars, material samples; solid bars, control. (*: statistically different 
from the control). 
 
As can be seen in Figure 3a and b, at 1 day of culture, MG63 osteoblast-like 
cells were already well attached and completely spread, displaying a flat configuration 
and a typical morphology (central spherical body with the cytoplasm extending away 
from the central area in all directions and adhering to the material surface). 
Neighbouring cells have an extensive connection with each other through cytoplasmic 
extensions. After 3 days of culture, the cells formed multilayers of flattened sheets, 
covering completely the material surface (Figure 3c and d). For this time of culture, 
CLSM appearance was suggestive of a proliferative cell population (Figure 3d, circled 
cells). No deleterious or cytotoxic responses were observed for the entire time of 
culture. Cultures grown on standard polystyrene culture plates showed a similar 
behavior (not shown).  
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Figure 3 - SEM and CLSM (phalloidin and propidium iodide labeling) photographs of MG63 cells cultured 
on NCD coated Si3N4 substrates for 1 (a, b) and 3 (c, d) days. ■■■ - mitosis; ••• - chromosome 
duplication. 
 
Behaviour of human bone marrow cells 
Human bone marrow cells attached to the NCD films and MTT reduction values 
increased especially in the first week, remaining approximately constant afterward. As 
compared to control cultures, MTT values were similar at day 3 and higher at longer 
incubation times (Figure 4a). Both in control and seeded material, confluence was 
attained by the second week and after that, cell proliferation decreased slowly, as a 
result of extracellular matrix accumulation and cell-to-cell contact inhibition. Total 
protein content is also a measure of cell proliferation and the pattern was similar to that 
observed for the MTT reduction (Figure 4b). ALP activity (Figure 4c) increased during 
the first 2 weeks, attaining maximal values around day 14 and decreased afterward, 
both on the polystyrene plates and seeded NCD. However, the enzyme levels were 
higher in the NCD films. 
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Figure 4 - Cell viability/proliferation (a), total protein content (b), and ALP activity (c) of human bone 
marrow cells grown on NCD coated Si3N4 for 28 days. Open bars, material samples; solid bars, control 
(*statistically different from the control). 
 
SEM (Figure 5a) and CLSM (Figure 6a) observations of seeded NCD samples 
showed that cells were well spread and completely covered the surface after 7 days. 
Cell growth was accompanied by the production of fibrillar matrix, as well evidenced in 
the observation at day 14 (Figure 5b). In addition, 21-day cultures presented 
mineralized globular structures intimately associated with the fibrous cell layer (Figure 
5c and b). The same sequence of events took place on the standard polystyrene 
culture plates, although with, apparently, less fibrillar matrix production (Figure 5e), and 
lower abundance of mineral deposition (Figure 5f).  
 
 
Figure 5 - SEM observation of human bone marrow osteoblastic cells cultured on NCD films at days 7 (a), 
14 (b), and 21 (c). For comparison, cell behavior observed on standard polystyrene culture plates at days 
7 (d), 14 (e), and 21 (f) is also shown. 
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Figure 6 - CLSM observation of human bone marrow osteoblastic cells cultured on NCD films at days 7 
(a) and 21 (b) (calcein, phalloidin, and propidium iodide labeling). 
 
The low SEM magnification in Figure 7a corresponding to the 21 days bone 
marrow cells cultures on NCD films, denotes the abundant presence of the referred 
mineralized deposits. The X-ray spectrum in Figure 7c from EDS analysis (labeled with 
an asterisk in Figure 7b), proves the inorganic nature of these structures by showing 
strong Ca and P peaks. 
 
 
Figure 7 - Formation of calcium phosphate deposits in human bone osteoblastic cell cultures grown on 
the NCD films at day 21. (a) low magnification SEM appearance; (b) detail of the mineralized structures; 
(c) representative EDS spectrum of the mineralized structures. 
 
Discussion 
The clinical success of any implant depends on the cellular behaviour at the 
host\biomaterial interface, and if coated, on the coating/substrate reliability, besides the 
osteointegration of the implant. In our recent works [31–33] it was demonstrated that 
NCD is highly adherent to Si3N4 substrates, presenting an interfacial crack resistance 
of ≈6 N m-1 in static indentation testing and a delamination threshold load of 60 N 
(≈3.5 GPa) in self-mated tribological experiments. Also, Si3N4 substrates did not induce 
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cytotoxic responses and were able to allow the complete expression of the osteoblastic 
phenotype [23]. 
The present article deals with the NCD chemistry and morphology that can 
affect the biological response including cell attachment, cell growth, and functional 
activity. Cell cultures on the materials surface are a reliable, suitable, and reproducible 
screening method to detect cell death and negative effects on cellular functions and 
represent the starting point to assess the biological response to foreign materials [1]. 
The biological performance of NCD coated Si3N4 ceramics was evaluated using cell 
cultures of MG63 osteoblast-like cells for a preliminary and quick screening and human 
bone marrow cells for assessment of osteoblastic cell growth and osteogenic 
differentiation. 
The results of the study with the MG63 osteoblast-like cells indicate excellent 
proliferation on NCD surface while keeping a normal cellular morphology (Figure 2 and 
3). Also, human bone marrow cells grown in experimental conditions that favor 
osteoblastic proliferation and differentiation [34,35] presented a high cell growth rate 
with the formation of abundant fibrillar matrix, production of high ALP levels and matrix 
mineralization following the maximal ALP activity (Figure 4–7). This behavior is 
representative of that reported for the development of the osteoblastic phenotype in 
several bone cell systems including human bone marrow cell cultures [34]. In addition, 
compared with cultures performed in standard polystyrene culture plates, NCD films 
induced osteoblastic cell proliferation, as shown by the higher growth rate presented by 
MG63 and bone marrow cells growing in the material surface, and stimulated metabolic 
differentiated activities, namely ALP activity and production of a mineralized matrix. 
These observations are suggestive of a bioactive behaviour of the NCD films. Recent 
studies on the in vitro osteoblastic biocompatibility of NCD coated surfaces also 
reported favourable results on osteosarcoma SaOS-2 cells, namely absence of 
cytotoxicity of a composite of NCD and amorphous carbon as observed by SEM [18] 
and upregulation of ALP on a BMP-2 treated NCD-coating of titanium disks [19].  
NCD is a nanostructured material composed by agglomerates of diamond 
nanocrystals surrounded by an amorphous matrix (Figure 1) with surface roughness 
within the nanoscale range. These nanofeatures are likely the responsible for the 
increased osteoblast proliferation and function, when compared with the control 
cultures. A variety of studies reports that cells respond differently to nanostructured 
compared with conventional structured material topographies in terms of cell adhesion, 
proliferation, and function [3,4]. Nanophase materials simulate surface properties of the 
constituents of living systems as biomolecules such as proteins, nucleic acids, lipids, 
and carbohydrates possess unique properties determined by the size, folding, and 
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patterns at the nanoscale [36]. Regarding the bone constituents, hydroxyapatite, the 
major inorganic component, is between 2 and 5 nm in width and 50 nm in length. 
Collagen type I, the major organic component of the bone tissue, is 300 nm in length, 
0.5 nm in width, and has a periodicity of 67 nm [36]. In this way, the osteoblasts 
interact with surfaces with a large degree of nanometric-scale morphological features. 
Webster et al, in a variety of studies investigating cellular reaction against orthopaedic 
and dental nanomaterials, found increased osteoblastic activity compared with 
conventional ceramics, polymers, carbon nanofibers, metals, and composites of these 
materials [5,6,37–40]. Improved cell performance appears to be related to the unique 
surface properties of nanophase materials, namely a higher number of atoms at the 
surface compared to bulk, greater areas of surface defects (such as edge/corner sites 
and particle boundaries) and larger proportions of surface electron delocalizations 
[41,42]. Such greater surface reactivity has been shown to influence initial protein 
adsorption in terms of concentration, conformation, and bioactivity, events that control 
cell adhesion and proliferation [43–46]. Also, the quantitative increase in the total 
length of particle boundaries and total number of pores between surface particles of 
nanophase materials provide a significantly extended surface area for osteoblast 
proliferation, compared with micron-structured surfaces.  
Results obtained under this study suggest that the prepared NCD coating 
presents excellent biocompatibility and bioactivity features, as shown by the improved 
human osteoblast proliferation and function. The ultimate biological assessment must 
now be performed in an animal model to evaluate the interfaces behaviour and the 
osteointegration through push-out strength measurements and histological studies. 
 
Conclusions 
NCD films induced human osteoblast proliferation and stimulated specific 
metabolic activities such as ALP activity and matrix mineralization. These 
biocompatibility and bioactivity features suggest the potential of NCD as a coating for 
orthopedic applications. The high chemical resistance and unique mechanical 
properties of NCD associated with its ability in simulating the nanometric features of the 
bone tissue might offer exciting possibilities in the design and efficacy regarding bone 
regeneration strategies. 
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Abstract 
The development of optimized hip joint materials is one of the most challenging 
opportunities in prosthetic technologies. In current approaches, ultra-high-molecular-
weight polyethylene (UHMWPE) has been a favorite material for the acetabular 
component and, regarding the cementless technique, several coating options may be 
considered to contain and stabilize bearing surfaces and establish an improved 
interface with bone. In this work, newly developed constructs of UHMWPE coated with 
either commercially pure titanium (cpTi-UHMWPE), by DC magnetron sputtering, or 
with commercially pure titanium and hydroxyapatite (cpTi/HA-UHMWPE), by DC/RF 
magnetron co-sputtering, have been prepared and biologically characterized with 
human bone marrow-derived osteoblastic cultures. The cpTi-UHMWPE samples 
allowed a high cell growth and the expression of the complete osteoblastic phenotype, 
with high alkaline phosphatase activity, expression of osteogenic-associated genes and 
evident cell-mediated mineralization of the extracellular matrix. In comparison, the 
cpTi/HA-UHMWPE samples reported lower cell proliferation but earlier cell-mediated 
matrix mineralization. Accordingly, these newly developed systems may be suitable 
candidates to improve the osteointegration process in arthroplastic devices; 
nevertheless, further biological evaluation should be conducted. 
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Introduction 
The increase in life expectancy, due to the advancements in the field of medical 
sciences, contributes to increasing number of the elderly demanding replacement of 
failed tissues with regenerative strategies, which embraces the implantation of 
biomaterials and artificial implants [1]. In the case of the hip joint, which is subjected to 
high levels of cyclic mechanical stress, it is expected that the aging process, in close 
association with the eventual development of degenerative or rheumatologic diseases, 
establishes a localized tissue destruction, outputting the need of tissue replacement [2]. 
In this way, the selection of adequate components for joint replacement must consider 
biological, as well as physical and mechanical issues [3].  
Ultra-high-molecular-weight polyethylene (UHMWPE) has gained widespread 
support as a material of choice for bearing surfaces routinely used in several 
arthroplastic applications (including total shoulder, knee and hip replacements), due to 
its adequate elastic properties, corrosion resistance and ability to achieve a smooth 
surface through machining techniques [4, 5]. Despite the clinical success attained with 
this material in hip arthroplasty, definitive long-term function has not been established 
yet, especially within cemented applications [6]. Major limitations include deleterious 
biological effects due to the exothermic reaction occurring during the cement curing 
process [7], and mechanical failure of the bone–cement interface, cement–implant 
interface or the cement mantle itself, generally leading to implant revision due to 
aseptic loosening [8]. In fact, the long-term failure rate of cemented polyethylene cups 
has been reported in the range of 22 to 49% [9–11]. Consequently, cementless 
acetabular components were developed with the introduction of a modular metal liner, 
aiming to contain and stabilize UHMWPE bearing surfaces and establish a direct 
interface with the bone tissue. This direct union has the ability to provide a dynamic 
and durable interface which is expected to be resistant to late aseptic loosening [11]. 
Even so, the metal-backed system has been reported to generate new complications 
including liner dissociation, expansile osteolysis and late debonding of the coatings 
[11], most of the time associated with reduced polyethylene thickness required by 
component modularity and suboptimal designs related to locking mechanisms and 
three-dimensional geometry [12, 13]. 
In this way, the development of a new approach that allows the control of 
surface properties and maintains the thickness and design of the UHMWPE 
component, at the same time favoring its long-time integration with the bone tissue, 
may improve the clinical outcome of total hip replacements [14]. Several coating 
options may be considered in order to control the physical and mechanical properties 
of the bulk material, enhancing, at the same time, the biological response. Either way, 
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depending on the strategy, the coatings  should either provide a stable, non-dissolving 
interface with tissues (achieved, for instance, with a titanium coating) or should 
dissolve gradually being substituted by newly formed bone (which can be achieved with 
a calcium phosphate-based coating) [14]. Titanium is a bioinert material that does not 
induce adverse reactions following tissue implantation [15]. In fact, titanium and 
titanium alloys have reported adequate biocompatibility both for in vitro and in vivo 
functions and are currently used in diverse arthroplastic fixative surfaces, mainly due to 
their apatite-inducing ability [16–18]. Furthermore, bioactive calcium phosphate 
coatings have also been used to provide a superficial environment that induces bone 
growth at the materials‘ surface, promoting a high strength interfacial bonding between 
the implant and the tissue [19–21]. Accordingly, and to the best of the authors‘ 
knowledge, the development and comparison of titanium and titanium plus 
hydroxyapatite (HA) coatings over UHMWPE substrates have not been previously 
reported, although these novel approaches are expected to significantly enhance the 
biological and biomechanical behavior of total arthroplastic applications. 
In this way, the purpose of this study consists in the evaluation of the biological 
behavior of two newly developed coatings onto UHMWPE substrates, i.e. UHMWPE 
coated with commercially pure titanium (cpTi) and UHMWPE coated with cpTi and HA. 
The coatings were applied by DC magnetron sputtering and DC/RF magnetron co-
sputtering, respectively, techniques which allow the deposition of thin, dense, fine-
grained and uniform coatings with strong adhesion and compact structure that can 
survive without delamination in body fluids and are able to withstand high surface 
pressures [14, 22]. 
 
Materials and methods 
Materials preparation 
UHMWPE polished disks (diameter of 16.1 mm and thickness of 5.1 mm) were 
used as substrates. cpTi and phase pure HA were used as sputtering target materials. 
UHMWPE substrates were coated with cpTi byDC magnetron sputtering (cpTi-
UHMWPE) and with cpTi/HA by DC/RF magnetron co-sputtering. HA preparation, as 
well as cpTi-UHMWPE and cpTi/HA-UHMWPE samples‘ preparation and 
physicochemical characterization, was studied in detail in a previous report [23]. Briefly, 
cpTi and cpTi/HA coatings exhibited slight differences in the wettability (contact angle 
of 93.5◦ ± 7.4 and 84.0◦ ± 14.4 for water, respectively), estimated surface tension (38.2 
mN m−1 and 26.6 mN m−1, respectively) and zeta potential (−55.1±5.2mV and −45.4± 
3.7 mV, respectively). On scanning electron microscopy (FEIQuanta 400FEG scanning 
electron microscope equippedwith X-ray EDS microanalysis capability, EDAX Genesis 
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X4M), both coatings presented a homogeneous coverage of the substrate surface, 
although distinct morphologies were observed, as shown in Figure 1. Regarding the 
cpTi/HA samples, the presence of calcium, phosphorus and titanium was analyzed by 
x-ray mapping, which reported a homogeneous distribution of these elements. 
Representative maps are shown in Figures 1D, E and F and represent the distribution, 
in weight percentage, of these three elements in the cpTi/HA samples [23]. 
Evaluation of samples‘ cross section allowed the determination of the thickness 
of the coating. cpTi-UHMWPE coatings presented a uniform thickness of 1.61 ± 0.35 
μm, while cpTi/HA-UHMWPE presented a thickness of 0.22 ± 0.04 μm [23]. A 
representative cross-section image of cpTi-UHMWPEis shown in figure 1(C). As a 
result of the deposition process, by DC/RF magnetron co-sputtering, the ceramic 
material deposited presented an amorphous structure rather than a crystalline one, 
which impaired XRD quantification. 
 
 
Figure 1 - SEM morphology of the surface of cpTi-UHMWPE (A) and cpTi/HA-UHMWPE (B) samples. 
Cross section of a cpTi-UHMWPE sample (C). X-ray mapping of the surface of the cpTi/HA-UHMWPE 
samples for calcium (D), phosphorus (E) and titanium (F). 
 
 Adhesion measurement was performed using a Sebastian V tester, which has 
the same functional principle as the pull-off test. The cpTi-UHMWPE samples 
presented inferior adhesion compared to that of the cpTi/HA-UHMWPE samples (3.26 
± 1.19 MPa and 5.00 ± 1.61 MPa, respectively) [23].  
Prior to the in vitro biological study, all samples were sterilized with ethylene 
oxide gas. 
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Cell cultures 
Human bone marrow cells were collected from orthopedic surgical procedures 
of traumatic reconstruction, after patients gave their informed consent. The patients 
were males, between 25 and 40 year old, and reported the absence of systemic 
associated pathologies. The bone marrow cells were cultured in an α-minimal essential 
medium (α-MEM) supplemented with 10% of fetal bovine serum, 50 μg.ml−1 of ascorbic 
acid, 100 IU.ml−1 of penicillin, 100 μg.ml−1 of streptomycin and 2.5 μg.ml−1 of fungizone, 
at 37 ◦C and 5% CO2 in air. The culture medium was changed twice a week. The 
primary culture was maintained until near confluence, and first subcultured cells were 
seeded (104 cells cm−2): (i) under control conditions (standard polystyrene culture 
plates) and (ii) onto the cpTi-UHMWPE and cpTi/HA-UHMWPE coated samples, both 
under the ‗as-prepared‘ condition (A samples) and after pre-incubation treatment with a 
fully supplemented culture medium over 24 h (B samples). The cells were cultured, for 
21 days, under the same conditions as used in the primary culture, but the culture 
medium was further supplemented with 10 mM β-glycerophosphate and 10 nM 
dexamethasone—conditions known to induce the osteogenic phenotype [24]. Cultures 
were characterized throughout the incubation time for proliferation and osteoblastic 
function, as follows. 
 
Cell viability/proliferation.  
Evaluation of the cellular viability/proliferation was performed through the MTT 
assay at days 7, 14 and 21. MTT is reduced, by living cells, to purple formazan 
crystals. Cultures were incubated with 0.5 mg.ml−1 of MTT (37 ºC, 5% CO2 in air, 4 h), 
following which the medium was decanted, the formazan crystals dissolved with 
dimethylsulphoxide and the absorbance determined (600 nm) with an ELISA reader 
(Denley Wellscan). The results were expressed as absorbance per square centimeter 
(A.cm−2). 
 
Protein content and alkaline phosphatase activity 
At days 7, 14 and 21, the cultured samples were washed twice with PBS and 
the total protein content was determined according to the Lowry method, using bovine 
serum albumin as a standard. The activity of alkaline phosphatase (ALP) was 
determined in cell lysates (obtained by treatment of the cultures with 0.1% triton) and 
assayed through the hydrolysis of p-nitrophenyl phosphate, (30 min, 37 ºC), in an 
alkaline buffer solution (pH 10.3), followed by colorimetric determination of the product, 
p-nitrophenol, at 405 nm. The results were expressed as nanomoles of p-nitrophenol 
produced per minute per microgram of total protein (nmol.min−1/μg protein). 
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Total RNA extraction and RT-PCR analysis  
RT-PCR was used to access the expression of ALP, bone morphogenic protein-
2 (BMP-2) and collagen type I (Col I) genes by bone marrow-derived osteoblastic cells, 
grown for 21 days on the surface of control, cpTi-UHMWPE and cpTi/HA-UHMWPE 
samples. Total RNA was extracted using the RNAeasy® Mini Kit from Qiagen, 
according to the manufacturer‘s instructions and was quantified by measuring the 
absorbance of the samples at 260 nm. RT-PCR was done using the TitanOne TubeRT-
PCR System from Roche Applied Science, according to the manufacturer‘s 
instructions. Briefly, 0.5 μg of total RNA from each sample was reverse transcribed into 
cDNA (30 min at 50 ºC), while PCR was performed with an annealing temperature of 
55 ºC, for 25 cycles. The used primers are reported in Table 1. 
 
 
 
Following, the PCR products were electrophoresed in a 1% agarose gel, 
stained with ethidium bromide. Densitometric analysis was performed with the ImageJ 
software (version 1.41o, National Institutes of Health, USA) after normalization to the 
housekeeping gene GADPH. 
 
Immunostaining of F-actin cytoskeleton.  
At days 3 and 14 of the culture, the cells were fixed (4% formaldehyde, 15 min), 
permeabilized with 0.1% triton and incubated in 10 mg.ml−1 bovine serum albumin with 
100 μg.ml−1 RNAse. F-actin filaments were stained with Alexa Fluor-conjugated 
phalloidin (1:100) and nuclei were counterstained with 10 μg.ml−1 propidium iodide. 
Images were obtained using aLeica TCP SP2 AOBS confocal microscope. 
 
Matrix mineralizarion 
At days 14 and 21, the cultures were fixed (1.5% of glutaraldehyde in 0.14 M of 
sodium cacodilate buffer, 10 min), dehydrated in graded alcohols (70, 80, 2 × 90 and 
99.8%), dried at critical point and sputter-coated with gold. The samples were observed 
by SEM and analyzed by x-ray spectroscopy (EDS), under a FEI Quanta 400FEG 
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scanning electron microscope equipped with EDS microanalysis capability, EDAX 
Genesis X4M. 
 
Statistical analysis.  
The results are presented as arithmetic means ± standard deviation of five 
replicates. Analysis of the results was carried out with the use of Student‘s t-test, with a 
significance level of P < 0.05. 
 
Results 
Cell viability/proliferation 
Cell viability/proliferation, evaluated through the MTT assay, is presented in 
Figure 2. The cells grown on the surface of the culture plate (control cultures) 
proliferated through the culture time, with a stationary phase during the third week. 
Regarding the cpTi-UHMWPE samples, MTT reduction was lower at days 7 and 
14, and similar at day 21. The pre-incubation treatment did not have a significant effect 
on the cell viability/proliferation of the seeded cpTi/UHMWPE samples. Comparatively, 
seeded cpTi/HA-UHMWPE presented lower MTT reduction values through the culture 
time. The outcomesof the pre-incubation revealed to be significant for this material. At 
days 7, 14 and 21, the values were significantly higher than those observed in the non-
pre-incubated samples. 
 
 
Figure 2 - Cell viability/proliferation of human bone marrow osteoblastic cells cultured for 21 days on 
the culture plate (control), and on the surface of cpTi-UHMWPE and cpTi/HA-UHMWPE. A: ‘as prepared’ 
samples; B: pre-incubated samples. *Significantly different from control. **Significantly different from 
cpTi-UHMWPE. 
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Immunostaining of the cytoskeleton 
Confocal laser scanning microscopy (CLSM) appearance of the material 
samples labeled for F-actin and nuclei is shown in Figure 3. On cpTi-UHMWPE (both 
on ‗as-prepared‘ and pre-incubated samples), at day 3, the cells were well distributed 
on the material surface and presented an elongated morphology and cell-to-cell contact 
(Figures 3A, B); at day 14, the cell layer covered a significant area of the material 
surface (Figures 3E, F). ‗As-prepared‘ cpTi/HA-UHMWPE presented a poor 
performance; the few cells attached to the surface displayed a disrupted morphology, 
which further deteriorated throughout the culture time (Figures 3C, G). However, on the 
pre-incubated samples, the cells appeared well spread and, at day 14, disperse cell 
aggregates were found throughout the materials‘ surface (Figures 3D, H). At a high 
magnification, the organization of the actin cytoskeleton of both pre-incubated cpTi-
UHMWPE and cpTi/HA-UHMWPE samples appeared similar to that of control, Figures 
3I–K. 
 
 
Figure 3 - CLSM appearance of the cpTi-UHMWPE and cpTi/HA-UHMWPE samples cultured with human 
bone marrow osteoblastic cells for 3 days (A)–(D) and 14 days (E)–(H). cpTi-UHMWPE A (A, E) and 
cpTi/HA-UHMWPE A (C, G): ‘as prepared’ samples; cpTi-UHMWPE B (B, F) and cpTi/HA-UHMWPE B (D, 
H): pre-incubated samples. High magnification of control cultures (I); pre-incubated cpTi-UHMWPE (J) 
and pre-incubated cpTi/HA-UHMWPE (K), at 14 days. 
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Cell function 
Figure 4 shows that, regarding ALP activity, both ‗as-prepared‘ and pre-
incubated cpTi-UHMWPE samples, as well as the pre-incubated cpTi/HA-UHMWPE 
materials, presented a profile similar to that of the control cultures, i.e. a significant 
increase in the enzyme activity during the third week of culture. By contrast, ALP was 
practically absent on the seeded ‗as-prepared‘ cpTi/HA-UHMWPE samples.  
 
 
Figure 4 - ALP activity of human bone marrow osteoblastic cells cultured for 21 days on the culture plate 
(control) and on the surface of cpTi-UHMWPE and cpTi/HA-UHMWPE. A: ‘as prepared’ samples; B: pre-
incubated samples. *Significantly different from control. 
 
Regarding the assessment of osteogenic-related gene expression by RT-PCR, 
following 21 days of culture over both control and material samples pre-incubated with 
the culture medium, there were no significant differences found regarding the 
expression of ALP, BMP-2 and Col I, as shown in Figure 5. 
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Figure 5 - Results from the RT-PCR of osteogenic-associated genes (ALP, BMP-2 and Col I) in cultures 
established for 21 days on the surface of control and pre-incubated samples. Representative agarose gel 
and densitometric analysis. 
 
SEM observation of the cpTi-UHMWPE samples at days 14 and 21 (Figure 6) 
showed an excellent proliferation profile with the surface completely covered by a cell 
layer, at day 21. In addition, the 21 day cultures displayed discrete mineralized 
deposits which contained calcium and phosphorus. The pre-incubation treatment did 
not affect the cell behavior. On the other hand, cpTi/HA-UHMWPE seeded under the 
‗as-prepared‘ condition showed few attached cells with a disrupted structure (Figures 
7A and D, 14 day cultures). However, the pre-incubated cpTi/HA-UHMWPE samples 
presented cell clusters with evident formation of cell-mediated mineralized deposits at 
day 14 (Figures 7B, C and E). For comparison, Figure 8 shows the SEM appearance of 
human bone marrow cells cultured on the tissue culture plate (control cultures), at days 
14 and 21. The presence of calcium phosphate deposits was observed by day 21. 
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Figure 6 - SEM appearance of the cpTi-UHMWPE samples cultured with human bone marrow 
osteoblastic cells for 14 days (A)–(D) and 21 days (E)–(H). High magnification of the mineralized deposits 
in 21 day samples (I) and (K) and the respective EDS spectra (J) and (L). cpTi-UHMWPE A (A, B, E, F, I, J): 
‘as prepared’ samples; cpTi-UHMWPE B (C, D, G, H, K, L): pre-incubated samples. 
 
 
 
Figure 7 - SEM appearance of the cpTi/HA-UHMWPE samples cultured with human bone marrow 
osteoblastic cells for 14 days (A)–(E). (F) EDS spectrum of the mineralized deposits present on pre-
treated cp-Ti/HA-UHMWPE. cpTi/HA-UHMWPE A (A, D): ‘as prepared’ samples; cpTi/HA-UHMWPE B (B, 
C, E, F): pre-incubated samples. 
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Figure 8 - SEM appearance of human bone marrow osteoblastic cells cultured on standard tissue culture 
plates (control cultures) for 14 days (A) and 21 days (B), (C). (D) EDS spectrum of the mineralized 
deposits. 
 
Discussion 
The development of UHMWPE samples coated with cpTi (cpTi-UHMWPE) or 
cpTi and HA (cpTi/HA-UHMWPE), by DC magnetron sputtering and DC/RF magnetron 
cosputtering, respectively, aimed the conception of a novel acetabular component 
made of just one piece, in which the metallic shell is substituted by a coating material. 
The cellular biocompatibility of the coated UHMWPE samples was assessed with 
human bone marrow cells cultured under experimental conditions known to favor 
osteoblastic differentiation [24]. The material samples were tested ‗as-prepared‘ and 
after a pre-incubation treatment with fully supplemented culture medium for 24 h.  
The seeded cpTi-UHMWPE samples exhibited the complete 
proliferation/differentiation sequence of human bone osteoblastic cells,with a high cell 
growth, the synthesis of high ALP levels, expression of osteogenic-related genes, and 
the formation of a calcium-phosphate-containing mineralized matrix by day 21. 
Compared to control, fewer cells attached to the material surface, as suggested by the 
lower values in the MTT assay, at day 7. This is most probably related to the seeding 
procedure in which a cell suspension was poured over the surface of a disk and, as 
expected, a significant percentage of cells slipped off to the bottom of the culture plate. 
This event was further enhanced by the smooth features of the material surface. 
However, subsequently, the attached cells presented a high proliferation rate forming a 
cell sheet over the surface, from 2 weeks onward. At day 21, the MTT reduction values 
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were similar to control suggesting a good performance of this material. Pre-incubation 
treatment revealed to have no significant influence on the biological behavior of the 
cpTi- UHMWPE samples. The present results are in agreement with the known 
behavior of titanium surfaces, which are reported to be biocompatible, supporting 
osteoblast proliferation and differentiation, as well as adequate osteointegration in vivo 
[16]. 
The results regarding the cpTi/HA-UHMWPE samples showed that the 
performance of this coating was very sensitive to the pre-incubation treatment. The ‗as-
prepared‘ samples reported few attached cells with disrupted morphology and low 
viability. This behavior might be related to the leaching of the HA component leading to 
an altered ionic concentration on the surface microenvironment impairing cell 
anchorage and adhesion which compromises the subsequent proliferation event. 
These limitations are favored by the in vitro stationary system used, which does not 
allow the renewal of the medium, resulting in accumulation of the leaching material on 
the coating surface. In vivo, the impairment of the cell response due to these surface 
events is expected to be attenuated by the permanent flow of body fluids at the 
cell/biomaterial interface. In addition, the material surface is conditioned by bioactive 
molecules present in the extracellular fluid, providing a suitable environment for the 
adhesion of the available osteoprogenitor cells. In this way, pre-incubation of the 
cpTi/HA-UHMWPE samples with a complete culture medium, before cell seeding, 
should decrease the deleterious effects resulting from the accumulation of leaching 
products on the material surface and also provide some biological conditioning of the 
surface. Accordingly, results showed that pre-incubation of the cpTi/HA-UHMWPE 
samples improved cell behavior, i.e. the cells exhibited a normal morphology and 
organized into small cell clusters that expressed high levels of ALP and showed earlier 
exuberant cell-mediated matrix mineralization compared to cpTi-UHMWPE coating. 
Several works in the literature using CaP-sputtered coatings support these results. For 
instance, Hulshoff et al stated that proliferation of mouse osteoblastic cells was 
significantly higher on noncoated samples compared to CaP-coated Ti samples, 
although increased matrix mineralization was established on the coated surfaces. Also, 
TEM analysis showed that the cells were embedded by crystallized needle-shaped 
CaP structures, entrenched in collagen fibers [25]. Further, Perozzolo et al reported 
that osteogenic cells from a newborn rat calvaria presented significantly more ‗bone-
like nodules‘ when cultured over HA-coated surfaces compared to titanium-coated 
ones [26]. One of the mechanisms associated with the increased differentiation 
process may be related to the early dissolution of the CaP coating, increasing the 
availability of calcium and phosphate in the microenvironment, followed by the 
129 
 
formation of a bonelike mineral layer by re-precipitation. This mineral layer may favor 
early protein adhesion that enhances cell behavior, namely the differentiation process 
of osteoblastic cells [27]. The surface characteristics of cpTi-UHMWPE and 
cpTi/HAUHMWPE might also contribute to the different cell behavior on the material 
samples. In regard to surface topography, as visualized by high magnification SEM 
micrographs, the observed differences may contribute to the distinct biological 
behavior. In addition, the characterization of the adhesion values of the deposited 
coatings on the substrate was considered to be among those which are strong enough 
to be used in the envisaged applications. Unlike HA coatings on metallic implants, 
there are no minimum requirements for this kind of coating in the medical field. The 
association of HA with cpTi led to a slight increase of the coatings‘ hydrophilicity, as 
was determined by contact angle measurements with water, and to a less negative 
zeta potential, as was determined by streaming potential measurements. However, the 
biological significance of these differences is most probably negligible considering that 
the behavior of the cpTi/HA-UHMWPE coating, under cell culture conditions, was 
highly conditioned by material leaching, hampering a correlation with surface charge 
and hydrophobicity effects. Additional biological characterization should be conducted, 
reaching the level of dynamic in vitro cell culture models or preliminary in vivo 
experiments, in order to further address and compare the biological profile of both 
developed systems. 
 
Conclusion 
The cpTi-UHMWPE and cpTi/HA-UHMWPE systems, prepared by DC 
magnetron sputtering and DC/RF magnetron co-sputtering, respectively, might 
constitute useful approaches to the development of novel acetabular components 
made of just one piece, in which the coating material establishes a direct interface with 
the bone tissue. The cpTi-UHMWPE samples allowed a high cell proliferation and ALP 
expression, while the cpTi/HA-UHMWPE system induced earlier cell-mediated matrix 
mineralization—the final event of the in vitro osteogenic differentiation. These newly 
developed systems may be suitable candidates to improve the osteointegration 
process in arthroplastic devices; nevertheless, further biological evaluation should be 
conducted.  
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Abstract 
Glass-reinforced hydroxyapatite composites (GR–HA) are bone regenerative 
materials that are characterized by their increased mechanical properties, when 
compared to synthetic hydroxyapatite. Bonelike® is a GR–HA that is a result of the 
addition of a CaO–P2O5 based glass to a HA matrix. This biomaterial has been 
successfully applied in clinical bone regenerative applications.  
This work aims to evaluate the ability of Bonelike® to support the adhesion, 
proliferation and phenotypic expression of human endothelial cells, aiming to establish 
new bone tissue engineering pre-endothelialization strategies. Bonelike® discs, 
regardless of being submitted to a pre-immersion treatment with culture medium, were 
seeded with first passage human umbilical vein endothelial cells, and characterized 
regarding proliferation and differentiation events. Pre-immersed Bonelikeallowed the 
adhesion, proliferation and phenotype expression of endothelial cells. Seeded 
materials presented positive immunofluorescent staining for PECAM-1 and a tendency 
for the formation of cord-like arrangements under angiogenesis-stimulating conditions, 
although, compared to standard culture plates, a slight decreased cell growth was 
observed. In this way, Bonelike® may be a suitable candidate for pre-endothelialization 
approaches in bone tissue engineering applications. 
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Introduction 
The current interest about the process of angiogenesis—the formation of new 
blood vessels from pre-existing ones—is growing in all research and clinical fields, 
aiming to solve several pathological conditions, including the impaired tissue 
regeneration. The interaction between the bone and the vascular system has long been 
known [1] although, for a long time, research focused on the osteogenic process. More 
recently, a paradigm shift was driven into the establishment of adequate vasculature 
given that insufficient or inappropriate tissue irrigation is associated with decreased 
bone formation [2]. Also, inhibition of the angiogenic process leads to the formation of 
fibrous tissue in animal models of bone fracture repair [3] and distraction osteogenesis 
[4]. It is also established that poor blood supply is a risk factor for bone healing and that 
several other risk factors may act negatively over the vasculature, impairing an 
adequate biological response [5–7]. 
Upon implantation of a bone graft, the first days are critical, with inflammation 
and revascularization occurring. Current evidence reflects that the establishment of 
adequate vascularisation, right after the implantation, is essential for the development 
of the repair process and wound healing [7, 8]. An adequate vascular network allows 
the nutritional support and removal of metabolic waste products from the regenerating 
area, and provides a continuous availability of precursor cells to the target area, along 
with a large variety of biological mediators involved in cell-to-cell communication [9, 
10]. In this way, endothelial cells play an essential role in the wound healing as they 
constitute the inner surface of the blood vessels and are the primary cells involved in 
the process of angiogenesis. They are also actively engaged in the release of 
cytokines and the expression of cell adhesion molecules, thus participating in the 
inflammatory response and contributing to the intercellular cross-talk. This process is 
particularly relevant when established within cells of the osteoblastic lineage, which are 
responsible for the bone formation events at the material‘s surface [7]. 
Accordingly, several approaches have emerged to enhance the rate of 
vascularization from the surrounding tissues into the implanted bone grafts. These 
include the incorporation of angiogenic factors into the materials [11,12], deposition of 
an angiogenic extracellular matrix on the materials‘ surface [13, 14] and delivery of 
genes encoding angiogenic factors [15–17], all aiming to induce the endothelial 
function. Other promising approach is the materials‘ pre-vascularization with 
autologous endothelial cells which, upon implantation with the host‘s vascular system, 
would allow a rapid vascular supply throughout the biomaterial. Regarding this, recent 
in vitro studies addressed the potential of several bone regenerative materials to 
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perform as appropriate substrates for endothelial cell growth and differentiation, to be 
used on tissue regeneration applications [18, 19].  
New approaches on biomaterial‘s production for tissue engineering strategies 
include natural and synthetic materials, designed in a biomimetic approach regarding 
the bone tissue composition. Biological apatite (which comprises the mineral phase of 
the calcified tissues) contains mainly Ca2+, PO4
3– and OH- ions, although several trace 
ions like Mg2+, F– and CO3
2– are also present and contribute to an important biological 
purpose. Synthetic hydroxyapatite (HA), with the chemical composition of 
Ca10(PO4)6(OH)2, differs from the biological one regarding the stoichiometry, 
composition, crystallinity and other physical and mechanical properties [20]. Bonelike® 
is a  glass-reinforced HA with the ability to mimic bone‘s inorganic chemical 
composition, with a microstructure composed by HA, -tricalcium phosphate (-TCP) 
and -TCP phases spread throughout the material, creating fully interpenetrated 
matrices of HA and TCP [21, 22]. Bonelike® supports the proliferation and 
differentiation of human osteoblastic cells [23, 24] and allows fast bone formation at the 
bone/material interface in animal models [25, 26]. Regarding clinical application, 
Bonelike® grafts have been successfully applied in several areas of regenerative 
surgery, namely, in oral and maxillofacial surgery, implantology and orthopaedics, in a 
particulated form [27–30], as well as in a tridimensional macroporous scaffold, 
prepared by a biomodelling technique [31]. Clinical data clearly shows that Bonelike® 
presents appropriate features to perform as a bone graft [27–31]. 
Considering the relevance of angiogenic strategies in bone tissue engineering 
applications, the present work evaluates the ability of Bonelike® to support the 
adhesion, growth and differentiation of human endothelial cells. This aims to access 
the potential suitability of this biomaterial for pre-endothelialization approaches in order 
to improve graft vascularization, in bone tissue regenerative applications.  
 
Material and Methods 
Preparation of Bonelike® 
For the production of Bonelike®, a glass was prepared with the chemical 
composition of 65P2O5–15CaO–10CaF2–10Na2O in mol% from reagent-grade 
chemicals using conventional glass making techniques. The composite was obtained 
by adding the milled glass to HA powder (Plasma Biotal; Tideswell UK) in 2.5% (wt/wt), 
using isopropanol as a solvent. The powders were mixed, dried and sieved to less than 
dies to obtain 8 mm diameter discs. The discs were then sintered at 1300ºC (using a 
ramp rate of 4ºC/min), with the temperature being maintained for 1 h, followed by 
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natural cooling inside the furnace. Detailed description of Bonelike® preparation has 
been previously reported [22]. Phase identification and quantification was assessed by 
X-ray diffraction and Rietveld analysis. 
For in vitro testing, the discs were mechanically polished to the same final 
topology of 1 m using silicon carbide paper, ultrasonically degreased, cleaned with 
ethanol followed by deionized water and sterilized by autoclaving. Before cell seeding, 
Bonelike® samples were observed by scanning electron microscopy (SEM) for the 
assessment of the surface topography. 
 
Culture of human endothelial cells on Bonelike® 
Primary cultures of endothelial cells were established from human umbilical 
veins, from umbilical cords, following a standard procedure [13]. This biological 
material, that would be otherwise discarded, was obtained through local hospitals 
under the approval of the appropriate Ethical Committee, with patient informed 
consent. 
Briefly, umbilical cords were perfused with isotonic solution to remove blood 
and cellular debris. Following, endothelial cells were released from the umbilical vein 
with 0.1% collagenase in medium M199 (7 min, 37ºC, 5% CO2/air) and the resultant 
cell suspension was centrifuged (1,500 rpm, 5 min). Cells were resuspended and 
seeded in culture plates pre-coated with 0.2% gelatine (1 h, 37ºC). Cultures were 
established (37ºC, 5% CO2/air) in medium M199 supplemented with 20% foetal bovine 
serum, penicillin–streptomycin (100 UI/ml and 100 lg/ml, respectively) and 1% L-
glutamine. At 70–80% confluence, primary cultures were enzymatically released 
(0.04% trypsin in 0.25% EDTA solution), and the obtained cell suspension was seeded 
(2 x 104 cells/cm2) in standard 48-well plates (control cultures) and on the surface of 
Bonelike® discs, both previously coated with 0.2% gelatine. Bonelike® samples were 
assayed with or without being submitted to a preimmersion treatment of 3 h, in 
complete culture medium. Cultures were maintained for 7 days in the medium 
described above, further supplemented with 1% sodium heparin and 1 g/ml 
endothelial cell growth supplement (ECGS). Control and seeded Bonelike® samples 
were characterized throughout the culture time for cell viability/proliferation, 
cytoskeleton organization, expression of platelet endothelial cell adhesion molecule-1 
(PECAM-1) and ability to form tube-like networks upon the addition of a collagen type I 
gel. 
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Cell viability/proliferation: visualization of cell growth 
MTT assay - reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide to a purple formazan product by viable cells - was used to estimate endothelial 
cell viability/proliferation, during the 7 day culture period. At determined time points, 
samples were incubated with 0.5 mg/ml of MTT for the last 4 h of the culture period; the 
medium was then decanted, formazan salts were dissolved with dimethylsulphoxide 
microplate reader. Results 
were expressed as A/cm2. 
calcein-acetoxymethylester (calcein-AM) for 30 min at 37ºC. Calcein-AM is taken up by 
viable cells and converted by intracellular esterases into the membrane- impermeable 
fluorescent calcein that spreads throughout the entire cytoplasm of the cell. 
Fluorescence was visualized by confocal laser scanning microscopy (CLSM). 
 
Immunofluorescent staining of F-actin cytoskeleton filaments and PECAM-1 
At days 3 and 6, immunodetection of F-actin and PECAM-1 was conducted by 
CLSM. Briefly, samples were fixed with 4% formaldehyde (methanol free), 
permeabilized with 0.1% Triton (5 min, RT) and incubated in 10 mg/ml bovine serum 
albumin (BSA, 1 h, RT) with 100 g/ml RNAse. Following, samples were either stained 
for F-actin or PECAM-1.  
F-actin filaments were stained with Alexa-Fluor-conjugated phalloidin® (1:100, 
1 h, RT) and nuclei were counterstained with 10 g/ml propidium iodide (10 min, RT). 
Alternatively, samples were incubated overnight with primary PECAM-1 antibody 
(1:100, 48ºC), followed by the addition of the secondary antibody (1:1000, anti-mouse 
Alexa-Fluor®; 1 h, RT), and then counterstained with 10 g/ml propidium iodine (10 
min, RT). 
 
Culture under angiogenesis-inducing conditions 
At adequate confluence (around 80% at 5 days of culture), control cultures and 
seeded Bonelike® discs were covered with a 1.5 mg/ml solution of collagen type I in 
M199 (pH ≈ 7.2–7.4). Within 30 min, the collagen mixture formed a gel. Complete 
culture medium was carefully overlayed on top of the gel and incubation was 
continued. Samples were analysed for cell viability/growth by calcein-AM staining, 24 h 
after the addition of the collagen gel. 
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Statistical analysis 
Three independent experiments were performed using cell cultures from 
different patients. On the MTT assay, each point represents the mean ± standard 
deviation of three replicates. Statistical differences between control and Bonelike® 
seeded discs were analyzed by Student‘s t-test. P-values ≤ 0.05 were considered 
significant. Qualitative assays were performed in triplicate. 
 
Results 
Human endothelial cells, cultured on the surface of Bonelike® discs and on 
standard polystyrene culture plates, were characterized for cell viability/proliferation 
and differentiation events. 
Bonelike® XRD data revealed a microstructure with a main crystalline phase of 
HA, with - and -TCP as secondary phases (Figure 1a). SEM observation of the 
polished discs, prior to cell culture, revealed a uniform and smooth surface (Figure 1b). 
 
 
Figure 1 - X-ray diffraction pattern of Bonelike®, showing the presence of HA and -and -TCP phases 
and SEM appearance of the polished material samples (inset). 
 
Cell viability/proliferation. Pattern of cell growth 
Bonelike® samples pre-coated with gelatine, but not submitted to the pre-
immersion treatment with culture medium, presented a poor performance. Cells were 
able to attach to the material‘s surface, as demonstrated by the micrograph taken at 24 
h, but few cells were visible at 48 h and evident cytoskeleton modifications were 
visualized by F-actin staining (Figure 2). In addition, distributed cellular debris could be 
observed at 24 and 48 h of culture, on the material‘s surface. 
142 
 
 
 
 
Figure 2 - Life span of human endothelial cells cultured on the surface of Bonelike® discs not submitted 
to the pre-immersion treatment with culture medium. Cells were able to attach to the material surface 
(A, 24 h) but died within few hours (B, 48 h). Also, morphological alterations were visualized by F-actin 
staining (C, 48 h). 
 
CLSM observation revealed that endothelial cells attached to the pre-immersed 
Bonelike® samples and proliferated throughout culture time. Seeded materials, stained 
for F-actin cytoskeleton and nucleus, presented a tendency for a circular orientation 
during the proliferative phase, at 3 days of culture (Figure 3A). Calcein-AM staining 
demonstrated the viability of these circular arrangements (Figure 3B). In addition, cells 
presented a normal morphology, with a well defined nucleus, several 
cytoplasmicspreading and cell-to-cell contacts (Figure 3C). Pattern of cell growth and 
cell morphology were similar to those observed on standard tissue culture plates 
(Figure 3D – F). 
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Figure 3 - Organization and morphology of human endothelial cells cultured on Bonelike® discs (A-C) and 
polystyrene culture plates (D-F) for 3 days. On Bonelike®, cells presented a trend for a circular 
organization (A, B) and a normal morphology with well-defined nucleus, cytoplasmic spreading and cell-
to-cell contact. Pattern of cell organization and cell morphology were similar to those on standard 
culture plates (D–F). CLSM images: F-actin and nucleus staining (A, C, D, F); Calcein-AM assay (B, E). 
 
Regarding the MTT assay (Figure 4), cultures grown on Bonelike® samples 
presented an initial lag phase (during approximately 2 days) and proliferated 
afterwards. Compared to control cultures, MTT reduction values were lower throughout 
the culture time, with statistical significance at days 3 and 5. 
 
 
Figure 4 - Cell viability/proliferation (MTT assay) of human endothelial cells cultured on Bonelike® discs 
(□) and polystyrene tissue culture plates (♦). 
144 
 
Expression of the endothelial phenotype 
Endothelial cells grown on Bonelike® samples exhibited a positive staining for 
the presence of PECAM-1 at the junction of adjacent cells, similar to that observed in 
control cultures, respectively Figure 5A,B and Fig. 5D,E, regarding 6-day cultures. 
Addition of a collagen type I gel to the cultures growing on Bonelike® induced a 
trend for a reorganization of the cell layer with the formation of viable cord-like 
arrangements after 24 hours, as observed in calcein-AM stained cultures (Figure 5C). 
In the same experimental conditions, control cultures presented a better organization of 
the collagen-induced tubular structures (Figure 5F). 
 
 
Figure 5 - Expression of functional parameters by human endothelial cells cultured on Bonelike® discs 
(A–C) and polystyrene culture plates (D–F), at day 6. On Bonelike®, cells exhibited a positive staining for 
the presence of PECAM-1 at the junction of adjacent cells (A, B) and formed cord-like arrangements 
upon the addition of a collagen type I gel (C, 24 h after the adhesion of the gel). This behavior was 
similar to that observed on control cultures (D–F). CLSM images: PECAM-1 staining (A, B, D, E); Calcein-
AM assay (C,F). 
 
Discussion 
Endothelial cell cultures are a valid in vitro assay in the study of vascular 
system/biomaterials interactions since they are able to mimic most steps of the 
complex angiogenic cascade, including endothelial cell proliferation, migration and 
differentiation [32, 33]. In addition, with the intimate association of the vascular system 
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with bone and osteogenic cells being stressed, endothelial cell cultures are now 
considered as a valuable tool in the implementation of bone tissue engineering 
strategies, namely regarding the possibility of developing pre-vascularization 
approaches for biomaterials prior to implantation [33, 34]. In the present study, 
Bonelike® was seeded with first passage human endothelial cells (derived from 
umbilical veins) and grown for appropriate time periods and conditions for optimal cell 
proliferation and differentiation [35].  
Bonelike® samples assayed in the present work presented a XRD spectrum 
representative of this material [22]. All materials tested were coated with a gelatine 
solution. It has been previously reported that several biomaterials require prior coating 
with adhesion molecules e.g. collagen, gelatin, laminin or fibronectin, in addition to 
those present in the serum component of culture medium. In their absence, endothelial 
cell attachment is not efficient and determines an unpredictable cellular spread and 
growth [36-38]. In this way, cell adhesion and proliferation was first assayed on 
samples pre-coated with gelatine, but not submitted to a pre-immersion treatment with 
culture medium (i.e. in the ―as-prepared‖ condition). A reduced biological performance 
was verified with few cells attached to the material‘s surface, at 48 hours of culture, 
with significant cytoskeleton modifications being visualized by F-actin staining. F-actin 
is highly concentrated just beneath the plasma membrane, forming an organized layer 
which controls cellular shape and surface movement and is expected to modulate 
cellular mechanics subjacent to the proliferation and differentiation events [39]. Early 
cytoskeleton modifications may compromise adequate cell growth and phenotypic 
expression. Further, cellular debris can be visualized by CLSM at 24 and 48 hours of 
culture, which is in accordance with the impaired biological behaviour of non-pre-
immersed samples.  
Bonelike® is a glass-reinforced HA with a HA stable phase and the more 
soluble phases of - and -TCP, and the contact with the culture medium causes an 
initial superficial leaching [22] resulting in a significant increase in the concentration of 
ionic species on the material surface difficulting the anchorage of the adhering cells 
and having deleterious effects on the subsequent cellular events. Accordingly, 
improved cell behaviour was observed when Bonelike® samples were pre-immersed in 
the culture medium. Endothelial cells attached to the material surface, exhibiting a 
normal morphology with cytoplasmic spreading and cell-to-cell contact, and showed a 
trend for a circular orientation during the proliferative phase, as evident by CLSM 
observation of the stained samples – either with calcein-AM or F-actin. Pre-immersion 
of the material with culture medium causes a superficial ionic leaching and, 
simultaneously, deposition of bioactive molecules from the medium, apparently, 
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rendering the surface more compatible to cell attachment and growth. These dynamic 
events are more significant at early incubation times and tend to a progressive 
equilibrium leading to a stabilization of the material surface [22], which probably 
explains the initial delay in the cell growth and the following improved cell behaviour.  
Immunofluorescent staining of PECAM-1 on seeded Bonelike® and control 
cultures throughout the incubation time was performed in order to access the 
expression of the endothelial phenotype in culture. PECAM-1 is a 130-KDa 
transmembrane glycoprotein found in large amounts on endothelial cells, that plays a 
major role in several cellular interactions, namely in the adhesion cascade between 
endothelial cells and other cell types involved in the inflammatory process and, also, 
between adjacent endothelial cells during the process of angiogenesis [40]. These 
cellular junctions are crucial to maintain the integrity of the endothelial layer and play 
an essential role in the process of vessel sprouting and elongation [40]. According to 
some studies, the distribution of PECAM-1 represents a very sensitive marker of 
endothelial cell functionality [34]. Both seeded standard culture plates and Bonelike® 
exhibited a positive localized staining at the junction of adjacent endothelial cells. 
Under culture conditions, the cells are spread flatly and the PECAM-1 concentration 
along the borders highlights the established cell-cell contacts. In addition, phenotypic 
characterization was conducted at angiogenesis-stimulating conditions, i.e. upon the 
addition of a collagen type I gel.  Cells growing on standard tissue culture plates 
showed an evident trend for reorganization with the formation of cord-like structures, in 
agreement with that reported for the behaviour of cultured endothelial cells in these 
conditions [41, 42]. Seeded Bonelike® presented a similar trend, an effect independent 
of the subjacent surface topography, considering the SEM appearance of the material 
surface before cell seeding. In both situations, these structures maintained their 
viability, as shown by calcein-AM assay. However, Bonelike® showed a poorer 
definition of these arrangements which might be related with the surface reactive 
properties of this material, mentioned above. 
Results showed that the in vitro performance of Bonelike® regarding endothelial 
cell culture was similar to that occurring in standard tissue culture plates, although with 
an initial impairment regarding cell proliferation. The behaviour of human endothelial 
cells on ceramic-based biomaterials, aiming at vascularization strategies, was 
addressed in few recent studies. Choong et al showed that hydroxyapatite-coated 
polycaprolactone substrates were superior for human bone marrow endothelial cell line 
(HBMEC-60) attachment and proliferation, compared to untreated substrates [19]. 
Hunger et al reported that human dermal microvascular endothelial cells (HDMEC), 
growing on three-dimensional porous hydroxyapatite and calcium phosphate 
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substrates, did not migrate to form microcapillary-like structures as they did on cell 
culture plastic [19]. In the present work, rudimental cord-like arrangements could be 
observed on the Bonelike® samples. Established differences to the reported studies 
might account for these observations, namely those related to the in vitro system, i.e. 
endothelial cell type, cell passage, cell plating density, and also, differences regarding 
the biomaterials tested and pre-treatments carried out. Endothelial cells are very 
sensitive to the surface properties and chemistry, structure and porosity of the 
materials, characteristics known to affect cell adhesion, spreading, growth and function 
[43-45].  
The present results provide information regarding the ability of Bonelike® to 
support the adhesion, proliferation and differentiation of endothelial cells. However, due 
to the known complex interactions between endothelial and osteoblastic cells in the 
regeneration environment [7, 33, 34], which has been clearly evidenced in co-culture 
systems [34, 35], the suggestive suitability of Bonelike® for endothelialization 
strategies needs to be addressed in more complex and representative models. 
 
Conclusion 
Bonelike® allowed the adhesion and spreading of human endothelial cells. 
Also, this bone graft supported the subsequent proliferation and phenotype expression, 
with growing cells showing positive immunofluorescent staining for PECAM-1 at cell-
cell interfaces and a trend for the formation of cord-like arrangements under 
angiogenesis-stimulating conditions. The surface reactive properties of Bonelike® are 
compatible with the proliferation and differentiation of endothelial cells, a relevant cell 
type involved in the bone regenerative process, suggesting the potential suitability of 
this bone graft for pre-endothelialization strategies in bone tissue engineering.  
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Abstract 
Semi-synthetic tetracyclines are commonly used antibiotics that also seem to 
play an important role in the modulation of the immuno-inflammatory imbalance, 
verified in several bone diseases. The association of a therapeutic agent (that prevents 
bacterial infection and induces tissue formation) to a biomaterial aiming to 
repair/regenerate bone defects could contribute to a more predictable clinical outcome. 
The present study intends to evaluate the proliferation and functional activity of 
osteoblastic-induced human bone marrow cells, cultured on the surface of 
hydroxyapatite (HA) and Bonelike®, in the presence of therapeutic concentrations of 
doxycycline and minocycline.  
First passage bone marrow cells were cultured for 35 days on the surface of HA 
and Bonelike® discs, in the absence or presence of 1 g/ml doxycycline and 
minocycline. Cultures performed in standard tissue culture plates were used as control. 
Doxycycline or minocycline induced cell proliferation and increased extent of 
matrix mineralization in osteoblastic cell cultures established in the three substrates. 
Also, an improved biological behavior was verified in seeded Bonelike® comparing to 
HA. Results suggest that the local delivery of tetracyclines might associate the 
antimicrobial activity in implant-related bone infection with an eventual induction of 
osteoblastic proliferation and maintenance of the characteristic biological activity of 
these cells. 
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Introduction 
Tetracyclines are commonly used bacteriostatic antibiotics active against a wide 
range of both aerobic and anaerobic gram-positive bacteria. Their antimicrobial activity 
is due to the inhibition of bacterial protein synthesis, by binding to the 30S ribosome 
subunit, blocking the bond to the tRNA, on the mRNA-ribosome complex [1].  
In the last years, several observations converge to justify the therapeutic 
effectiveness of tetracycline (as well as its semi-synthetic derivatives, minocycline and 
doxycycline) in the modulation of the immuno-inflammatory imbalance verified in 
several animal and human bone diseases [2-4]. Different mechanisms, distinct from the 
antimicrobial action, have been proposed to justify the pro-anabolic activity of these 
pharmacological agents regarding bone metabolism. These include enhancing of bone 
formation, decreasing of connective tissue breakdown and diminishing of bone 
resorption [5-10]. Clinical application of these agents targeting bone might also be 
favored by their cation quelation activity and consequent avidity for mineralized tissue 
[11].  
Currently, ceramic-based biomaterials have been used in bone tissue repair 
strategies for their adequate mechanical properties and chemical composition – similar 
to those of the bone tissue. Among them, HA has generated a great deal of interest in 
the last years [12]. This synthetic bone graft substitute, although lacking osteogenic 
properties that can only be found on autologous grafts, still offer advantages that 
include a reduced local tissue morbidity, absence of complications at donor site and 
unlimited material availability [13]. This biomaterial, being similar to the mineral 
component of natural bone revealed good osteoconductivity and bone bonding ability 
[14]. However, HA presents low load bearing capacity [15] and the introduction of 
phosphate based glasses as a sintering aid is known to reinforce HA mechanically [16]. 
Glass-reinforced HA with bioactive properties has been applied with success in medical 
and dental clinical applications aiming to regenerate the bone tissue [17, 18]. Bonelike® 
is a registered and patented glass-reinforced HA with improved mechanical properties 
and enhanced bioactivity that result from the addition of CaO - P2O5 based glasses 
during the liquid phase sintering process of HA, leading to several ionic substitutions in 
the lattice that are responsible for the reduction of porosity and grain size [19, 20]. 
Recently, it has been successfully applied in regenerative procedures aiming to restore 
bone structure and function in oral, maxillofacial and orthopedic procedures [21, 22].    
Although the wide application of synthetic biomaterials in order to 
repair/regenerate the bone tissue, several clinical complications are established and 
prove difficult to remedy. Among them, osteomyelitis, septic arthritis and prosthetic joint 
infection are specially caused by Gram-positive organisms and known to contribute to a 
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heavy clinical and economic burden [23]. Treatment is often complicated at sites of 
reduced vascularization, requiring prolonged antimicrobial use, usually associated with 
surgical drainage or debridement [24]. In this way, the selection of the most effective 
therapeutic approach, based on several parameters that include the specificity of the 
pathogenic agents, their sensitivity profile, pharmacokinetics of the drug, local vascular 
supply, presence or absence of a biomaterial and individual factors, is essential in 
order to minimize tissue and function loss, as well as to reduce discomfort and need of 
further medical/surgical intervention [24]. Also, it is known that local and systemic 
measures to control the colonization of the surgical wound at the early healing phase, 
associated with reduction of the infections‘ spreading, may increase the predictability of 
the results [25]. Tetracyclines have been proven to be effective in several bone and 
joint related infections [26-28]. 
Regarding bone regeneration strategies, the association of a biomaterial and a 
therapeutic agent that might induce bone formation at the same time that prevents 
bacterial infection could, undoubtedly, contribute to a more predictable clinical 
outcome. In this way, the objective of this research was to evaluate the proliferation 
and functional activity of osteoblastic-induced human bone marrow cells, cultured on 
the surface of HA and Bonelike®, in the presence of therapeutic concentrations of 
doxycycline and minocycline.  
 
Materials and Methods 
Preparation of samples 
Bonelike® was prepared with the chemical composition of 65P2O5-15CaO-
10CaF2-10Na2O in mol% from reagent grade chemicals using conventional glass 
making techniques. The composite was obtained by adding the milled glass to HA 
powder in 2.5% (wt/wt), using isopropanol as a solvent. The powders were then dried 
and sieved to less then 75 m under nitrogen atmosphere. Disc samples were 
therefore prepared for in vitro testing by uniaxial pressing at 200 MPa, using steel dies 
to obtain 12 mm diameter discs. The discs were then sintered at 1300ºC (using a ramp 
rate of 4ºC/min), with the temperature maintained for 1 hour, followed by natural 
cooling inside the furnace. Phase identification and quantification was assessed by X-
ray diffraction and Rietveld analysis. XRD was performed on Bonelike® samples using 
a Siemens D5000 diffractometer with Cu-K radiation (=1.5418 Å). The scans were 
made in the range of 25–35º (2) with a step size of 0.02º and a count time of 2 s/step. 
 Detailed description of Bonelike® preparation has been previously reported (20).  
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For in vitro testing, discs were mechanically polished to the same final topology 
of 1 m using silicon carbide paper, ultrasonically degreased, cleaned with ethanol 
followed by deionised water and finally sterilized, prior to cell culture.  
HA samples were also prepared as 12 mm diameter discs in order to compare 
to the biological behavior of Bonelike®. 
 
Cell culture 
Human bone marrow was obtained from orthopedic surgical procedures 
conducted in adult patients (aged between 25 and 45 years). Informed consent was 
obtained to use this biological material that would be otherwise discarded. Bone 
marrow was cultured in -MEM culture medium containing 10% foetal bovine serum, 
50 µg/ml gentamicin, 2.5 µg/ml fungizone and 50 µg/ml ascorbic acid. Primary cultures 
were maintained in a humidified atmosphere (5% CO2 in air at 37 ºC) for 10-15 days 
until sub-confluence condition. At this stage, cells were enzymatically released (0.05% 
trypsin and 0.025% collagenase) and the resultant suspension was cultured at a 
density of 104 cell/cm2, in the previous described culture medium further supplemented 
with 10 mM -glycerophosphate and 10 nM dexamethasone. Cell cultures were 
established for 35 days and maintained in the surface of the culture plate (control 
cultures), HA or Bonelike® in the absence or presence of doxycycline or minocycline (1 
µg/ml). Tetracyclines were both renewed at every medium change that occurred twice 
a week.  
 
Culture characterization 
Cell viability/proliferation and total protein content 
MTT assay was used to estimate cell viability/proliferation. This assay is based 
on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to a 
purple formazan product by viable cells. Cultured cells were incubated with 0.5 mg/ml 
of MTT during the last 4 hours of each test time. The medium was then decanted, the 
stained product dissolved with dimethylsulphoxide and absorbance determination was 
conducted at 600 nm in an ELISA reader. Results were expressed as absorbance per 
square centimeter (A/cm2). 
Total protein content was determined by Lowry method after treatment of the 
cell layer with 0.1 M NaOH for 1 hour. Bovine serum albumin was used as a standard 
and absorbance determination was conducted at 750 nm. 
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Alkaline phosphatase (ALP) activity 
Activity of ALP was determined in cell lysates (obtained after treatment of 
cultured cells with 0.1% triton) by the hydrolysis of p-nitrophenyl phosphate (30 minutes 
at 37º C) in an alkaline buffer solution (pH 10.3). Colorimetric determination of p-
nitrophenol was established at 405 nm. Enzyme activity was normalized by total protein 
content and results were expressed as nanomoles of p-nitrophenol produced per 
minute per µg of protein (nmol/min/µg protein). 
 
Cai loss from the culture medium 
Culture medium from cultures in control and experimental conditions was 
collected every 2-3 days (and cultures reefed with fresh medium) between days 10 and 
35 of the culture. Analysis of Cai content was conducted using Sigma Diagnostics Kit, 
procedure number 587. Results were expressed as milimoles per litre of ionized 
calcium loss from medium (Cai mmol/L). 
 
Scanning electron microscopy (SEM)  
Glutaraldehyde (3%) fixed cultures were dehydrated in graded alcohols (70, 80, 
2 x 90 and 99.8%), critical-point dried, sputter-coated with gold and analyzed in a JeoL 
JSM 6301F scanning electron microscope equipped with a X-ray energy dispersive 
spectroscopy (EDX) microanalysis capability (Voyager XRMA System, Noran 
Instruments). 
 
Statistical Analyses 
Results presented in this study are from three separate experiments using cell 
cultures from different patients. In each experimental situation, three replicas were 
accomplished. Groups of data were evaluated using a two-way analysis of variance 
(ANOVA) and no significant differences in the pattern of the cell behaviour were found. 
Statistical differences found between control and experimental conditions were 
determined by Bonferroni‘s method. P-values ≤0.05 were considered significant. 
 
  Results 
Human bone marrow stromal cells were characterized for proliferation and 
differentiation events, on the surface of the culture plate, HA and Bonelike®, in the 
presence of an osteogenic inducing medium, further supplemented with 1 g/ml 
doxycycline or minocycline.  
XRD analysis revealed that due to the reaction between the HA matrix and 
P2O5-based glass during the sintering process, the Bonelike
® microstructure had a 
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main crystalline phase of HA with - and -tricalcium phosphate as secondary phases 
(Figure 1). 
 
Figure 1 – X-ray diffraction pattern of Bonelike®. Bonelike® is composed of HA and - and -TCP phases. 
 
Cell viability/proliferation 
The results regarding the evaluation of cell proliferation by the MTT assay are 
reported on Figure 2A. 
Cultures grown on the surface of the culture plate proliferated gradually till day 
21, followed by a decrease in the remaining time of culture. Seeded Bonelike® 
presented a similar behavior to control, while cultures established on the surface of HA 
showed an initial lag phase of approximately two weeks and maximal MTT reduction 
values were only achieved by day 28.  The presence of doxycycline or minocycline (1 
g/ml) increased cell proliferation in control cultures and on seeded sample materials. 
Results were statistically significant (p≤0.05) at days 21, 28 and 35 for cultures grown 
on the culture plate, and at maximal MTT reduction values for cultures established on 
the surface of the materials – day 21 for Bonelike® and 28 for HA. The stimulatory 
effect was evident after an initial lag stage (during approximately the first week) and 
maximal MTT values were around 30% and 40% higher in the presence of minocycline 
and doxycycline, respectively, comparing to those obtained on non-treated cultures.  
 
160 
 
 
Figure 2. Cell viability/proliferation (A) and alkaline phosphatase activity (B) of human bone marrow 
osteoblastic cells cultured for 35 days on the surface of culture plate, Bonelike® and HA in the absence 
(♦) and presence of 1 g/ml Doxycycline (■) or Minocycline (▲). * Significantly different from control 
cultures (p≤0.05). 
 
Alkaline phosphatase activity 
Results regarding the activity of alkaline phosphatase are presented on Figure 
2B. 
ALP activity was low during the first week of culture and increased significantly 
afterwards achieving maximal values by day 14 in control and cultures established on 
the surface of Bonelike® and, later, by day 21, on seeded HA. Subsequently, ALP 
activity decreased throughout the remaining culture time. Comparing to control 
cultures, reduced enzymatic activity was verified in seeded Bonelike® and HA.  
No significant differences were found in ALP activity in the presence of 
doxycycline, although, in minocycline-treated cultures, a tendency for a reduction in the 
enzyme activity was verified and statistically significant (p≤0.05), comparing to cultures 
grown on the surface of the culture plate.  
 
Mineralized deposits in the extracellular matrix 
The presence of mineralized deposits (calcium phosphate) in the cell layer was 
evaluated by the analysis of ionized calcium (Cai) loss from the culture medium 
throughout days 10 to 35 and by SEM observation. 
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Cai loss from the culture medium 
The Cai (in association with Pi) is consumed in the formation of calcium 
phosphate deposits in the extracellular matrix, reflecting the mineralization process. In 
the present work, the Cai consumption reflects the changes occurring between every 
medium change (intervals of 2-3 days), since the medium was totally replaced at every 
change, outputting values that are not cumulative. Results are presented on Figure 3. 
 Levels of Cai were determined in the absence of cultured cells and a relatively steady 
value of 1.7 mmol/L was verified in the absence of materials. A higher variation of Cai 
levels (between 1.6 and 1.8 mmol/ml) occurred in incubated Bonelike® and HA 
samples.  
Cultures grown on the surface of the culture plate revealed almost no Cai loss 
from the culture medium, between day 10 and 17. Since this day onwards, a significant 
and progressive increase of the Cai loss was verified and, at day 30, values around 
1.35 mmol/L were attained. Medium collected from cultures established on the surface 
of Bonelike® revealed a similar behavior. Cai loss regarding cultures grown on the 
surface of HA, was significant from day 20 onwards, achieving approximately 1.15 
mmol/L around day 30.  
In the presence of doxycycline and minocycline, levels of Cai followed a similar 
pattern. However, in cultures established on the surface of culture plate and Bonelike®, 
the initial rate of calcium deposition (between days 17 and 23) was higher compared to 
non-treated cultures, especially in the presence of doxycycline (results statistically 
significant, p≤0.05). 
 
 
Figure 3. Levels of ionized calcium (Cai) loss from the culture medium regarding human bone marrow 
osteoblastic cell cultures performed on the surface of the culture plate, Bonelike® and HA. Cai loss was 
not cumulative, as the medium was totally replaced at each medium change (twice a week), and levels 
measured reflect changes occurring in intervals of 2-3 days throughout the culture period. Cultures were 
grown in the absence (♦) and presence of 1 g/ml Doxycycline (■) or Minocycline (▲). * Significantly 
different from control cultures (p≤0.05). 
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SEM  
Representative scanning electron micrographs of the cell layer, at day 21, are 
presented on Figure 4 corresponding to different experimental conditions.  
Control cultures and seeded HA and Bonelike® revealed a continuous cell layer 
with distributed globular mineral deposits in close association with the matrix (Figure 
4A-C). Treatment with doxycycline (Figure 4D-F) or minocycline (Figure 4G-I) 
increased mineral deposition. Regarding cultures established on the surface of HA, 
significantly less mineral deposits were visualized both in the absence (Figure 4C) and 
presence of doxycycline (Figure 4F) and minocycline (Figure 4I).  
 
 
Figure 4. SEM appearance of human bone marrow osteoblastic cell cultures grown in the absence (A-C) 
or the presence of 1 g/ml Doxycycline (D-F) and 1 g/ml Minocycline (G-I), at day 21, in the surface of 
the culture plate (A, D and G), Bonelike® (B, E and H) and HA (C, F and I). 
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Discussion 
Each year, almost two million patients worldwide undergo bone graft surgery in 
order to repair skeletal lesions resulting from trauma, tumor resection or degenerative 
diseases [29] and several synthetic graft materials, with osteoconductive and 
osteoinductive properties have been designed to fulfill this need [30]. The implantation 
of a bone graft causes an inflammatory reaction and, frequently, an infectious process 
[31]. The direct contact of the material surface with blood and/or tissue fluid enhances 
the formation of an adsorbed protein film. Several of the adsorbed proteins (including 
fibronectin, vitronectin and fibrinogen) provide anchoring sites for bacteria via the 
expression of adhesion molecules from the pathogenic agents. When the adhesion 
process is established, the bacteria proliferate and create an infectious process in 
close association with the implanted material [32]. In order to control the infection, 
several methodologies have been proposed. Local control offers many advantages 
over systemic antibiotic chemotherapy [25, 32]  and, in addition, the association of 
antimicrobial activity with a positive modulation of the host response contributes to a 
more predictable and rapid clinical outcome in bone regeneration therapies [33]. 
Tetracyclines are broad spectrum antibiotics important in the treatment of bone 
and joint infections [26-28] which have been associated with a positive effect in bone 
metabolism [5-10]. In previous studies, performed in standard tissue culture plates, we 
reported that therapeutic levels of doxycycline and minocycline were able to induce 
proliferation of osteoblastic bone marrow cells while maintaining their specific 
phenotype [34]. In the present study, HA and Bonelike®, a glass-reinforced HA, were 
cultured with human bone marrow cells in a medium known to induce osteogenic 
differentiation [35, 36], and cell proliferation and function were assessed in the 
presence of 1 g/ml doxycycline or minocycline, representative of the plasmatic levels 
attained with standard therapeutic systemic dosages [37]. 
Bone marrow cells grown on standard polystyrene culture plates, in the 
absence of tetracyclines, presented active proliferation during the first three weeks 
associated with expression of high levels of ALP. The maximum levels of ALP, 
achieved on day 14, indicate the subjacent differentiation process being established at 
this stage. ALP is associated with the availability of high levels of phosphate ions, 
essential to the onset of the mineralization process, being subsequently down-regulate 
[38]. Accordingly, the pattern of Cai loss from the culture medium and SEM observation 
showed that mineral deposition closely associated with the cell layer occurred from day 
17 onwards. Over the last two weeks of culture, cell proliferation was greatly reduced 
by the embedding of the cells in the mineralized extracellular matrix, as in accordance 
with the established model for the in vitro development of the osteoblastic phenotype 
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[35, 36, 38]. Cell response on the surface of Bonelike® was similar. HA showed a poor 
performance during the initial stages of the culture, reflected by a long lag phase, which 
resulted in delayed maximal values in the MTT assay and ALP activity, compared to 
Bonelike®. Upon cell seeding, surface chemical and topographic changes resulting 
from the interactions between the material surface and the culture medium are of 
particular importance to the subsequent cell growth and differentiation events. 
Appropriate surface features for normal cell behavior seem to take place earlier on 
Bonelike®, comparing to HA. Bonelike® is composed by an HA matrix with soluble - 
and -tricalcium phosphate phases (Figure 1) and the ongoing release/deposition 
events of Ca and P ionic species leads to a rapid formation of an apatite layer, 
according to previous studies [39]. This behavior appears to contribute to the improved 
biological performance of Bonelike®, both in vitro [40, 41] and in vivo [22, 42, 43]. 
Comparatively, formation of an apatite layer on the surface of HA occurs slowly [39] 
with favorable surface conditions for cell growth being observed later. However, the 
interfacial reactions tend to an equilibrium rendering the surface of the two materials 
with similar features. Accordingly, after two weeks, cell behavior on HA surface showed 
a pattern similar to that observed on Bonelike® samples. Also, the presence of F in the 
composition of Bonelike® and/or its release may also contribute to the improved initial 
response, as this ion is reported to stimulate osteoblastic proliferation [44]. 
Doxycycline or minocycline affected the proliferation of osteoblastic cells in a 
time-dependent manner. After a small lag phase during the first week, induced cell 
proliferation was observed in all experimental situations, i.e. control cultures, seeded 
HA and Bonelike®. ALP activity was similar, although somewhat reduced in 
minocycline-treated cultures performed in standard culture plates. Rate of mineral 
deposition, as assessed by the pattern of Cai loss from the culture medium, was 
slightly higher in tetracycline-treated cultures, which is probably related with the 
presence of increased cell number of functional active cells in these experimental 
conditions.  
Osteoblastic cell response to tetracyclines was addressed in few previous 
studies, performed in standard tissue culture plates. Minocycline (up to 3 g/ml) was 
reported to increase the efficiency of rat bone marrow stromal cells regarding colony 
forming capacity [45]. Also, induction of early differentiation events and cell proliferation 
improvement were observed in osteoblast-like MG63 cells cultured in tetracycline pre-
coated dentin [46]. In contrast, doxycycline failed to cause any anabolic effect in murine 
calvarial osteoblasts and MG63 osteoblast-like cells [47]. A recent study assessed the 
effect of a variety of antibiotics on human bone trabecullar bone derived cells and on 
the cell line MG63, exposed during 48 hours, and found a mean IC20 of 60 g/ml for 
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tetracycline [48]. As mentioned above, we reported previously that long-term exposure 
of osteogenic-induced human bone marrow cells to 1 g/ml doxycycline and 
minocycline resulted in increased cell growth, while higher levels caused dose-
dependent deleterious effects [34]. Positive effects of tetracyclines over osteoblastic 
cells were also reported in an in vivo model of normal bone metabolism [10]. 
Tetracycline administration to squirrel monkeys over a period of 17 days increased 
osteoblastic activity and osteoid formation in alveolar bone [10], consistent with similar 
effects of other tetracycline compounds in animal models of bone-deficiency diseases 
[5-8]. 
The mechanisms underlying the effects of tetracyclines over osteoblastic cells 
remain unclear. However, changes in the collagenous extracellular matrix, expected 
from the well established inhibitory effect of tetracyclines over matrix 
metalloproteinases (MMPs) [4, 49, 50] might play a role. Tetracyclines can inhibit 
collagenase and/or the breakdown of collagen under a variety of conditions [51-54]. 
Also, additional effects on collagen metabolism may occur, particularly increased 
collagen synthesis after tetracycline administration verified on pathological models of 
bone-associated diseases and cell population from soft tissues [53, 54]. In addition, it is 
interesting to refer that progressive consolidation of collagenous connective tissue at 
the apical portions of periodontal pockets is reported to occur in patients receiving 
subantimicrobial doses of doxycycline [55, 56]. These events might result in improved 
osteoblastic behavior, since a stable collagenous matrix is know to play a significant 
role in the osteoblastic proliferation/differentiation sequence [38, 57, 58]. 
In the present study, treatment with doxycycline or minocycline, 1 g/ml, 
induced cell proliferation and increased extent of matrix mineralization in human 
osteoblastic cell cultures growing on HA or Bonelike®. Results suggest that the local 
delivery of tetracyclines might associate the antimicrobial activity in implant-related 
bone infection with an eventual induction of osteoblastic proliferation and maintenance 
of the characteristic biological activity of these cells. In this way, tetracyclines may 
become suitable candidates to drug confinement and delivery applications regarding 
the use of ceramic matrices for hard tissue regeneration.    
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Abstract 
Silicon-substituted hydroxyapatite (Si-HA) coatings have been plasma sprayed 
over titanium substrates (Ti-6Al-4V), aiming to improve the bioactivity of the constructs 
for bone tissue repair/regeneration. X-ray diffraction analysis of the coatings has shown 
that, previous to the thermal deposition, no secondary phases were formed due to the 
incorporation of 0.8wt% Si into HA crystal lattice. Partial decomposition of 
hydroxyapatite, which lead to the formation of the more soluble phases of - and -
tricalcium phosphate and calcium oxide, and increase of amorphization level, only 
occurred following plasma spraying.  
 Human bone marrow-derived osteoblastic cells were used to assess the in vitro 
biocompatibility of the constructs. Cells attached and grew well on the Si-HA coatings, 
putting in evidence an increased metabolic activity and alkaline phosphatase 
expression comparing to control, i.e., titanium substrates plasma sprayed with 
hydroxyapatite. Further, a trend for increased differentiation was also verified by the 
up-regulation of osteogenesis-related genes, as well as by the augmented deposition 
of globular mineral deposits within established cell layers.   
Based on the present findings, plasma spraying of Si-HA coatings over titanium 
substrates demonstrates improved biological properties regarding cell proliferation and 
differentiation, comparing to HA coatings. This suggests that incorporation of Si into the 
HA lattice could enhance the biological behavior of the plasma-sprayed coating. 
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Introduction 
Titanium (Ti) and Ti containing alloys have been favorite materials for dental, 
orthopedic and maxillofacial surgical applications, reporting long-term clinical function 
with a substantial success rate [1,2]. Even so, in order to maintain mechanical 
properties of the metallic substrates, and simultaneously improve the implants‘ 
bioactivity, coating of the titanium‘s surface has been assayed with calcium phosphate-
based ceramics [3-5]. One of the most widely used biomaterial for bone regenerative 
coating applications is synthetic hydroxyapatite (HA), with the chemical formulation of 
Ca10(PO4)6(OH)2 and a Ca to P ratio of 5:3, which exhibits a similar chemical and 
crystallographic structure to the bone‘s inorganic apatite [6]. However, biological apatite 
reports calcium, phosphate and hydroxyl deficiencies and several anionic and cationic 
substituents [7]. In this regard, carbonate (up to 8 wt%), as well as trace elements like 
sodium (up to 0.8 wt%) and magnesium (up to 0.5 wt%) play an important role along 
with ultra-trace level substituents including potassium, strontium, zinc, fluorine, chlorine 
and silicon [7-9].  
Accordingly, increasing evidence regarding the enhanced biological response 
induced by silicon (Si) has been gained since the early 70‘s by Schwarz [10] and 
Carlisle [11,12] works‘, which reported that a deficient diet in silicon retarded the growth 
and disturbed the development of bone structure, in animal models. More recently, it 
was established by a cohort study that higher dietary silicon intake is positively 
correlated with improved bone health in humans, as translated by increased levels of 
bone mineral density [13]. Also, several authors substantiate the positive effects of Si 
at molecular and cellular level by reporting increased DNA synthesis [14] and induced 
osteoblastic proliferation [15], as well as increased alkaline phosphatase (ALP) activity, 
collagen type I and osteocalcin expression [16,17].  
In order to take advantage of the Si-induced bioactivity within the bone tissue, it 
was thought to incorporate silicon in the composition of diverse biomaterials for bone 
regeneration. Cumulative data support that the addition of Si to bioceramics and 
ceramic-glass composites has a direct anabolic effect on bone tissue, namely by 
inducing osteoblastic proliferation and expression of phenotypic characteristics [18,19]. 
Overall, silicon-substituted bioceramics have been developed and extensively 
characterized, especially, in the granule or bulk form, as reviewed by Vallet-Regí et al 
[20] and Pietak et al [21]. However, few studies report the preparation and 
characterization of silicon substituted hydroxyapatite in the form of coating, apart from 
magnetron sputtering [22], electrospraying [23], sol-gel [24] and pulsed laser deposition 
[25]. Further, fewer of these evaluated the biological behavior of the coatings either by 
in vitro or in vivo methodologies [22,23].  
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Although all technologies have attractive features, thermal spraying, especially 
the conventional atmospheric plasma spraying method, has been studied most 
extensively and is still the most frequently used technology for producing clinical 
applications embracing HA-based coatings over metallic implants [26]. These 
constructs (plasma-sprayed HA over metal substrates) allow for the combination of 
adequate strength and ductility of the metal with the improved biocompatibility and 
bioactivity of the HA, essential for load-bearing bone applications [26]. An improved 
biological behavior may be expected from plasma-sprayed substrates, including earlier 
and greater fixation to the surrounding tissues and a strong direct bonding to the bone 
[26,27].  
To take advantage of the plasma-spraying technology and the benefits of Si-
HA, a new construct was developed, composed of Ti-6Al-4V substrates plasma-
sprayed with 0.8%wt Si-HA, obtained by a precipitation chemical route. The Si-
substituted HA, in a bulk form, has proven enhanced osteoblastic activity in vitro [28], 
and increased bone apposition in an experimental model of in vivo bone regeneration 
[29]. In order to access the biological performance of Si-HA plasma sprayed Ti-6Al-4V 
substrates, the constructs‘ were assayed in vitro, with human bone marrow-derived 
osteoblastic cell cultures, and compared to the behavior of Ti-6Al-4V substrates 
plasma-sprayed with HA.   
 
Materials and Methods 
Preparation of samples 
HA and 0.8 wt% Si-HA were prepared according to the technique previously 
described by Gibson et al [30]. Briefly, an aqueous precipitation chemical reaction was 
established between calcium hydroxide and orthophosphoric acid solutions. In order to 
produce Si-HA, silicon tetraacetate [Si(CH3COOH)4] was incorporated into the mixture. 
Precipitation was carried out at room temperature, with the pH being maintained at 
10.5 by the addition of ammonium hydroxide solution. After complete mixing, the 
suspensions were aged overnight. The obtained powders (HA or Si-HA) were filtered, 
washed and dried at 80ºC. Following, powders were fine grounded and compacted 
uniaxially at 18 MPa, and sintered at 1300 ºC  for 2 hours, followed by natural cooling 
inside the furnace. Sintered discs were milled and sieved to obtain a fine powder with a 
specific particle size distribution between 45 and 125 m.  
Titanium alloy (Ti-6Al-4V) disks with 14 mm of diameter and 3 mm of thickness 
were pre-treated prior to plasma spraying: samples were grit blasted with Al2O3 
spheres and chemically degreased. Plasma spray coating was performed with a 
Plasma Technik® automated equipment at atmospheric conditions. Parameters of the 
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plasma spraying, including chemical composition and flow rate of used gases are 
depicted on Table 1.  
 
Table 1 - Plasma spraying parameters, chemical composition and flow rate of gases used for the 
preparation of the HA and Si-HA coatings. 
 
 
For in vitro testing, HA and Si-HA coated Ti discs were ultrasonically 
degreased, cleaned with ethanol followed by deionised water and finally sterilized by 
autoclaving, prior to cell culture.  
 
Materials’ characterization 
Phase identification  
 X-ray diffraction (XRD) analysis was used to identify the crystalline phases 
present in the Si-HA coating. The coating was removed from Ti-6Al-4V alloy 
substrates, ground to a fine powder and analyzed using a Bruker D8 Advance X-ray 
diffractometer. A flat plate geometry and Cu K radiation were used. Data was 
collected using a scintillation counter from 10 to 70 (2), with a step size of 0.02 º and a 
counting time of 5 seconds per step. Quantitative phase analysis was performed by the 
Rietveld method using TOPAS software. 
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Ionic release/adsorption of silicon, calcium and phosphorous from Si-HA and HA 
samples 
The assessment of the ionic release of silicon, calcium and phosphorous was 
evaluated in simulated body fluid (SBF), pH 7.4, for both Si-HA and HA constructs. 
Specimens were immersed into an acellular SBF (volume of SBF / surface area of 
specimen  0.1 ml/mm2), and maintained at 37 ºC, for adequate time. The fluid was 
prepared accordingly to the specifications reported by Oyane et al [31]. All materials 
were soaked for periods of 1, 3, 5, 7, 14 and 21 days, and, at the end of each time 
point, the specimens were removed from the fluid and carefully washed with deionised 
water and dried in air. The concentration of silicon, calcium and phosphorous ions was 
measured by inductively coupled plasma emission spectroscopy (ICP: Optima 
2000DV), with a detection limit of around 0.2 ppm.  
 
Surface analysis of the Si-HA and HA samples 
In order to characterize the surface microstructure of the materials before and 
after immersion in SBF, a scanning electron microscope [SEM: S-4800, Hitachi, Ltd., 
Japan coupled to an energy dispersive X-ray microanalyzer (EDS: EMAX ENERGY 
EX-400, Horiba, Ltd., Japan)] was used. 
 
Coating adhesion to the substrate 
 A standard testing method (DIN 50161) was used to characterize the adhesion 
strength of the coating to the substrate. The adhesion test was performed on Si-HA 
and HA samples, before and after the immersion in SBF, for 21 days, at 37ºC. In the 
test, compressive stresses were applied, at a rate of 10 mm/min. Results were 
expressed according to the following equation:  
  
    
     
 
 F=shear strength (MPa), Fmax=maximum shear force (N), h=maximum height (mm) 
and =diameter of the sample (mm). Additionally, SEM observation was used in order 
to determine the type of failure mechanism.   
 
Cell cultures 
Human bone marrow was obtained from femoral regenerative surgical 
procedures conducted in adult male individuals (aged between 25 and 45 years), 
without associated bone metabolic diseases. Informed consent to use this biological 
material, that would be otherwise discarded, was obtained.  
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Bone marrow was cultured, for 10-15 days until adequate confluence, in -MEM 
culture medium containing 10% fetal bovine serum, 100 IU/ml penicillin, 100 g/ml 
streptomycin, 2.5 g/ml fungizone and 50 μg/ml ascorbic acid. Cultures were 
maintained in a humidified atmosphere of 5% CO2 in air, with the temperature being 
maintained at 37 ºC. At adequate confluence, adherent cells were enzymatically 
released with 0.05% trypsin - 0.025% collagenase and counted using a 
hemocytometer. Cells were then seeded over HA and Si-HA coated Ti samples at a 
density of 2 x 104 cells/cm2 and cultured using the previously described experimental 
conditions, with the culture medium being further supplemented with 10 mM sodium -
glycerophosphate and 10 nM dexamathasone. Cell cultures were established for 21 
days and the culture medium was changed twice a week. Cultures were characterized, 
at adequate time points, for cell viability/proliferation, total protein content, alkaline 
phosphatase (ALP) activity, expression of osteogenic-associated genes (ALP, bone 
morphogenic protein – 2 (BMP-2) and collagen type I (Col I)) by reverse transcription-
polymerase chain reaction (RT-PCR), scanning electron microscopy (SEM) and 
confocal laser scanning microscopy (CLSM). In addition, culture medium was analyzed 
for ionized calcium, in order to quantify the mineralization process. 
 
Culture characterization 
Cell viability/proliferation and total protein content 
MTT assay was used to estimate cell viability/proliferation. This assay is based 
on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to a 
purple formazan product by viable cells. At each endpoint test, cultured cells were 
incubated with 0.5 mg/ml of MTT during the last 4 h of the culture. Following, the 
medium was decanted, the stained product dissolved with dimethylsulfoxide and 
absorbance was determined in an ELISA reader at 600 nm. Results were expressed as 
absorbance per square centimeter (A/cm2). 
Total protein content was determined by the Lowry method after treatment of 
the cell layer with 0.1 M NaOH for 1 h. Bovine serum albumin was used as a standard 
and absorbance was determined at 750 nm.  
 
Alkaline phosphatase (ALP) activity 
ALP activity was determined in cell lysates which were obtained with the 
treatment of cultured cells with 0.1% triton. Enzymatic activity was established with the 
hydrolysis of p-nitrophenyl phosphate (30 min at 37 ºC), in an alkaline buffer solution 
(pH 10.3), following colorimetric determination, at 405 nm, of p-nitrophenol. The 
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enzyme activity was normalized by the total protein content and results were expressed 
as nanomoles of p-nitrophenol produced per minute per microgram of protein 
(nmol.min-1/g.protein). 
 
Total RNA extraction and RT-PCR analysis 
RT-PCR was used to access the expression of ALP, BMP-2 and Col I genes by 
bone marrow-derived osteoblastic cells, grown for 14 days on the surface of Si-HA or 
HA plasma sprayed titanium substrates.  
Total RNA was extracted using the RNeasy® Mini Kit from Qiagen, according to 
manufacturer‘s instructions. RNA was quantified by measuring the absorbance of the 
samples at 260nm.  
RT-PCR was done using the Titan One Tube RT-PCR System from Roche 
Applied Science, according to the manufacturer‘s instructions. Briefly, 0.5 g of total 
RNA from each sample was reverse transcribed into cDNA (30 minutes at 50 ºC), while 
PCR was performed with an annealing temperature of 55ºC, for 25 cycles. To amplify 
the human ALP transcript, the forward primer (5‘-ACGTGGCTAAGAATGTCATC-3‘) 
was used in combination with the reverse primer (5´-CTGGTAGGCGATGTCCTTA-3‘). 
To amplify the human BMP-2 transcript, the forward primer (5‘-
GACGAGGTCCTGAGCGAGTT-3‘) was used in combination with the reverse primer 
(5´-GCAATGGCCTTATCTGTGAC-3‘). To amplify the human Col I transcript, the 
forward primer (5‘-TCCGGCTCCTGCTCCTCTTA-3‘) was used in combination with the 
reverse primer (5´-ACCAGCAGGACCAGCATCTC-3‘). To amplify the human GADPH 
transcript, the forward primer (5‘-GGAAGGTGAAGGTCGGAGTCAAC-3‘) was used in 
combination with the reverse primer (5´-GTGGCAGTGATGGCATGGACTGT-3‘). 
Following, the PCR products were electrophoresed in a 1% agarose gel, stained with 
ethidium bromide. 
Analysis of RNA levels was performed by densitometry with ImageJ software 
(Version 1.41, National Institutes of Health, Bethesda, MD), after normalization to the 
housekeeping gene (GAPDH). 
 
Ionized calcium in culture medium  
Culture medium was collected at each medium change and analyzed for 
ionized calcium (Cai), using an adapted Sigma procedure (Sigma Diagnostics Kit – 
procedure number 587) based on the interaction between the ion and a cromogenic 
agent (o-cresolphthalein complexone). This reaction occurs on alkaline medium, with 
pH 10-12, resulting on the formation of a purple complex. Coloration intensity is 
proportional to the concentration of Cai and was determined in a spectrophotometer at 
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575nm, using a calibration curve (standard solution, Sigma nº 360-11). Results were 
expressed in mmol of Cai per litre of medium (mmol/L). 
 
Confocal Laser Scanning Microscopy (CLSM) and Scanning Electron Microscopy 
(SEM) 
For CLSM observation, cells were fixed with 3.7% formaldehyde (methanol 
free), permeabilized with 0.1% triton and incubated for 1 hour in a 10 mg/ml bovine 
serum albumin solution, in order to block non-specific interactions. Following, F-actin 
filaments were stained with 488 AlexaFluor-conjugated phalloidin (1:100) and nuclei 
were counterstained with 10 g/ml propidium iodide. Samples were washed with PBS 
and mounted in Vectashield®. Images were acquired on a Leica TCP SP2 AOBS.  
For SEM observation, cells were fixed with 1.5% glutaraldehyde in 0.14 M 
sodium cacodylate. The samples were dehydrated in graded series of alcohols (70, 80, 
2x90 and 99.8%) and critical point dried. Specimens were mounted and sputter-coated 
with gold previously to observation in a scanning electron microscope (S-4800, Hitachi 
Ltd., Japan), coupled to an energy dispersive X-ray microanalyzer (EMAX ENERGY 
EX-400, Horiba Ltd., Japan). 
 
Statistical analysis 
Results presented in this study are from three separate experiments using cell 
cultures from different patients. Four replicates for each experimental situation were 
conducted. Groups of data were evaluated using a two-way analysis of variance 
(ANOVA) and no significant differences in the pattern of the cell behavior were found.  
Statistical differences found were determined by Bonferroni‘s method. Values of 
p≤0.05 were considered significant. 
 
Results 
Materials’ characterization 
Figure 1 shows representative XRD patterns of Si-HA, before and after plasma-
spraying, over metallic substrates. The analysis of the attained pattern, previous to 
plasma-spraying, reveals that the material is a pure phase HA, since no secondary 
phases were formed. Due to the high temperature and rapid cooling of plasma-
spraying coating process, the material suffered partial phase decomposition which lead 
to the development of TCP (-TCP (27%), and -TCP (26%)) and CaO (13%) phases, 
besides HA (34%). Simultaneously, the ceramic became more amorphous, as 
indicated by the broader background.  
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Figure 1 - X-ray diffraction pattern of feedstock and plasma-sprayed Si-HA coatings, showing the 
presence of a hydroxyapatite phase (unmarked diffraction peaks), with impurities of -Ca3(PO4)2 (○), 
CaO (•) and indication of a trace of -Ca3(PO4)2  (▼). Note the presence of an amorphous phase which is 
visible as the broader background, regarding the plasma sprayed graphic line.  
 
Regarding the evaluation of the released ions from the Si-HA coatings (Figure 
2), it could be seen that there was a small increase in the ionic concentration of silicon 
in SBF with pH 7.4, throughout the evaluation period. Ionic concentration of Si was 
around 0.05 mM following 3 days of immersion, and around 0.1 mM following 7 days of 
immersion. Throughout the remaining test time, a tendency for a stable Si release was 
verified, with a concentration around 0.12 mM. HA did not report Si release during the 
evaluated period. In which regards Ca and P ionic concentrations in SBF, a continuous 
decrease of both ionic species was attained, regarding both tested materials. The 
decrease in the ionic concentration was high during the first 5-7 days of the test – 
decreased from around 2.5 mM to 2 mM and from 1.0 mM to 0.5 mM, regarding Ca 
and P, respectively. Following, a tendency to the maintenance of a stable concentration 
was verified throughout the remaining test time – around 1.7 mM and 0.5 mM for Ca 
and P, respectively. Initial decrease of Ca and P concentrations, in SBF, was higher for 
Si-HA immersed samples, attaining statistical significance at days 1 and 3 of the 
assayed procedure. In addition, the formation of an apatite layer could be visualized in 
the surface of both materials, with continuous globular agglomerates, assessed by 
SEM, following 7 days of immersion (Figure 3).  
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Figure 2 – Ionic release/adsorption of silicon, calcium and phosphorous from Si-HA and HA coated 
samples following immersion in SBF, for 21 days.  
 
 
Figure 3 – SEM images of HA (A-C) and Si-HA (D-E) samples in the as-prepared condition (A and D), and 
following 7 days of immersion in SBF (B, C, E and F). The insets in A and D show the macroscopic 
appearance of the HA and Si-HA constructs, respectively – scale bar 5 mm. 
 
 In which regards to the adhesion test, which was accessed by the DIN 50161 
standard, no significant differences were verified between the adhesion strength of 
both Si-HA and HA coatings, before and after soaking in SBF, for 21 days, at 37ºC 
(Figure 4A). Adhesion values were around 30 MPa. The SEM characterization of the 
Si-HA sample surface following test establishment, and before SBF immersion, 
revealed three distinct zones: the Ti alloy substrate (Z1), the failure zone (Z2) and the 
coating (Z3) (Figure 4B). High magnification micrographs (Figure 4C and 4D) revealed 
that the cleavage plans are clearly identified, as well as an irregular surface.    
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Figure 4 - Adhesion stress results measured according to DIN 50161 standard, for Si-HA and HA coatings, 
before and after soaking in SBF, for 21 days (A). SEM images of the samples tested for Si-HA coating, 
before soaking in SBF (B). Z1 corresponds to the Ti-6Al-4V alloy surface, Z2 to the failure zone and Z3 to 
the coating.  C – high magnification of the Z2 area. D – high magnification of the Z3 area. 
 
Osteoblastic cell response 
Cell viability/proliferation 
The viability/proliferation of the cells was inferred from the MTT assay, Figure 
5A. Both HA and Si-HA coated surfaces were able to support cell growth, as the 
metabolic activity of human osteoblasts increased from early time points until day 14, 
decreasing afterwards. Si-HA coated samples reported increased MTT values at every 
time point and significant differences were attained at days 7 and 14. 
 
Alkaline phosphatase activity 
 Results regarding the activity of alkaline phosphatase are presented in Figure 
5B. ALP activity increased significantly during the second week, achieving maximal 
values by day 14, in cultures established on the surface of both coatings. 
Subsequently, ALP activity decreased throughout the remaining culture time. ALP 
activity was significantly higher in the cultures established on the surface of Si-HA 
coated titanium samples, at day 14.  
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Figure 5 - Cell viability/proliferation (A) and alkaline phosphatase activity (B) of human bone marrow 
osteoblastic cells cultured, for 21 days, on the surface of HA and Si-HA plasma sprayed titanium 
substrates. * Significantly different from HA (p≤0.05). 
 
Osteogenic-related gene expression 
The differentiation of bone marrow-derived osteoblastic cells was assessed by 
RT-PCR, following 14 days of culture over both HA and Si-HA constructs. As shown in 
Figure 6, ALP, BMP-2 and Col I genes were transcribed by the cultures established 
over both materials, under osteogenic inducing conditions. Additionally, increased 
expression of the evaluated genes can be visualized in cultures performed over Si-HA. 
 
 
Figure 6 - Results from the RT-PCR showing amplification of osteogenic-associated genes (ALP, BMP-2 
and Col I) in cultures established for 14 days on the surface of both HA and Si-HA coatings. 
Representative agarose gel is shown in the left panel with corresponding densitometric analysis on the 
right panel. Densitometric analyses of transcription levels were standardized using GAPDH, as a 
housekeeping gene. * Significantly different from HA. 
 
Ionized calcium (Cai) in culture medium  
Results regarding the concentration of Cai in the culture medium are presented 
on Figure 7. During the first 2 weeks of culture, values for Cai were kept more or less 
stable in the cultures established over both constructs. Following, at day 14, Cai 
concentration began to decrease in seeded Si-HA samples, while in which regards to 
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seeded HA constructs, the decrease in Cai concentration was only attained following 
day 17.  
 
 
Figure 7 - Ionized calcium (Cai) concentration in culture medium of seeded Si-HA and HA constructs, for 
21 days. * Significantly different from HA (p≤0.05). 
 
Confocal Laser Scanning Microscopy (CLSM) and Scanning Electron Microscopy 
(SEM) 
CLSM images of cells cultured over HA and Si-HA coated substrates, after 3, 7, 
14 and 21 days are presented in Figures 8 and 9, while representative SEM 
micrographs of cultures established for 21 days over both materials, are presented on 
Figure 10. 
CLSM images report that cells were able to adhere well to the coated Ti surface 
since early cytoplasmic spreading was established with several philipodia being 
visualized contacting with the irregularities found on the materials‘ surface. As soon as 
day 3, cells adopted an elongated morphology with a prominent nucleus and multiple 
cell-to-cell contacts, as it can be observed by the high magnification images of Figure 
9. Cells were distributed randomly over both coatings and following, cells proliferated 
actively throughout culture time, covering a significant area of the materials‘ surface at 
days 7 and 14, although, qualitatively, more cells could be visualized on the surface of 
Si-HA samples, at these time points. At day 21, the surface of the samples was 
covered by dense and multiple cell layers, over both coatings. Representative images 
are shown on Figure 8. 
 Regarding SEM observation, multiple cell layers can be visualized over both 
materials‘ surface, interspersed with mineral globular deposits closely associated with 
the fibrous matrix. The Si-HA coating seems to report increased mineral deposition 
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comparing to that attained over the HA coating, as more globular mineral deposits can 
be observed. Representative high magnification images are reported on Figure 10. 
 
 
Figure 8 - High magnification CLSM images of the cultures established for 3 days over HA (A) and Si-HA 
(B). Labeling: phalloidin – green, propidium iodide – red, material’s surface – grey. The scale bar 
represents 50 m. 
 
 
 
 
Figure 9 – CLSM images of the time-course behavior of cultures established for 21 days over HA (A to D) 
and Si-HA (E to H) plasma sprayed substrates. Labeling: phalloidin – green, propidium iodide – red. A and 
E – 3 days, B and F – 7 days, C and G – 14 days, D and H – 21 days. The scale bar represents 300 m. 
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Figure 10 – High magnification SEM micrographs of cultures grown for 21 days over HA (A) and Si-HA (B) 
coatings. Note the globular mineral deposits interspersed with the thick cell layer. The scale bar 
represents 100 m. 
 
Discussion 
Titanium based alloys have been widely used for orthopedic and dental 
applications due to their satisfactory mechanical properties and adequate 
osseointegration [1,2]. However, since primary fixation is one of the most important 
factors for establishing adequate clinical function, several approaches have been 
employed to maximize bone formation and implant fixation, including the deposition of 
ceramic films and coatings over the surface contacting the biological tissues [32].  
Among the available techniques, plasma spraying appears to be the most 
favorable, and thus, most commonly used for fabricating bioactive ceramic-based 
coatings on implants [26]. In fact, deposition of plasma-sprayed HA increases surface 
roughness and porosity of the construct, establishing a favorable microenvironment for 
cell adhesion and proliferation, and though, promoting osteointegration by direct bone 
interlocking [33].  
Taking advantage of this technique and the benefits of Si-HA, we report the in 
vitro biological evaluation of Ti-6Al-4V substrates, plasma-sprayed with 0.8 wt% Si-
substituted HA, regarding proliferation and differentiation events of human bone-
marrow derived osteoblastic cultures, established for 21 days in conditions known to 
induce the osteoblastic phenotype [34]. Ti-6Al-4V substrates plasma-sprayed with HA 
were used as control.  
The addition of 0.8 wt% Si to the HA lattice did not induce modifications in the 
phase composition since no secondary phases were detected in the Si-HA powder, 
regarding XRD analysis. In fact, the substitution of PO4
3- groups by SiO4
4- groups, up to 
a certain level, introduces only small changes in the cell unit which does not lead to 
HA‘s phase decomposition [30,35]. Accordingly, new and more soluble phases 
(including tricalcium phosphate – -TCP and -TCP – and calcium oxide) were only 
obtained following plasma-spraying of feedstock powders, both regarding HA and Si-
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HA materials. As previously published by the research group [36,37], pure phase HA, 
after plasma spraying, becomes more amorphous and suffers phase decomposition 
leading to the formation of CaO (6.4%) and -TCP (6.4%) phases, besides HA 
(87.2%). Decomposition occurs as a consequence of the high temperature followed by 
a rapid cooling rate – characteristics of the thermal deposition technique [33]. 
Additional characterization of the coatings has also shown that the adhesive strength of 
the plasma sprayed surfaces (around 30 MPa before and following immersion in SBF) 
satisfies the stress requirements for coated bearing biomedical applications [36,37]. 
Fracture surfaces of the samples subjected to DIN 50161 have shown that failure 
occurred by the coating – cohesive failure.        
By comparing the phase analysis results of both coating materials, Si-HA material 
suffered the highest conversion of HA, and showed the presence of -TCP phase that 
was not detected in the HA coating. The introduction of Si into HA lattice led to its 
distortion [38], and therefore the Si-HA feedstock powder was more susceptible to 
suffer phase transformation than HA feedstock powder, during plasma spraying. 
Moreover, silicon has been shown to stabilize TCP phases, preventing the fully 
conversion of -TCP into -TCP – as described following the decomposition of HA, 
after plasma spraying [39,40]. The initial increased Ca and P adsorption associated 
with Si-HA materials might suggest the early formation of the apatite layer on this 
material over HA constructs, nevertheless following 7 days of immersion, similar 
globular agglomerates were assessed by SEM. 
In cultures established over Si-HA and HA sprayed substrates, cells showed 
early attachment and spreading, as well as an elongated fibroblast-like morphology 
with a close interaction with the materials‘ surface irregularities and intense cell-to-cell 
contact. In a general way, Si-HA coatings allowed an increased viability/proliferation, as 
well as the expression of higher levels of ALP. Maximum values of these parameters, 
observed at day 14, were significantly higher than those of control – HA coatings. 
Further, several osteogenic markers like ALP, BMP-2 and Col I were shown to be up-
regulated by cultures grown over Si-HA-coated substrates, while assessment of the Cai 
in the culture medium indicates that calcium deposition began around day 14 for the 
cultures established over Si-HA constructs and later on regarding seeded HA 
constructs. These results are in concordance with ALP activity which is expected to 
reach maximal value just before the beginning of matrix mineralization. SEM 
observation suggested an increased mineralization of the extracellular matrix in Si-HA, 
comparing to control. This might converge to substantiate an increased osteogenic 
differentiation by cultures established on the surface of Si-HA plasma sprayed 
substrates.  
190 
 
Regarding previous in vitro biological evaluation of Si-containing coatings over 
titanium substrates, Thian et al. reported improved cell growth on a magnetron 
sputtered 0.8 wt% Si-containing hydroxyapatite over titanium surfaces, comparing to 
uncoated ones [22]. Further, a porous CaP layer was observed from day 16 onwards, 
which grew denser and thicker till day 42. In comparison, uncoated substrates revealed 
a very porous layer comprising only CaP crystallites, after 42 days of culture [22]. 
However, these studies compared Si-containing coatings with uncoated titanium 
substrates and not with the control surfaces, i.e. the deposited ceramic coatings 
without the addition of Si to the formulation. Therefore, no information is provided 
regarding the specific role of Si in the evaluated cell response, since other ions are 
released during the coating incubation with the culture medium, and expected to 
influence the biological response [41]. 
In a general way, the results presented in this study regarding the positive effect 
of Si-HA compared to HA are in accordance with previously reported data from the 
literature which have shown an improved biological response induced by Si-containing 
biomaterials [18-21,30]. Although no definitive mechanisms have been established, 
silicon release may contribute to the attained biological response. In the present work, 
the ionic release of Si was assessed throughout the cell culture period (21 days) in 
SBF, at pH 7.4. During the test period, a continuous Si release was established and a 
concentration of around 0.12 mM (around 3.4 ppm) was attained, after 21 days of 
immersion. This concentration is within the range of the large interval, between 1 and 
100 ppm, which lead to a dose dependent increase in human osteoblast-like cells‘ 
proliferation and differentiation, in short-term cultures [15-17].    
In humans, the silicon concentration is highly variable according to the 
biological location. For instance, serum concentration is around 0.6 ppm, while for 
muscle and lung tissues, it is around 40 and 50 ppm, respectively [42,43]. Other 
mammals show a similar range of silicon concentrations in multiple tissues [44]. 
Therefore, the levels of Si released from the Si-HA plasma-sprayed constructs reported 
in the present work are well within the physiological range of Si levels. In addition, and 
of particular relevance, an experimental rabbit model of bone regeneration with a Si-
rich bioactive glass, revealed that nevertheless the attained high Si concentration 
neighboring the implant location, this ion was continuously released into the blood and 
promptly excreted into the urine, with no adverse physiological effects or accumulation 
in major organs, substantiating the biosafety of Si-releasing biomaterials [45]. 
Previous work regarding the biological performance of the present material, 
0.8% Si-HA, in a bulk form, did not show significant differences on the proliferation 
profile, ALP activity and matrix mineralization of osteogenic-induced human bone 
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marrow cells, comparing to HA, although a slight increase in the expression of 
osteocalcin was noted over Si-HA [46]. This might suggest that the incorporation of Si 
in the composition of a plasma-sprayed ceramic coating could lead to an improved cell 
response, compared to that occurring on Si containing bulk ceramic materials. This 
might be related with the intrinsic properties of plasma-sprayed materials, i.e., 
increased surface area, porosity and roughness [26,33], as well as with the increased 
solubility associated with the phase modifications‘, elicited by the thermal spraying 
deposition. Both may contribute to an improved pattern of Si release, comparing to that 
observed in a bulk material with similar composition. In fact, plasma sprayed ceramics 
report a faster dissolution rate which is known to contribute to the formation of a 
supersaturated microenvironment that may potentiate the precipitation of 
physiologically produced apatite over the coatings, enhancing bone ingrowth [47,48]. In 
agreement, in the present work, a continuous globular apatite layer could be visualized 
in the surface of both materials, from early time points, following immersion in SBF. 
Furthermore, it is also reported that bone growth occurs at a faster rate when the 
coating has a higher content of amorphous phase, as reported in plasma-sprayed 
substrates [26].  
The addition of Si to the HA composition may assemble, along with the plasma 
spraying characteristics‘, an optimized microenvironment that is more favorable for cell 
adhesion, proliferation and differentiation than that achieved with the plasma spraying 
of non-doped HA. 
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Abstract 
In vivo research with animal models has been a preferred experimental system 
in bone-related biomedical research since, by approximation, it allows relevant data 
gathering regarding physiological and pathological conditions that could be of use to 
establish more effective clinical interventions. Animal models, and more specifically 
rodent models, have been extensively used and have contributed greatly to the 
development and establishment of a wide range of translational approaches aiming to 
regenerate the bone tissue. In this regard, the calvarial defect model has found great 
application in basic and applied research, nonetheless the controversial rationalization 
for the use of critical size defects – defects that are unable to report spontaneous 
healing – or sub-critical size defects in the proposed applications.  Accordingly, this 
work aims to review the advantages and limitations of the use of rodent models in 
biomedical bone-related research, emphasizing the problematic issues of the use of 
calvarial critical and sub-critical size defects. Additionally, surgical protocols for the 
establishment of both defects in rat calvarial bone, as well as the description and 
exemplification of the most frequently used techniques to access the bone tissue 
repair, are portrayed.  
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The bone tissue is characterized by an adequate capacity to regenerate itself 
following the establishment of a lesion or a defect, when the physiological stimuli 
converge to establish a proper response. Nevertheless, determined conditions 
associated with an unfavorable micro-environment, sub-optimal surgical techniques or 
biomechanical instability can lead to a poor prognosis on bone tissue regeneration [1]. 
Furthermore, large orthopaedic defects, in which the physiological regenerative 
capabilities are exceeded, rely on the application of mechanically- and biologically-
suited biomaterials, including ceramics, metals, polymers and composites, for 
adequate tissue reconstruction [2]. The reported situations are established major 
clinical and socio-economic burdens with serious implications in patients life-style and 
life quality [3]. Furthermore, several systemic conditions are known to affect bone 
physiological equilibrium and may contribute to the impairment of an adequate healing 
process [4-6].  
Regenerative medicine and tissue engineering approaches to the bone tissue 
enclose a wide range of applications that aim to repair, augment, substitute and 
regenerate lost tissues [2]. De novo bone formation relies on the recruitment, 
transplantation, homing or modulation of progenitor or differentiated cells. These cells 
require the availability of an adequate substrate to play their biological function by 
adhering, proliferating and differentiating in a controlled way, giving rise to a mature 
tissue with adequate biomechanical properties [2, 3].  
The design of experimental models to evaluate the efficacy and biosafety of 
these regenerative strategies – that encompass cells, materials and modulators – 
requires both methodical control and modulation of specific variables – situations that 
cannot be met on a single model. According to Muschler et al, in order to aim the 
clinical translation of bone tissue engineering strategies, used models should  meet 
several criteria: mimic the clinical and biological environment in which the experimental 
methodology will be assessed; allow quantifiable parameters to access the success, in 
a quantitative and qualitative way, and functional performance of the regenerated 
tissue; and identify and foresee relevant differences in the biological performance 
between assayed methods [7].   
In vitro assays give great contribution to the comprehension of fundamental 
biological mechanisms (i.e., transcription, translation, intra-cellular signaling events, 
regulation of the cell cycle, ligand-receptor interactions, etc.), screening of the 
biological activity, toxicity and immunogenicity  of specific compounds,  and evaluation 
of the direct or indirect cell response to a seeded material [8, 9]. Additionally, in vitro 
models of higher complexity have been developed, enclosing the use of bioreactors to 
access the biological response of 3D constructs and co-culture models with different 
200 
 
cell populations, to further recreate the complexity of multiple cell interactions [10, 11]. 
Even so, in vitro assays reveal significant limitations in the capacity to recreate the 
intricacies of the in vivo milieu and though, are incapable of predicting clinical output 
and performance. 
In vivo research with animal models has been a preferred experimental system 
since, by approximation, provides relevant data regarding physiological and 
pathological conditions that could be of use to establish more effective clinical 
interventions. In vivo research establishes a link between in vitro studies and clinical 
trials. Experimental animal models are essential to provide an adequate approximation 
to the real settings. Accordingly, the selection of the appropriate design and model 
relies, in the very end, in the therapeutic modality that is being tested [7]. In this 
context, and in which relies to the bone tissue, one may consider five domains of 
biological activity: 1) Osteogenesis – associated with the cellular function – i.e, the 
biological process by which committed cells at different stages of differentiation are 
recruited, activated, proliferate and differentiate in order to produce de novo bone 
tissue; 2) Osteoconduction – associated with the support function – i.e., the process by 
which a specific volume of tissue is preserved from the infringement of neighboring 
tissues and allows osteogenic cells to play their biological role; 3) Osteoinduction – 
associated with the modulators function – i.e., the process by which soluble or matrix-
associated molecules influence the biological fate of osteoblastic cells; 4) Mass transfer 
and 5) Biophysical effects – processes which are mainly associated with biochemical 
and biomechanical events that contribute to the establishment of an adequate tissue 
healing [12].  
Animal models, and more specifically rodent models, have been extensively 
used and have contributed greatly to the development and establishment of a wide 
range of approaches to regenerate the bone tissue. For instance, and focusing on 
osteogenesis, rodent models have provided great amount of data regarding the cellular 
behavior of multiple populations relevant to bone regeneration [13-15]. Moreover, and 
in which regards to osteoconduction, rat and mouse models have also proven to be of 
great importance regarding the assessment of the biocompatibility of granular, 
scaffolds or bulk materials, in the evaluation of the surface osteoconduction and 
specific toxicity, and degradation rate of synthetic materials aiming bone repair [7, 15, 
16].  These models have been also used for the evaluation of the biosafety profile of 
the osteoinduction process, following the administration of biomodulators [15, 17, 18]. 
Among the available orthotopic models to evaluate the bone function, calvarial 
bone defects have gained a widespread reputation and use in the published literature, 
reporting valuable data from basic and applied research. Nonetheless, a major point of 
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debate relies on the selection of either critical size defects – the ones that do not report 
spontaneous healing during the lifetime of the animal – or sub-critical size defects – 
defects in which complete bone regeneration is expected, without the contribution of 
induced-recruited or added factors.  
In this way, we aim to review the advantages and limitations of the use of 
rodent models in biomedical bone-related research, in particular the calvarial bone 
model, emphasizing the problematic issues of the use of critical size and sub-critical 
size bone defects. Additionally, surgical protocols for the establishment of both defects 
in rat calvarial bone, as well as the description and exemplification of the most 
frequently used techniques to access the bone tissue repair, are portrayed.  
 
Selection of animal species – the relevance of rodents 
A large variety of mammalian species have been used in bone-related 
research. O‘Loughlin reviewed the use of animal models in fracture repair studies 
published for the past 10 years in 6 orthopaedic journals and realized the following 
relative order of frequency: rat 38%, rabbit 19%, mouse 13%, sheep 11%, dog 9%, 
goat 4% and other 4% [19]. This report clearly states the relevance of rodents in 
orthopaedic research. Fundamental research, feasibility and bioactivity testing greatly 
rely on the use of mice and rats due to the high definition of the models in a biological, 
genetic and immunological point of view, which allows the attainment of a high level of 
experimental reproducibility. 
In fundamental research, the availability of biological tools (e.g., primers for 
PCR testing, microarrays, probes, antibodies, etc.), the fast turnover of individuals and 
the rapid occurrence of biological processes are of the utmost importance, allowing for 
a facilitated observation of the processes under study. In an additional way, the 
sequencing of mouse [20] and rat [21] genome smoothed the progress of transgenic 
and knockout models which contributed to the knowledge of  the function and 
modulation of specific genes [22, 23].  
Going one step further fundamental research, feasibility and bioactive testing 
directs the research process along the translational application pathway. Specific 
evaluation broadly includes the efficacy of materials‘ or agents‘ delivery, cytotoxicity 
and biocompatibility testing and screening for adverse or unwanted reactions. The 
same models used in feasibility studies, with relevance for both mice and rat, are also 
utilized for the quality control screening and bioactivity of products or implants. In 
addition, route of administration and assessment of the target tissues may be 
evaluated in compliance with the proposed clinical setting.  
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The assessment of clinical modeling and efficacy, also referred as preclinical 
testing, is broadly performed in large skeletally mature animals including dogs, goats, 
sheep and pigs, reporting phylogenetical resemblance. Structure and composition of 
these animals‘ bone tissue has been found to be highly similar to those of humans [24]. 
Point variations are generally associated with modest differences in cancellous and 
cortical density, response to uferectomy and diet restriction, extent of sexual 
dismorphism, age of peak bone mass, and rate and extension of harversian remodeling 
[7, 24, 25]. Nevertheless the stated variations, there is no substantiation that one model 
proves to be a better match than other to address clinical translation of assayed 
therapeutic approaches. As a result, individual selection should rely on economic 
issues, local access, housing requirements and availability, staff expertise, and 
considerations of the experimental protocol.  Nonhuman primates (NHPs) have also 
been used in the study of bone repair, nevertheless the established increase in the 
research cost and the raise of cultural and ethical questions. Arguments substantiated 
by the evolutionary proximity and anatomic and physiological resemblance converge to 
indicate NHPs as first choice models in bone-related research. Nevertheless, the 
diversity and variability attained in effector responses limit the efficacy of clinical 
translation – response variations between primate species has been shown to be 
greater than in quadrupeds and even humans [26, 27]. In addition, biomechanical 
differences have been largely stated and reports concerning differential biological 
responses – e.g., baboons seem to be hypersensitive to the administration of bone 
morphogenic proteins [28] – contribute to the fact that NHPs do not attain a valid 
consensus as providing a first choice model, comparing to other large animals [7]. 
As stated, a wide range of animal models is available not only for fundamental, 
feasibility and bioactivity bone-related biomedical research, but also for pre-clinical 
testing. Individual choice should be made according to the knowledge of established 
biological differences, advantages and inconveniences, but also taking into account 
methodological and operational features of each model. Comparing the characteristics 
of the bone tissue between the described animals, several differences can be 
outputted. For instance, rodents continue to model their skeleton throughout their life 
cycle - regarding grow and reshape - and growth plates remain open throughout 
adulthood. Mice and rats also report limited trabecular bone content and haversain 
remodeling - by tunneling osteoclasts - does not occur, although cancellous remodeling 
is established [29, 30]. Furthermore, rodent models are not suited to the establishment 
of long-term studies, in which multiple biopsies or large blood samples are required, 
due to biological constrains. On the other hand, and comparing to large animal models, 
rodents are inexpensive, easy to house and manipulate, and report minimal social 
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concern. Furthermore, if trustworthy and validatable data can be acquired, animals 
placed at the lower end of the phylogenetic scale should be preferably used – in the 
case, rodents are a first choice option over large mammals.  Due to their widespread 
utilization, much is known regarding the biological processes associated with bone 
turnover, diet modifications and drug administration. Furthermore, the reduced lifespan 
of these animals allows for the study of the influence of aging in the bone metabolism 
and regeneration processes.   
Over viewing the stated arguments, rodent models prove to be quite useful in 
bone-related research, being among first choice models for in vivo testing of 
regenerative and/or therapeutic approaches to the bone tissue.    
 
In vivo models of bone regeneration – the calvarial defect model 
Currently, several in vivo models are used to evaluate the bone regeneration 
process, the bone-biomaterial interaction and the physiological or pathological 
evidence of the modulation of the ossification pathway. Experimental models can be 
classified as heterotopic or orthotopic, based on the vicinity to the autologous bone 
tissue.  The characterization of materials aiming bone regeneration is generally 
assayed, on a first approach, in a heterotopic model, i.e. subcutaneous, intramuscular, 
intraperitoneal or mesentery location, which are generally used prior to the assessment 
of the materials‘ behavior in direct contact with the bone tissue. Moreover, if the 
material reveals a paste-like consistency, it can be easily injected into the targeted site.  
The surgical implantation of granular, scaffolds or bulk materials has been 
widely conducted in rodents. Accordingly, the rat heterotopic model has been used 
successfully to show the sequence of events involved in the ossification process [31]. 
Most common implantation sites include the subcutaneous tissue on the back or upper 
abdominal area [32]. Although the use of heterotopic bioassays in rodent models 
prevails in the biocompatibility assessment of materials, there is a scarcity of data 
regarding translational and clinical applications, no matter how quantitative the data 
from the heterotopic bioassay may be [33]. 
In order to solve inherited limitations from heterotopic applications, intraosseous 
defects have been used to test for the capacity of materials and constructs to promote 
the repair of discontinuous and weight-bearing lesions. The selection of orthotopic 
models in bone research relies broadly in one of the following options: calvarial, long 
bone or mandible segmental, partial cortical and cancellous bone defects [34]. The 
calvarial model outreaches as an adequate model to evaluate complex materials and 
tissue engineering constructs aiming bone regeneration, especially in which refers to 
the regeneration of craniofacial defects. This model has been established in a wide 
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range of animal species including, mice, rats, rabbits, dogs, sheeps, goats, pigs and 
non-humane primates, although rats and rabbits are the most commonly used animals. 
The calvarial model is very adequate and popular among researchers, mainly 
due to the following reasons: the calvarial bone structure allows the establishment of a 
uniform, reproducible and standardized defect that is easily evaluated by radiographic 
and histological analysis; the anatomic location reflects an adequate size for surgical 
access and intra-operative handling;  the dura and the overlaying skin set up an 
adequate support for implanted materials, without the need of internal or external 
fixation; and the model has been widely used and studied, allowing a precise 
comparison of grafted substances [32].  Nonetheless, it does not allow the assessment 
of the biological response of the implanted material to a physiological biomechanical 
loading which may be a limitation in some applications. In this case, alternative 
anatomical load bearing locations, like the mandible, the femur or tibia, should be 
preferably selected.    
 
Calvarial critical size and subcritical size defect models 
The use of the calvarial model implies the selection of the defect size, 
particularly the knowledge of the critical size of the defect, which varies according to 
the animal species, strain, gender, age, anatomic site, shape, size and micro-
mechanical environment [35-37]. According to Schmitz et al, the CSD can be described 
as the smallest wound established intraosseously in a particular bone, which does not 
report spontaneous healing during the lifetime of the animal [35, 36]. Accordingly, the 
CSD can be considered the prototype of discontinuity defects, as a specific condition of 
failed osteogenesis for overcoming the threshold of the physiological process of tissue 
repair/regeneration.  
Nevertheless the stated knowledge, the processes associated with the cease of 
bone healing during the repair of CSD have not been fully understood. Honma et al 
compared the regeneration process in sub-critical (3.8 mm in diameter) and critical (8.8 
mm in diameter) size defects established in Wistar rats‘ calvaria [38]. New bone 
formation was observed in both defect sizes, with small defects being almost 
completely filled by 24 weeks, while large defects remained unrepaired, becoming non-
unions with fibrous connective tissue in the areas in which the bone formation was 
absent. Radiographic analysis reported that the bone formed per week was maximal at 
week 4, for both defect sizes, data supported by a high expression of collagen type I 
and osteocalcin, by osteoblasts and osteocytes, as assessed by in situ hybridization. 
Moreover, collagen and osteocalcin production was very low at week 24 – for both 
defect sizes – suggesting that bone cells may greatly reduce bone formation and the 
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differentiation process of new osteoblasts may be severally impaired at this time point. 
In this way, the authors suggested that the bone formation process ceases within 24 
weeks, regardless the dimension of the defect size and completation of defect repair 
[38]. The influence of the post-surgical inflammatory response on the osteogenic 
activity may be important to substantiate the attained data, and has been reported in 
several in vitro and in vivo models [39-42].     
All the same, the evaluation of the CSD relies not only on the assessment of the 
repair of the wound size but, above all, on the quality of the regenerated tissue. This 
evaluation should be based on the relativity of the model, i.e. according to the 
specificities of the experimental protocol and time points, since the best tissue quality 
ought to be achieved in the shortest lapse of time. Regarding tissue quality on bone 
regeneration, it is wide established that fibrous connective tissue regenerates faster 
than bone, relying on the faster migration of fibroblasts to the wound site, comparing to 
osteoblasts [43-46]. Early works, in the 1970‘s, by Najjar et al showed that the first 
healing of bone wounds in animal models was set on fibrovascular connective tissue, 
followed by immature bone replacement , which in turn remodeled into mature bone 
[47]. Accordingly, one ought to attain a fast osseous healing which can prevent the 
establishment of undesirable results such as fibrous non-union or fibrous encapsulation 
of implanted materials [48, 49].  
Furthermore, apart from the size of the defect, other factors determine the 
quantity and quality of the new bone tissue formed. For instance, the anatomical site 
and its stability are relevant since the load stress and the degree of mobility can have a 
profound effect on the final outcome [50, 51]. Other factors, proven to be relevant, 
include the intrinsic structure of the bone tissue, adequacy of vascular supply, 
involvement of the cortical bone, and presence or absence of periosteum [35, 36, 46, 
52]. Animals‘ age is also an important point to consider in experimental planning since 
juvenile animals have been shown to report an increased healing capacity of calvarial 
defects, which may be related to differential transcriptional gene expression profiles 
[53-56]. Wu et al, in order to determine the CSD in neonatal mice, established circular 
defects of 0.8, 1.0, and 1.5 mm in diameter, in the parietal bone. Healing assessment 
reported statistically significant differences in bone filling percentages: 1.5 mm defects 
(4.49%), 1.0 mm defects (47.65%), and 0.8-mm defects (73.45%) [57]. These result 
output the 0.8 and 1.0mm defects as sub-critical size defects and the 1.5 mm as a 
CSD. In another experimental setting, Aalami et al aimed to compare the bone 
regeneration process in juvenile and adult mice.  Non-suture associated cranial 
defects, with 3mm, 4mm and 5mm in diameter, established in the calvarial bone of 
juvenile (6-day old) and adult (60-day old) mice, were evaluated. Following 8 weeks of 
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healing, histological and radiographic evaluation allowed to conclude that all three 
defect sizes were found to be critical in the adult, whereas significant healing (59, 65 
and 44%, respectively, of the total defect area) was seen in juvenile mice [53].   
In rats, controversial data regarding the dimensions of CSD have been 
reported. Turnbull et al. described the surgical establishment of a 2mm in diameter 
defect, in Wistar rats‘ calvaria, and their incapacity to heal up to 3 months, as assessed 
by radiographic and histological techniques [58]. Following, Mulliken et al. reported a 4 
mm CSD in Charles River rats [59]. Takagi et al. characterized the CSD as 8 mm in 
diameter, in 6 months Sprague Dawley rats [60] as it has been reported earlier by Ray 
et al for Long Evans rats [61]. Later on, Hollinger et al substantiated the 8 mm defect 
as the CSD for Long Evans and Walter Reed rats, reporting the inability of the defect to 
heal spontaneously, following 13 months, and a maximum of 10% of de novo bone 
formation [35, 36].  
Other bibliographic reports have acknowledged the 5mm defect as a CSD for 
adult rats. Bosh et al reported that a 5 mm defect, apart from minor bone formation on 
the defects‘ margins, was unable to heal spontaneously up to 12 months after the 
surgery [62]. The stated advantages of the use of 5mm CSD  include the possibility to 
establish 2 defects per animal, and the avoidance of the inclusion of the sagittal suture 
in the defect, minimizing the risk of midsagittal sinus lesion [62]. On the other hand, 
laterally performed craniotomies – opposing those which include the sagittal suture, like 
in the 8mm defect – may allow substance diffusion and impair local repair/regeneration, 
due to the close vicinity of adjacent defects, which may blight the relevance of the 
model [63]. Accordingly, the 8mm defect continues to be used in many reports aiming 
to assess different bone therapeutic strategies. This is established not only for the 
described limitations of the 5mm CSD design, but also due to the increased challenge 
associated with the higher diameter of the defect.  
Apart from the need to establish a CSD, with an increased challenge for the 
regenerative process, sub-critical size calvarial defects allow to evaluate the impact 
that a wide range of conditions, biological processes or added substances have on the 
physiological equilibrium of the bone tissue regeneration, through an intramembranous 
ossification process. Specifically, sub-critical size calvarial defects have been generally 
used to evaluate the biological response of the bone regeneration process following the 
establishment of pathological conditions [64, 65], within the evaluation of therapeutic 
options to enhance bone regeneration [66, 67] and optimization of hard tissues-related 
surgical techniques [68, 69]. In mice, 1 mm diameter defects have been routinely used 
as sub-critical size defects due to the fast healing – normally complete around 14 days 
– allowing the determination of stimulatory or inhibitory effects of locally or systemically 
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applied substances. In rats, defects created with 3 mm trephines, or less, have found 
generalized application as standardized sub-critical size defects.   
These surgical procedures, due to the technique-dependent and sensitive 
applied protocol, as well as the significance of the anatomical neighboring structures, 
should be conducted by clinical professionals with surgical expertise, following an 
adequate training period. Additionally, due to the expected amount of pain induced by 
the orthopedic procedure, a local anesthetic should be used in conjunction with a 
general anesthetic, as well as an appropriate regimen of post-operative analgesia. 
Following we describe a refined surgical protocol for the establishment of CSD 
and sub-critical size defects in Wistar rats‘ calvarial bone, for the evaluation of the 
biocompatibility of a ceramic granular material.  
 
Establishment of calvarial critical size and subcritical size defects on rodents  
The animals – male Wistar rats with 3 months, weighing between 260-280g – 
were purchased from Charles River Laboratories. National regulations for the care and 
use of laboratory animals were observed at all times. All experiments were approved 
by the local IACUC. Animals were housed in plastic cages in a monitored environment 
(21°C; 12h light/dark cycle).  
Anaesthesia and pain control followed recommended routines for the species. 
Prior to the surgical intervention, the animals were anesthetized using sevoflurane 
inhalation anesthesia (4% to 5% induction; 2% to 3% maintenance). Following, the skin 
that covered the skull, around the incision area, was shaved and disinfected with 
iodopovidone solution.  An intraperitoneal injection of tramadol (10 mg/kg) for post-
operative analgesia was given, and the animals were then transferred onto a heating 
pad, maintained at 37 °C, in the operating field. A subcutaneous injection of 0.3-0.4 mL 
of 1% lidocaine, used as a local anesthetic, was administered along the sagittal midline 
of the skull. Following, a surgical blade was used to perform a midline incision, from the 
nasofrontal area to an anterior location of the external occipital protuberance (Figure 
1A). The skin was then reflected bilaterally and a new midline incision, of around 3 cm, 
allowed the division of the subcutaneous fascia and the bilateral reflection of the 
periosteal flaps following blunt dissection, to expose the calvarial bone surface (Figure 
1B-D). Careful drilling with an 8 mm diameter trephine bur, mounted on a low-speed 
dental handpiece, was done around the sagittal suture, and a standardized, round, 
segmental defect was made. During drilling, the area was continuously irrigated with 
sterile saline solution and extreme care was taken not to damage the dura mater or the 
underlying blood vessels and sinus (Figure 1E-F). The obtained calvarial disk was 
carefully removed to avoid tearing of the subjacent cranial structures (Figure 1G). After 
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thoroughly rinsing of the defect with physiological saline, to wash out any bone 
fragments, the material in the granular form – a modified hydroxyapatite – was 
implanted within the defect (Figure 1H-I). The periosteum and scalp were closed over 
in layers with interrupted 4-0 Vicryl resorbable sutures (Figure 1J-K). Following surgical 
intervention, the animals were given a subcutaneous injection of sterile saline (10 
mL/kg/hr of surgery). The rats were placed into soft-bedded plastic cages and housed 
individually after the procedure. Each animal received a subcutaneous injection of 
tramadol (10 mg/kg) at 12, 24, and 36 hours after surgery for continued post-operative 
analgesia. Animals were given free access to food and water and were monitored daily, 
in the post-operative period until euthanasia, for any complications or abnormal 
behavior. 
Alternatively, the establishment of sub-critical calvarial defects, in rats, can be carried 
out with the use of 3 mm trephines or less in diameter, allowing the establishment of 
multiple defects in the calvarial bone (Figure 1L). 
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Figure 1 – Surgical protocol for the establishment of critical size defects (A-K) and subcritical size defects 
(L), on rat calvarial bone. 
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Evaluation methodologies of the bone regeneration process  
The assessment of the bone regeneration process can be carried out by 
reaching hand of multiple and complementary methodologies. Histological analysis, 
electron microscopy and radiological techniques are among the most commonly used. 
As follows, the authors described the most relevant techniques used with given 
examples from their personal experience.    
 
Histological evaluation  
Characterization of the regenerated bone tissue is commonly performed by 
histological evaluation with light microscopy, following standard dying of the sample.  
Descriptive histology and histomorphometry are the two major classes of histological 
evaluation. Descriptive histology is used to provide a general assessment of the tissue 
of interest, giving data regarding cell morphology, structure and arrangement within the 
interface with the extracellular matrix or with an implanted material. Semi-quantitative 
analysis could be performed using a score system, in which the data can be evaluated 
using nonparametric analysis of variance.  Histomorphometry allows quantitative 
analysis of histological data, namely regarding length and distance, area and number 
of the components of interest [29, 70]. These are the basic parameters which can be 
assessed in two-dimensional histomorphometric analysis. Three-dimensional 
evaluation can be conducted from two-dimensional sampled images following specific 
considered assumptions. Due to the use of multiple designations and 
misinterpretations in histomorphometric analysis, a consensus report aimed to 
establish a system for standardization of nomenclature, symbols, and units, and has 
generally been adopted [71].  Despite the aim to perform a reproducible analysis in the 
evaluation of the attained results, histological observation is lined by significant inter-
method and inter-observer variability, especially in which regards histomorphometric 
analysis [72]. 
Bone tissue can also be labeled in vivo with intravital markers, in order to 
assess the quantitative evaluation of bone formation and remodeling events [73]. Used 
fluorochromes are irreversibly deposited and rely on their calcium-binding properties to 
be embedded into the mineralization fronts of the remodeling bone [73]. Prepared 
samples can be visualized under fluorescent light. Specific binding to newly 
mineralizing surfaces of mineralized tissues may be due to the smaller size of the 
apatite crystals formed during the early stages of the mineralization process, compared 
with older mineralizing sites [74, 75]. The most commonly used fluorochromes are 
tetracycline, calcein dyes, alizarins and xylenol [76].   
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Immunohistochemistry (IHC), by a direct or indirect technique, could also be 
used to identify and specifically localize peptides or proteins of interest in bone tissue 
section, based on the principle of the specific interaction between antibodies and 
antigens [77]. In order to improve reproducibility and standardization of the data 
attained with IHC, quantitative methodologies have been developed, relying upon pixel-
counting and cumulative signal strength algorithms [78, 79].  
As an example, on Figure 2, representative images of some of the depicted 
techniques are shown.  
 
 
 
Figure 2 –Images of non-decalcified resin-embedded calvarial samples, following the surgical 
establishment of an 8 mm CSD on rat calvarial bone and the implantation of a ceramic material. Figure 
2A and 2B are stained with toluidine blue, 15 days following implantation. Figure 2C shows a 
tetracycline-stained sample, 3 months following material implantation. Mat – pellets of the implanted 
material; DM – defect margin; Arrows – areas of new bone formation; OB – old bone; * - areas of 
primary ossification. 
 
Electron microscopy 
Scanning electron microscopy (SEM) is also an important tool used on the 
evaluation of the structure and morphology of the bone tissue. In biomedical bone-
related research, it has been used to characterize trabecular and cortical bone 
surfaces, implant surfaces, wear debris, implant beds and implant-tissue interfaces [80-
82]. With the use of corrosion-cast tissues, SEM has been able to assess the vascular 
structure in the evaluated tissues – which is of the utmost importance for the 
development and maintenance of an adequate bone tissue quality  [83, 84]. Major 
212 
 
limitations associated with SEM application are related to the relative small size of the 
evaluated samples and the need for drying the specimen for observation, which has 
been shown to induce modifications in morphology and spatial structure of the tissues 
[85]. New technologies have allowed the development of low-temperature or cryo-SEM, 
and environmental SEM systems, which aim to solve the dehydration-related problems 
[80]. 
As an example, on Figure 3, images of rat calvaria specimens assessed by 
environmental SEM are portrayed.  
 
 
Figure 3 – Micrographs of rat calvaria assessed by environmental SEM, 3 days following the 
establishment of sub-critical monocortical defects, are presented. The defects were established with a 
1mm diameter burr (A and C) and with a high-intensity Erb:YAG laser (B and D). Figures 3C and 3D are 
detailed high magnification images of Figures 3A and 3B, respectively. 
 
Electron microscopy techniques also make use of transmission methodologies 
– TEM, transmission electron microscopy – in which a beam of electrons is transmitted 
through an ultra thin specimen, interacting with the specimen as it passes through. This 
is a very powerful methodology to evaluate the ultrastructure and morphology of 
subcellular components, cells and tissue-biomaterial interaction [86-88]. Nevertheless 
the very high resolution, samples require extensive sample preparation and the field of 
view is relatively small, raising the possibility that the analyzed region may not be 
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characteristic of the whole sample. Additionally, samples may suffer modifications from 
the preparation process or directly damaged by the electron beam [87, 88]. 
Illustrating this application, two images of ceramic-based materials‘ debris 
interacting with rat calvarial osteoblastic cells, are shown on Figure 4.      
 
 
Figure 4 –Transmission electron micrographs of ceramic-derived material debris interacting with 
osteoblastic cells from rat calvarial bone. 
 
Radiological techniques 
Radiologic techniques have also been employed with success in the evaluation 
of the bone repair and regeneration processes. Radiography is the basic method for 
the evaluation of fracture healing and bone-defect repair. In clinical or experimental 
settings, pre-surgical evaluation allows the assessment of the specific anatomy and 
bone dimensions, facilitating the selection of fixation devices and implants. Post-
operative evaluation also benefits from the radiographic assessment allowing the 
determination of the fracture placement or the quality of the defect fill. Periodic 
evaluation permits the monitoring of the repair process. High-resolution radiography 
and microradiography are complementary techniques that allow the evaluation of the 
detailed structure of the bone tissue. Quantification of bone aposition and densitometric 
analysis can be conducted, even in the neighboring of an implant [89].  
Sample radiographic images of the rat calvarial bone, with or without a grafted 
material, are shown on Figure 5.  
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Figure 5 – Radiographic images of the rat calvarial bone, without (Fig. 5A) or with (Fig. 5B) a grafted 
ceramic material, 6 months following the surgical establishment of an 8 mm CSD. Areas of newly formed 
bone following material resorption (open arrow) can be identified, simultaneously with areas of 
implanted biomaterial content, interspersed with the newly formed bone tissue (full arrow). 
 
X-ray computed microtomography (μCT) is a miniaturized form of conventional 
computerized axial tomography (CAT) that has been found to be a valuable application 
in bone-related research. This technology enables 3D reconstruction of the internal 
structure of small X-ray opaque objects in a noninvasive and non destructive way. μCT 
allows to qualitatively and quantitatively assess the spatial and temporal mineralization 
of bone formation. The availability of 3D analysis techniques, coupled to specific image 
processing methods opens up new possibilities for the analysis of bone structures [90, 
91]. Recent reports outline the use of μCT for the monitorization of the in vivo bone 
remodeling process [92].  
On Figure 6, μCT-reconstructed 3D images of rat calvarial bone are shown. 
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Figure 6 – μCT-reconstructed 3D images of rat calvarial bone, 3 months following the establishment of a 
8 mm CSD, without (Fig. 6A and 6C) and with the implantation of a ceramic material (Fig. 6B and 6D). 
Figures 6C and 6D are detailed high magnification images of Figures 6A and 6B, respectively.  
 
Conclusion 
Animal models play an important role in bone tissue-related research by 
providing methodological approaches to study detailed events and regenerative 
advances, which aim to establish adequate translational applications with clinical 
relevance. While no species fulfils the requirements of an ideal animal model, rodents 
reach out as easily available, easy to house and handle, and account for a high amount 
of background data due to the widespread use in the reported literature. Furthermore, 
the described models established on rodents calvarial bone allow the establishment of 
a standardized, reproducible orthotopic defect which permits not only the evaluation of 
the biocompatibility of implanted biomaterials or tissue engineering constructs, but also 
the assessment of the intramembranous ossification process in physiological and 
pathological conditions. Multiple methodologies, including histological analysis, electron 
microscopy and radiological techniques have reported relevant and complementary 
data, with proven adequacy, in the assessment of bone repair/regeneration process.  
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The adequacy and success of any material in the biological milieu is defined by 
its reaction to and from the surrounding environment. In this framework, apart from 
wide accepted generalizations, there is no specific universal consensus regarding the 
definition of biomaterial, or even strict directives for its biocompatibility assessment. 
Nonetheless, biocompatibility remains the central theme concerning the clinical 
application of biomaterials, and it is generally accepted that this term reflects not only 
the mere absence of cytotoxic effects, but also embraces a positive action in the sense 
of biofunctionality, i.e. the promotion of biological processes which further extend the 
intended aim of the application of a biomaterial.  
The national and international standards for testing regimes represent a lowest 
common denominator for such applications and do not necessarily ensure that optimal 
function is expected to be achieved. The most popular and accepted series of 
standards in this area are depicted in ISO 10993: Biological evaluation of medical 
devices, and address the issue of biocompatibility by categorizing the materials based 
on the nature and estimate duration of contact with the organism. Local and systemic 
reactions, acute or chronic effects during contact with tissues or blood, delayed 
sensitization reactions, potential of the material to elicit chromosomal aberrations, 
carcinogenic potential, etc. are of particular interest while designing and conducting 
qualification studies. Both in vitro and in vivo testing is addressed in ISO 10993, in 
order to evaluate local and systemic reactions. Hence, no individual test can be used 
for ascertaining the biocompatibility of a material and a material cannot be categorically 
stated as broadly biocompatible; on the other hand, it can be inferred, through a series 
of properly selected qualification studies, that a material is suitable for use in a specific 
application.  
An obvious first step approach regarding in vitro biomaterial biological testing 
embraces the general cytocompatibility evaluation and usually involves the use of 
various cell lines which can be easily cultivated and passaged in the laboratory for long 
periods. Within the scope of this thesis, reported examples are shown in chapters 2 to 
5, based on the use of human fibroblastic or osteoblastic-like cell lines with a wide 
variety of candidate materials, including ceramics, composites and surface-modified 
materials. A generic approach to the biological behaviour of candidate materials is 
possible and allows the detection of cytotoxic and/or mutagenic compounds in direct or 
indirect culture systems. As portrayed, used cultures allow for the assessment of cell 
adhesion, cell morphology, cell viability/proliferation, as well as the expression of 
generic cellular markers, parameters that can all be compared to the ones verified on 
cultures grown in standard control conditions, usually on the surface of the culture 
plate. This characterization methodology seems to be convenient and highly sensitive 
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for recognizing and exclude broadly cytotoxic materials at an early stage in the testing 
process. Nonetheless, these methods cannot be regarded as exhaustive and definitive 
regarding the in vitro cytocompatibility evaluation and it is proposed that such 
screening methodologies be followed by a second in vitro phase, in which the specific 
cytocompatibility assessment is conducted. In this stage, the material response to 
primary or early passaged cells of a type relevant to the proposed application of the 
medical device is thoroughly characterized. Accordingly, in chapters 4 to 9, this 
evaluation phase is exemplified within a wide range of materials. In the illustrated 
examples, human fibroblastic, osteoblastic and endothelial cells were cultured in direct 
contact with the testing materials and evaluated regarding broadly cell functions e.g., 
cell adhesion, viability and proliferation, and most of all, markers of functionality and 
expression of the specific phenotype. The later included the evaluation of, for 
osteoblasts, the expression of alkaline phosphatase, the gene/protein expression 
associated with the osteogenic commitment, and the formation of a mineralized 
extracellular matrix; and for endothelial cells, the formation of multicellular cord-like 
structures in pro-angiogenic conditions, and the expression of genes or proteins 
associated with the specific phenotype. The in vitro cytocompatibility evaluation is an 
attempt to simulate the in vivo situation as closely as possible, by selecting cell 
populations most likely to modulate the behaviour of implanted materials. In the case of 
materials aiming to perform in close contact with the bone tissue, osteoblasts and 
endothelial cells are of the upmost relevance within the bone regeneration, since they 
contribute directly and indirectly to the osteogenic and angiogenic processes.   
In the described biological systems it is thus possible to assemble a spectrum 
of in vitro changes, ranging from inhibition of growth with truthful cell death or 
inadequate expression of cell markers (cytotoxic materials), to stimulation of cell 
proliferation and/or other cell biological parameters (cytocompatible materials with 
eventual bioactivity). An expansion of in vitro testing methods can offer a methodology 
to tailor biomaterials, but does not eliminate the need to address the candidate 
biomaterial/tissue engineering construct in an in vivo biological system. 
Animal models are essential for evaluating biocompatibility, tissue response 
and mechanical function of candidate materials, prior to clinical use in human trials. 
Animal models allow the evaluation of materials in loaded or unloaded situations, over 
a wide range of time frames, ages, and in different biological constrains (e.g. 
healthy/physiological tissues or within pathological conditions). Moreover, not only 
tissues in the immediate vicinity of the implant can be assessed, but also tissues in 
remote locations, which is of particular relevance within the study of wear particle 
debris or degradable implants.  
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While animal models may closely represent the mechanical and physiological 
conditions of the clinical situation, it must be remembered that it is only an estimated 
approximation, with each model having unique advantages and disadvantages. 
Currently there are numerous models for testing implant materials in vivo, ranging in 
purpose from the assessment of orthotopic cellular behaviour and soft tissue 
adherence, to the osseointegration process and the dissemination of implant wear 
particles. A wide range of animal species and specific orthotopic models have been 
developed but currently, rodents reach out as easily available, easy to house and 
handle, and account for a high amount of background data due to the extensive use in 
the reported literature. These conditions broadly facilitate the widespread selection of 
these animals for bone related basic and translational research. In chapter 10, the 
rodents‘ calvarial defect model is discussed regarding the evaluation of the 
biocompatibility of implanted biomaterials or tissue engineering constructs, and also 
regarding the assessment of the intramembranous ossification process in physiological 
and pathological conditions. Critical appraisal is given to the choice of critical size vs 
non-critical size defects, and several methodologies to address the bone regeneration 
process are discussed.  
Overall, researchers working in bone tissue regeneration field are faced with 
highly complex biological systems that output a large amount of extremely intricate and 
multidisciplinary data that need adequate processing in order to output reliable and 
valuable information. From the biological point of view, recent advances have 
contributed to shed a new light into the development of investigative research tools, 
and in the understanding of the mechanisms involved in cell and tissue cross-talk with 
biomaterials, during bone regeneration. At the same time, material development (in 
regards to design and fabrication methodologies) have become increasingly 
sophisticated. The greatest challenge that has emerged as the result of the synergic 
multidisciplinary approach is the exponential increase of possibilities that have to be 
tested and validated. Trustworthy and effective paths have to be carefully considered in 
order to evaluate the increasing number of potential materials aiming human contact. 
High-throughput screening technologies can be combined with biological systems for 
rapid evaluation of cellular effects caused by the underlying substrates. With the 
technological advances, new tools will enable the rapid assessment of the interaction 
between cells and biomaterials, at the cellular, molecular and gene levels, offering a 
window of opportunity to comprehend the regulatory signals that rule the 
cell/biomaterial interaction. In vivo, screening models and biomarkers have been 
developed to more efficiently select the biomaterials from the great plethora of 
available options. Additionally, increased knowledge of laboratory animal 
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experimentation and the establishment of representative models of the human settings, 
in physiological and pathological conditions, have considerably increased the 
throughput of valuable data for subsequent stages of biocompatibility evaluation.    
Closer to mimicking the complexity of biological tissues, biomimetic approaches 
to regenerate damaged tissues will continue to emerge and further evolve due to the 
continued convergence of multiple fields of research. In vitro and in vivo 
biocompatibility testing will continue to set the ground base from which candidate 
materials aiming clinical application stand for, prior to the use in clinical settings.  
 
 
